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1 Introduction
1.1 Multidrug resistance
Cancer is one of the main causes of death in economically developed countries [1].
According to the data reported by the International Agency for Research on Cancer
(IARC) for 2008, 12.7 million patients were affected by cancer and 7.6 million cancer
deaths were registered worldwide [1, 2]. Those statistics makes cancer the second cause
of death after cardiovascular diseases, which are accountable of 17.5 million deaths in
2005 [3].
The multidrug resistance (MDR) is defined as the ability of cells and organisms to
resist treatment by structurally unrelated drugs [4] and it represents a critical problem
in cancer therapy, especially in acute leukemias [5]. MDR is divided into two forms: the
intrinsic drug resistance and the acquired drug resistance. The intrinsic drug resistance
is related to the capacity of a tumor to show resistance against chemotherapeutic drugs
already from beginning of the therapy. In acquired drug resistance, tumors respond
to initial therapy, but later appear to be strongly resistant to the original treatment.
The consequence of MDR is the failure of therapy and the intractability of the tumor
with chemotherapeutic drugs [6].
Multidrug resistance is related to overexpression of certain ATP binding cassette
(ABC) transporter proteins, a family of membrane transport proteins widely expressed
in all living organisms. These membrane transporters are characterized by the combi-
nation of one or more transmembrane domains and cytoplasmic ATP binding domains
[7].
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1.2 ATP-binding cassette (ABC) transporters
ABC transporters are membrane proteins which are able to transport several kind
of substrates, ranging from ions to small molecules, across the plasma membrane
or other intracellular membranes [8]. The physiological roles of these transporters
include the transport of metabolites and the protection of the organism from toxic
compounds [9]. ABC transporters are also widely distributed in the organism and
are expressed in a wide variety of tissues and organs. The tissue localizations of the
major human ABC transporters involved in MDR are reported in table 1.1. Several
diseases are associated with ABC transporters: The cystic fibrosis (ABCC7) and the
Dubin-Johnson syndrome (ABCC2) are only two examples of them [9, 6].
Table 1.1: Distribution of the major human ABC transporters involved in MDR.
ABC transporter Tissue localization
P-gp / ABCB1 kidney proximal tubule, placenta, adrenal
cortex, testis, uterus, lymphocytes,
hematopoietic cells [4]
MRP1 / ABCC1 lung, testis, kidney, placenta, skeletal and
cardiac muscles [10]
BCRP / ABCG2 brain (BBB), liver, kidney, lactating breast,
placenta, testis, small intestine, colon,
haematopoietic compartment [11]
At the moment, 48 members of the ABC transporter family are known in humans
[5] and are divided into seven subfamiles from ABCA to ABCG, according to their
gene structure, sequence similarity and phylogenetic analysis [8, 12, 13]. Among these
48 known humans members of the ABC transporter family, P-glycoprotein (P-gp /
ABCB1), the multidrug resistance associated protein 1 (MRP1 / ABCC1) and the
breast cancer resistance protein (BCRP / ABCG2) have been recognized to play an
important role in MDR [7, 14].
A functional ABC transporter requires the presence of at least two nucleotide bind-
ing domains (NBDs) and two transmembrane domains (TMDs) [15]. The nucleotide
binding domain of ABC transporters is highly conserved for all members of this family.
In particular, four conserved sequence elements and three highly conserved residues
are present with minimal variations in all members of the family. The conserved se-
quence elements consist of the Walker A, the Walker B, the ABC signature sequence,
and the D-Loop, while the highly conserved residues are the Q-loop, the A-loop and
the H-loop. [16, 17, 18].
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(a) (b)
Figure 1.1: (a) Representation of the two NBDs of Sav1866 (PDB-entry 2ONJ). The highly
conserved motifs are colored in green (Walker A), red (Walker B), orange (Q-
loop), cyano (D-loop) and yellow (signature sequence). The molecular structure
of AMP-PNP is colored in black. (b) The interaction of AMP-PNP with the A-
loop (Tyr349) the H-loop(His534), the Q-loop (Gln422), the Walker B (Glu503)
and the Walker A motif (Lys380) of the bacterial transporter Sav1866. Figures
are adopted from the work of Seeger et al. [16].
The Walker A and the signature sequence are in contact with the γ-phosphate moiety
of the nucleotide, while the A-loop contacts its adenine; the Walker B contains a highly
conserved glutamate residue, which is probably involved in the nucleophilic attack on
ATP through a water molecule; the Q-loop interacts with the γ-phosphate of the
nucleotide via a water molecule and is also involved in the interaction between NBD
and TMD; the D-loop could play a role in the communication between the two NBDs
and the H-loop has a direct interaction with the γ-phosphate of the nucleotide and is
directly involved in the catalytic hydrolysis of the nucleotide [16, 18]. In figure 1.1a are
shown the two nucleotide binding domains of the bacterial ABC transporter Sav1866
[19], where the Walker A, the Walker B, the signature sequence, the D-loop and the
Q-loop are highlighted in different colors. The 5’-adenylylimidodiphosphate (AMP-
PNP), a synthetically prepared non-hydrolyzable analog of adenosine 5’-triphosphate
that was co-crystallized with the protein, is presented in black. In figure 1.1b are
presented the principal amino acids that interact with the AMP-PNP in Sav1866. In
this figure, it is possible to recognize the interaction of the A-loop (Tyr349) with the
adenine of the nucleotide and the interactions of the H-loop (His534), of the Q-loop
(Gln422), of the Walker B (Glu503) and of the Walker A (Lys380) with the γ-phosphate
of the nucleotide.
In contrast to the NBDs, the transmembrane domains of ABC transporters show a
low degree of homology. The ABC exporters normally feature two membrane span-
ning domains (MSDs) with similar amino acid sequences interacting together to form a
3
1 Introduction
dimer interface. Each membrane spanning domain generally consists of six transmem-
brane spanning helices (TMHs), with a total of 12 transmembrane spanning helices
[16]. An important exception is the human ABC transporter BCRP, which consists
of two monomers with 655 amino acids each containing only one MSD and one NBD.
These two identical monomers interact together probably through disulfide bonds [20]
to form the complete BCRP structure [21].
1.2.1 P-glycoprotein (P-gp / ABCB1)
NH2	  
COOH	  NBD	  1	   NBD	  2	  
TMD	  1	   TMD	  2	  
Extracellular	  	  
Intracellular	  	  
Ce
ll	  
m
em
br
an
e	  
Figure 1.2: Topological model of P-glycoprotein.
P-glycoprotein (P-gp / ABCB1) also known as MDR1 is a member of the ABCB
subfamily. It was discovered in 1974 by Juliano and Ling in Chinese hamster ovary cells
mutants [22, 23]. Human P-gp is a 1280 amino acids protein, codified by a gene located
on the chromosome 7q21 [7]. The molecular weight of human P-gp is about 170 kDa in
fully glycosylated form [24]. As illustrated in figure 1.2, P-gp is characterized by two
membrane spanning domains (MSDs) and two nucleotide binding domains (NBDs)
both on the same amino acidic sequence. Observing the primary sequence from NH2
to -COOH-termini, the domains appear following the pattern MSD1-NBD1-MSD2-
NBD2. The -NH2 and -COOH-termini as well as the nucleotide binding domains are
located in the intracellular space. The first extracellular loop is N-glycosylated [25].
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The first information about the threedimensional structure of P-gp was obtained
using electron cryomicroscopy. This preliminary investigation provided evidence for a
dimeric association of P-gp in the reconstituted lipid bilayer [26]. Homology models of
P-gp, first based on the structure of MsbA [27] and later based on Sav1866 [28] were
generated in order to identify and analyze the structure of this transporter and in
particular its drug-binding site(s). The X-ray structure of mouse P-gp, that shares 87
% of identity with the human P-gp, was finally obtained at 3.8 A˚ resolution in 2009 by
Aller et al. [29]. This structure proofed to be wrong and was successively corrected by
Jin et al. [30, 31]. The obtained structure seems to confirm the hypothesis that this
transporter possesses at least two drug-binding sites located in the transmembrane
region. This hypothesis was already suggested by Shapiro and Ling more than ten
years before [32].
Transport mechanism of P-gp
Extracellular	  	  
Intracellular	  	  
Ce
ll	  
m
em
br
an
e	  
Classical	  
pump	  	  
Vacuum	  
cleaner	  
Flippase	  
Figure 1.3: The classical pump, vacuum cleaner, and flippase models for substrate transport
by P-gp, modified from [33].
The efflux mechanism of P-gp and, in more general, of ABC transporters is not yet
clearly explained. Until now, three different models of substrate transport mediated
by P-gp were suggested. The first and the most accepted hypothesis about substrate
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transport mediated by P-gp was suggested by Gottesman et al.. The results suggested
that P-gp works as a vacuum cleaner for hydrophobic molecules, which are embedded
in the membrane [34]. Two years later Higgins and Gottesman formulated another
theory how substrate transport is mediated by P-gp: They considered P-gp working
as a flippase. In this transport model the substrate interacts with the lipid bilayer
and enters into the core of the membrane-associated transporter in contact with the
inner leaflet of the membrane and either is pumped directly from the inner leaflet of
the bilayer to the extracellular space or is flipped from the inner leaflet to the outer
leaflet of the membrane. In this second case, the substrate successively diffuses from
the outer leaflet to the extracellular space [35]. The third proposed model of transport
was suggested in 1994 by Altenberg et al. on the basis of data obtained by observations
of the transport of rhodamine 123 mediated by P-gp. Altenberg et al. hypotesized
that P-gp extracts the substrate not from the membrane, as postulated by the flippase
and by the vacuum cleaner theories, but directly from the cytosol [36]. The three
proposed transport models are summarized in figure 1.3.
P-gp substrates
P-gp substrates vary enormously in size and structure, ranging from small organic
cations to large molecules, like actinomycin D [37]. The first pharmacophore model
that describes the P-gp substrates was proposed by Seelig et al. [38]. In this work
was reported that many P-gp substrates have two or three electron-donor groups in
their structure, separated by 2.5 A˚ from each other and separated by 4.6 A˚ from the
other electron-donor group pair. Cianchetta et al. [39] suggested a pharmacophore
model with two hydrophobic groups 16.5 A˚ apart and two hydrogen-bond-acceptor
groups 11.5 A˚ apart. The molecular dimension was also found to play an important
role in recognition as P-gp substrate. Support Vector Machine was used by Huang et
al. to discriminate between P-gp substrates and non-substrates, with an accuracy of
higher than 90 % [40]. Other studies reported that some chemical characteristics are
important but not essential to be a P-gp substrate. Those characteristics include a logP
value higher than 2.92, a molecular axis longer than 18 atoms, a high value of Ehomo, the
presence of at least one tertiary basic nitrogen atom, and molecular weight lower than
800 Dalton [25]. Today, many drugs are recognized to be P-gp substrates and belong to
several drug classes such anticancers, cardiacs, antimicrobials, immunosuppressants,
gastrointestinal agents, HIV proteases, and neurologic agents [41]. A short list of
well-known P-gp substrates is given in table 1.2.
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Table 1.2: P-gp substrates.
Drug class P-gp substrates
Anticancers actinomycin D, colchicine, daunorubicin,
doxorubicin, etoposide, imatinib, irinotecan,
lapatinib, mitomycin C, nilotinib, paclitaxel,
taxol, topotecan, vinblastine, vincristine
Cardiacs antiarrhythmic agents (digoxin and vera-
pamil), Anticoagulant agents (warfarin), An-
tihypertensive agents (diltiazem, losartan,
propranolol), Antiplatelet agents (clopido-
grel, ticagrelor), Statins (atorvastatin, lovas-
tatin)
Antimicrobials erythromycin, ivermectin, posaconazol,
quinolones, rifampicin
Immunosoppressants cyclosporine A, everolimus, tacrolimus
Gastrointestinal agents cimetidine, domperidone, loperamide, on-
dansetron
Fluorescent dyes calcein AM, BCECF AM, rhodamine 123,
Hoechst 33342
P-gp inhibitors
P-gp inhibitors are able to reverse MDR mediated by P-gp. Like substrates, they
are structurally diverse. However, the majority of them are weakly amphipathic and
hydrophobic and often they contain a tertiary nitrogen atom. Many P-gp inhibitors
are also themselves transported by P-gp [42]. Inhibitors of P-gp are classified into
three generations according to their specificity, affinity, and toxicity. First generation
inhibitors are drugs normally used in pharmacological therapies that are also able to
inhibit P-gp. The usage of these compounds as P-gp inhibitors is limited due to their
low potency and high toxicity. Second generation inhibitors increase the inhibitory
potency against P-gp, and lack the pharmacological activities against other targets.
PSC 833 (a non-immunosuppressive analogue of cyclosporine A) and dexverapamil
are two members of this inhibitor generation. These compounds, however, are also
inhibitors and substrates of CYP3A4 enzyme and other ABC transporters. These
additional pharmacological effects complicate the pharmacokinetic of the administered
cytostatics. Third generation P-gp inhibitors are potent and selective P-gp inhibitors
with low toxicity, developed using structure activity relationship methods. XR 9576
also know as tariquidar is a member of this inhibitors generation [43]. A list of P-gp
inhibitors divided on the base of their generation is given in table 1.3.
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Table 1.3: Pg-p inhibitors categorized on the basis of their generation. The table is
based on Amin et al. [43].
Generation Inhibitors Specificity and limitations
First genera-
tion
verapamil, cyclosporine A, re-
serpine, quinidine, yohimbine,
tamoxifen, toremifena
Non-selective, partially also P-
gp substrates, pharmacologi-
cally active
Second gener-
ation
dexverapamil, dexniguldip-
ine, valspodar (PSC833),
dofequidar fumarate (MS-209)
Increased specificity with re-
spect to first generation in-
hibitors, also substrates and
inhibitors of CYP3A4 enzyme
and other ABC transporters
Third genera-
tion
zosuquidar (LY335979), ian-
iquidar (R101933), mitotane
(NSC-38721), biricodar (VX-
710), elacridar (GF 120918),
ONT-093, tariquidar (XR
9576), and HM30181
Potent and selective P-gp in-
hibitors, no limitations
1.2.2 Multidrug Resistance associated Protein 1 (MRP1 /
ABCC1)
Multidrug Resistance associated Protein 1 (MRP1) is the first member of the ABCC
family. MRP1 is expressed in most tissues throughout the body, especially in lung,
testis, kidneys, skeletal muscle, and peripheral blood mononuclear cells [44]. Also
MRP1 is involved in multidrug resistance and is overexpressed in many solid tumors
such hepatocellular carcinoma and breast cancer [45]. MRP1 was discovered in H69AR
cells, obtained from the lung cancer cell line H69 by stepwise selection in media con-
taining doxorubicin [10]. The human MRP1 gene is localized on the gene 16p13.1
[46]. This transporter consists of 1,531 amino acids, with a molecular weight of about
190 kDa, and contains three membrane spanning domains and two nucleotide binding
domains (MSD0-MSD1-NBD1-MSD2-NBD2). The first membrane spanning domain
contains only five transmembrane helices, while each of the other two membrane span-
ning domains contain six transmembrane helices as all the other ABC transporters
[44]. Unlike P-gp and BCRP, the -NH2 terminus is extracellular. MRP1 presents
two sites of N-glycosilation, localized near to the -NH2 terminus and on the MSD2,
involving the residues Asn19, Asn23 (-NH2 terminus) and Asn1006 (MSD2) [47]. The
topology of MRP1 is shown in figure 1.4.
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Figure 1.4: Topological model of Multidrug Resistance associated Protein 1.
MRP1 substrates
MRP1 substrates include a wide variety of anticancer drugs like doxorubicin, dauno-
mycin, epirubicin, menogaril, colchicine, vincristine, vinblastine, etoposide, gramicidin
D, idarubicin and heavy metal ions, such as arsenite, arsenate and antimonite [10].
Other xenobiotics transported by MRP1 are antivirals like saquinavir and ritonavir,
and antibiotics like difloxacin and grepafloxacin [48]. In contrast to P-gp, MRP1 is able
to actively transport GSH-, glucuronate-, and sulfate-conjugated organic anions. This
active efflux prevents the accumulation of conjugated toxic compounds, which could
react back to the parental compound ether spontaneously or by enzymatic reaction
[44]. Fluorescent substrates transported by MRP1 include calcein AM and BCECF
AM. Concerning a common pharmacophore for MRP1 substrates, it is only known
that the majority of them contain an hydrophilic and an hydrophobic portion [10].
Some MRP1 substrates are listed in table 1.4.
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Table 1.4: MRP1 substrates.
Drug class Substrates
Folate-based antimetabolites methotrexate
Anthracyclines doxorubicin
Plant alkaloids etoposide, vincristine, vinblastine, pacli-
taxel, irinotecan
Antiandrogens flutamide, hydroxyflutamide
Antivirals saquinavir, ritonavir
Antibiotics difloxacin, grepafloxacin
Metalloids arsenate, antimoniate
Toxicants aflatoxin B1, methoxychlor
GSH- Glucuronide- and
sulphate- conjugates
etoposide-gluc, SN-38-gluc, 2,4-
Dinitrophenyl-SG, doxorubicin-SG,
cyclophosphamide-SG, atraxine-SG,
aflatoxin B1-epoxide-SG, 4-nitroquinoline
1-oxide-SG, 14β-estradiol-17-β-D-gluc,
glucuronosylbilirubin, leucotriene-C4,
prostaglandin A2-SG, 15-Deoxy-∆
12−14
prostaglandin J2-SG, estrone 3-sulphate,
sulphatolithocholate
Folates folic acid, L-leucovorin
Other metabolites GSSG, GSH, bilirubin
Fluorescent substrates calcein AM, BCECF AM
MRP1 inhibitors
MRP1 inhibitors could be divided into non-specific MRP1 inhibitors and specific
MRP1 inhibitors. The non-specific inhibitors include indomethacin, probenecid, P-
gp inhibitors like verapamil and cyclosporine A, tricyclic isoxazoles like LY402913 and
LY465806, and several flavonoids [49]. Until today, the only specific MRP1 inhibitors
discovered are the leukotriene receptor antagonists MK571, ONO-1078 [50, 51], and
the 2-thioureidobenzo[b]thiophene-3-carboxylic acid derivates synthesized and evalu-
ated by Ha¨cker et al. [52]. The pharmacophore model for MRP1 inhibitors proposed
by Pajeva and Wiese [53] consists of at least one hydrogen bond acceptor group of
limited flexibility, an additional hydrophobic center in a flexible side chain, which is
connected to a planar hydrophobic ring, and a tertiary protonated nitrogen. Those
features have to be at a distance of about 5 A˚.
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1.2.3 Breast Cancer Resistance Protein (BCRP / ABCG2)
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Figure 1.5: Topological model of Breast Cancer Resistance Protein.
Breast Cancer Resistance Protein (BCRP / ABCG2) is the second member of the
ABCG family. This transporter was discovered by Doyle et al. in 1998 from highly
doxorubicin resistant cells MCF-7/AdrVp [54]. The name breast cancer resistant pro-
tein was given due to the origin of the MCF-7 cell line (breast cancer cells) [55]. The
human BCRP gene is located on chromosome 4q22 and codifies a 655 amino acid
protein with molecular weight of about 72 kDa [54, 55]. In contrast to other ABC
transporters, the primary sequence of BCRP and of all members of the ABCG family
contains only one N-terminal NBD and one C-terminal TMD. The most accepted hy-
pothesis suggested that BCRP could work as an homodimer, with two single BCRP
monomers connected each other with disulfide bridges that involve the cysteine 603
residue [56, 20]. An intramolecular disulfide bridge seems to be formed between the
two cysteine residues Cys-592 and Cys-608., located in the third extracellular loop
[57]. The transmembrane domain (residues ∼ 394 - 655) seems to consists of six
transmembrane spanning helices, according to the hydropathy analysis of the primary
sequence, with predictions based on the Hidden Markov Model algorithm (HMM), and
immunofluorescence experiments [21]. In the third extracellular loop are also located
two asparagines at positions 557 and 596, which are possible sites of N-glycosilation
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[58]. The topology of the breast cancer resistance protein is shown in figure 1.5. To
date, there are not crystal structures of BCRP available, therefore its detailed struc-
ture remains unknown. The 3D structural analysis of BCRP was performed for the
first time in 2006 by McDevitt et al. [59]. His research group obtained the 3D struc-
tures of the transporter at a resolution of about 18 A˚ using cryonegative stain electron
microscopy. They interpreted the observed tetrameric complex to be comprised of four
homodimeric BCRP complexes. Unfortunately, homology modeling is also not helpful
to understand the three-dimensional structure of BCRP, due to the very low identity
values between the primary sequence of this transporter and that of the other ABC
transporters for which crystal structures are available [60].
Localization of BCRP in human tissues
BCRP is present in a wide variety of human tissues where it plays an important role
in protection against xenobiotics. It has been identified in the apical membrane of
placental syncytiotrophoblasts, in the bile canalicular membrane of hepatocytes, in
the luminal membranes of villous epithelial cells in the small intestine and colon, in
cardiac muscle, in the endocrine cells of the pancreas, in sebaceous glands, in the
endothelium of the nervous system, in the zona reticularis of the adrenal gland, in the
Sertoli cells of the testis, and in the venous and capillary endothelial cells of almost all
tissues [61, 62]. Expression of BCRP was also observed in stem cells. Its role in stem
cells differentiation and protection against xenobiotics is object of investigations [63].
Physiological role of BCRP
BCRP is recognized to be important for protection against xenobiotics and in reg-
ulation of oral bioavailability. This transporter seems to be also involved in other
physiological roles, as the extrusion of porphyrins (conjugated and non-conjugated)
from hematopoietic cells or liver and the harderian gland, and the secretion of vita-
mins into breast milk [64]. BCRP is believed to protect the fetus from toxins as well
as to remove toxins from the fetal space. Presence of BCRP in intestine limits the oral
bioavailability of xenobiotics. The role of BCRP in kidney is supposed to be related
to renal drug excretion [62]. The physiological roles of BCRP in human tissues are
summarized in table 1.5.
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Table 1.5: Physiological role of BCRP in human tissues [61].
Tissue Physiological role
Placenta Protection of the fetus
Liver Hepato-biliary excretion
Stem cells SP-phenotype and protection against hy-
poxia
Intestine Reduction of xenobiotics absorption
Brain Protection against xenobiotics
Breast Transport of vitamins into breast milk [64]
Kidney Urinary excretion of drugs
BCRP substrates
Due to its protective role in human organism, BCRP is able to transport a wide
variety of substrates with very different structures. Most cell lines over expressing
BCRP are highly resistant against mitoxantrone, even if they were never treated with
mitoxantrone. Furthermore, the accumulation of mitoxantrone in cells transfected
with BCRP cDNA is significantly lower than in cells transfected with empty vectors.
These data suggest that BCRP is able to transport mitoxantrone with high efficiency
[65, 55].
Derivatives including topotecan, irinotecan and SN-38 (the active metabolite of
irinotecan) are also important substrates of BCRP. The accumulation of camptothecin
derivatives is also low in cells not previously selected with topotecan and in cells
transfected with BCRP cDNA [66].
Flavopiridol is a cyclin-dependent kinase inhibitor under clinical trials. Robey et al.
[67] exposed the human breast cancer cell line MCF-7 with incrementally increasing
concentrations of flavopiridol. The resulting resistant cell line MCF-7 FLV1000 re-
sulted to be resistant not only against flavopiridol, but also against mitoxantrone and
topotecan.
BCRP-overexpressing cell lines MCF-7/AdrVp3000 and S1-M1-80 are reported to
be highly resistant against anthracyclines, while the other BCRP-overexpressing cell
lines are not [68]. Further investigations reveled that these two cell lines express two
different mutants of BCRP, the mutant R482T (Thr at position 482) in the MCF-
7/AdrVp3000 cell line and the mutant R482G (Gly at position 482) in the S1-M1-80
cell line. BCRP with Arg at position 482 is considered as wild-type.
The antifolate drug methotrexate seems to be transported by the wild-type BCRP,
while it is not a substrate of BCRP mutants. Chen et al. [69] reported that methotrex-
ate and methotrexate polyglutamates are transported by wild-type BCRP and also
that this transporter has a high-capacity but low-affinity for these substrates.
Several fluorescent dyes like Hoechst33342, BODIPY-prazosine, BCECF-AM and
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pheophorbide A has been reported to be BCRP substrates [55, 70, 71, 72].
The BCRP substrates are summarized in table 1.6. In figure 1.6 the structures of
selected BCRP substrates are given.
Table 1.6: BCRP substrates (Based on Mao et al. [65]).
Drug class Substrate
Anthracyclines a daunorubicin, doxorubicin
Anthracenes mitoxantrone, bisantrene, aza-
anthrapyrazole
Camptothecin derivates topotecan, SN-38, 9-amino-campothecin,
irinotecan, diflomotecan
Antifolate b methotrexate, methotrexate polyglutamate
Nucleoside analogs AZT, AZT 5’-monophosphate, lamivudine
Conjugates estrone-3-sulfate, 4-MUS, E3040S, TLC-S, 4-
MUG, E3040G, E217βG, DNP-SG
Other drugs prazosin, indolocarbazole, popoisomerase I
inhibitors (NB-506, J-107088), flavopiridol,
ErbB1 tyrosine kinase inhibitor (CI1033),
imatinib mesylate (STI1571), pantoprazole
Fluorescent dyes Hoechst 33342, BODIPY-prazosine,
BCECF-AM, pheophorbide A
aSubstrate only of the BCRP mutants R482T and R482G.
bSubstrate only of the wild-type BCRP.
BCRP inhibitors
BCRP inhibitors are of interest as chemosensitizers for clinical drug resistance and
for improving the pharmacokinetics of chemotherapeutic drugs [73]. Today, several
BCRP inhibitors are known and they may be classified into four categories [74]:
• BCRP specific inhibitors
• Broad spectrum inhibitors
• Flavonoids and derivatives
• Inhibitors of other targets that are also BCRP-inhibitors (e.g. tyrosine kinase
inhibitors (TKIs) and HIV protease inhibitors)
Fumitremorgin C, a toxin extracted from Aspergillus fumigatus, is the first identified
specific BCRP inhibitor [66]. Due to its high neurotoxicity in mice, the use in vivo
is not practicable. Tryprostatine A, a further A. fumigatus secondary metabolite
was also recognized to be a selective BCRP inhibitor. Contrary to fumitremorgin
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Figure 1.6: Structures of selected BCRP substrates.
C, tryprostatin A does not show any cytotoxicity at effective concentrations but its
low inhibitory potency limits the possibilities of application in clinical therapy [75].
The new BCRP selective inhibitor Ko143, a synthetic fumitremorgin C analogue,
was developed in order to decrease the cytotoxicity of fumitremorgin C conserving
its inhibitory activity and selectivity for BCRP [73]. Novobiocin, a coumermycin
antibiotic, was also recognized to be a non-toxic and selective BCRP inhibitor. Its
inhibitory potency is however very low: indeed, novobiocin has an IC50 value of only
about 50 µM [76].
The broad spectrum BCRP inhibitors include the high affinity third generation P-gp
inhibitors elacridar (GF 120918) and tariquidar (XR 9576) [77, 78]. Both compounds
are able to reverse the BCRP mediated resistance in MCF-7 MX cells with IC50 values
barely lower than 1 µM. An other broad spectrum BCRP inhibitor is the pipecolinate
derivative VX-710 (biricodar), which is able to inhibit only the wild-type BCRP, but
not the mutant R482T. Its inhibitory activity is however lower than of fumitremorgin C
[79]. Calcium antagonists like nicardipine and nifedipine are also able to non-selectively
inhibit BCRP. The best BCRP inhibitor among them, nicardipine, is able to inhibit
BCRP with an IC50 value of 5 µM in HeLa/SN100 cells [80].
Flavonoids have been found to be also non-selective BCRP inhibitors. Morris et al.
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[81] evaluated the effect of 20 flavonoids on the cellular accumulation and cytotoxicity
in the resistant MCF-7 MX cell line and in the parental MCF-7 cell line. They have
reported that the two most potent tested compounds, chrysin and biochanin A were
able to increase in MCF-7 MX cells the mitoxantrone accumulation at concentrations
of 0.5 and 1.0 µM and the mitoxantrone toxicity at a concentration of 2.5 µM. Phytoe-
strogens like genistein, naringenin, acacetin, and kaempferol were reported as BCRP
inhibitors by Imai et al. [82]. In this work it has been also reported that genistein is
also a substrate of BCRP and its transport mediated by BCRP in BCRP-transduced
LLC-PK1 cells is abolished by fumitremorgin C. In the last years, several studies re-
garding the interaction of natural flavonoids, synthetic flavonoids derivates, and other
compounds with structures derived from the flavonoid structure with BCRP were per-
formed [83, 84, 85, 86]. The structure-activity relationship of flavonoids as BCRP
inhibitors [87] has reveled the important contribution of some structural features to
BCRP inhibition. Finally, Juvale et al. [88] have synthesized a 7,8-benzoflavone
derivative able to selectively inhibit BCRP, presenting also low cytotoxicity at higher
concentrations.
Canetinib (CI-1033, PD 183805) was the first Tyrosine Kinase Inhibitor (TKI) re-
ported to reverse the resistance against SN-38 of BCRP expressing cells [89]. Since
this discovery, other tyrosine kinase inhibitors like gefitinib [90] and imatinib mesylate
[91] were reported to be also BCRP inhibitors. Further investigations reveled also
that imatinib mesylate is not only inhibitor but also substrate of BCRP and its trans-
port mediated by this transporter could be blocked by addition of the specific BCRP
inhibitor Ko143 [92].
HIV protease inhibitors were also reported to be BCRP inhibitors by Gupta et
al. [93]. In particular, ritonavir, saquinavir, and nelfinavir inhibit wild-type BCRP
(R482) with IC50 values between about 4 and 20 µM. They are also able to inhibit the
two mutants R482T and R482G with IC50 values about 2-times greater than for the
wild-type BCRP. However, HIV protease inhibitors are not specific BCRP inhibitors,
but they are also able to inhibit other ABC transporters involved in MDR [94]. The
structures of selected BCRP inhibitors are given in figure 1.7.
The first pharmacophore model for BCRP inhibitors was proposed by Chang et al.
[95]. It was built using four potent BCRP inhibitors (GF120918, Ko143, nelfinavir,
and nicardipine) and consists of three hydrogen bond acceptors and three hydrophobic
features. Another pharmacophore model was more recently proposed by Matsson et
al. [96]. It consists of only two hydrophobic centers and one hydrogen bond acceptor
feature. The two hydrophobic centers are separated by a distance of 6.75 A˚ and they
are separated from the hydrogen bond acceptor feature by 9.84 A˚ and 3.47 A˚.
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2 Materials and Methods (Molecular
Modelling)
2.1 Descriptors
The purpose of QSAR descriptors is to represent physical properties of molecules by
numerical values. These numbers can be successively used in mathematical models to
predict chemical or biological properties of codified molecules. In the present work,
several molecular descriptors were calculated using the software Molecular Operating
Environment (MOE). The descriptors treated in this chapter are divided into classes,
according to their calculation and physical meaning. The following classification and
description of the used molecular descriptors is based on the manual of the software
MOE [97] and on the book Molecular Descriptors for Chemoinformatics by Todeschini
and Consonni [98].
2.1.1 1D and 2D MOE descriptors
Partial Charge Descriptors
Partial charge descriptors are calculated using partial charges of each atom of the
molecule. This class of descriptors is divided into two subgroups, according to the
method used to calculate the partial charges. The first subgroup includes descrip-
tors that are calculated using the partial equalization of orbital electronegativities
(PEOE) method. This method was developed by Gasteiger in 1979 [99]. It consists
of calculating the amount of charge transferred (q<α>) between two bonded atoms
(with χB > χA) until equilibrium. The convergence is guaranteed by an exponentially
decreasing scale factor, that damps down the amount of charge transferred at each
iteration. The amount of charge transferred at each iteration is calculated as:
q<α> =
χA − χB
χ+A
0.5α
where χ+A is the electronegativity of the positive ion of atom A, χA is the elec-
tronegativity of atom A, that dependents quadratically on partial charge, χB is the
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electronegativity of atom B and α (with α = 1,2,3, ..., ∞) is the number of iteration
steps. The use of a damping factor assures the reaching of convergence. The total
charge of an atom is calculated as the sum of the single charge transfers [99].
Descriptors using the PEOE charges are indicated in MOE as PEOE x charge de-
scriptors. Descriptors using charges calculated by an external program are indicated
as Q x charge descriptors.
Physical properties
Table 2.1: Physical properties.
Code Descriptor name
apol Sum of the atomic polarizabilities
bpol Sum of the absolute value of the difference between atomic polarizabil-
ities of all bonded atoms in the molecule. This descriptor is calculated
as follows:
∑
i |pi − pj |, where pi and pj are the polarizabilities of two
bonded atoms of a molecule
FCharge Total charge of the molecule
mr Molecular refractivity calculated from a 11 descriptors linear model [97]
SMR Molecular refractivity calculated as described in Scott et al. [100]
Weight Molecular weight
logP (o/w) Log of the octanol/water partition coefficient. This descriptor is calcu-
lated from a linear atom type model [97]
SLogP Log of the octanol/water partition coefficient calculated as described in
Scott et al. [100]
vdw vol van der Waals volume
density Molecular mass density
vdw area Area of van der Waals surface
In table 2.1 are reported the molecular descriptors describing simple physical prop-
erties. Their calculation does not require knowledge of molecular conformations and
only the connections of the atoms within the molecule are important. The first two
descriptors, apol and bpol use the atomic polarizability for their calculation, as re-
ported in the Handbook of Chemistry and Physics (1994). FCharge is the total charge
of the molecule, obtained as the sum of each atomic formal charge. This descriptor
takes values equal to 0, ± 1, ± 2, ... ± ∞ only. mr is the molecular refractivity
calculated from a linear model obtained by 1,947 small molecules. SMR is the molecu-
lar refractivity obtained from an atomic contribution model. Weight is the molecular
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weight. logP(o/w) is the octanol/water partition coefficient calculated from a linear
model obtained by 1,847 molecules. SlogP is the octanol/water partition coefficient
obtained from an atomic contribution model. vdw vol is the van der Waals volume
calculated using a connection table approximation: it means that for calculation of
the descriptor is considered only how the atoms in the molecule are connected, not
the molecular conformation. density is the ratio of Weight to vdw vol. vdw area is the
area of van der Waals surface calculated using a connection table approximation.
VSA-Type descriptors
The nature and calculation of van der Waals surface area (VSA) descriptors is well
described by Paul Labute, the author of this set of descriptors [101]. The VSA-type
descriptors are based on the van der Waals surface area (VSA). The VSA for each
atom in a molecule is obtained from the surface area of the atom, approximated as a
sphere with radius equal to the van der Waals radius, which is not contained in any
other atom of the molecule. The molecular VSA is then calculated as the sum of each
single VSAs in the molecule. The calculation of the descriptors occurs in two steps:
Firstly, the VSA for each atom of a molecule is calculated. The calculated atomic
VSAs are successively combined with physicochemical properties as molar refractivity
(MR), lipophilicity (logP) (both calculated using the Wildman and Crippen’s method)
and atomic partial charges (calculated using the Gasteiger method) taken only in a
certain range, as described in the following equation:
P V SA(u, v) =
∑
i
Viδ(Pi ∈ [u, v])
where Vi is the atomic VSA, and P is the calculated atomic property in the predefined
range. The result is a set of 10 descriptors for logP, 8 descriptors for MR and 14
descriptors for the atomic partial charges. The interval boundaries for logP are: −∞,
-0.4, -0.2, 0, 0.1, 0.15, 0.2, 0.25, 0.3, 0.4, ∞. The interval boundaries for MR are: 0,
0.11, 0.26, 0.35, 0.39, 0.44, 0.485, 0.56, ∞. The interval boundaries for the atomic
partial charges are: −∞, -0.3, -0.20, -0.15, -0.10, -0.05, 0, 0.10, 0.15, 0.20, 0.25, 0.30,
∞. Together, the VSA-Type descriptors describe a 10 + 8 + 14 = 32 dimensional
chemistry space.
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Atom Counts and Bond Counts
Table 2.2: atom counts and bound counts descriptors.
Code Descriptor name
a aro Number of aromatic atoms
a count Number of atoms
a heavy Number of heavy atoms
a ICM Atom information content (mean)
a IC Atom information content (total)
a nH Number of hydrogen atoms
a nB Number of boron atoms
a nC Number of carbon atoms
a nN Number of nitrogen atoms
a nO Number of oxygen atoms
a nF Number of fluorine atoms
a nP Number of phosphorus atoms
a nS Number of sulfur atoms
a nCl Number of chlorine atoms
a nBr Number of bromine atoms
a nI Number of iodine atoms
b 1rotN Number of rotatable single bonds
b 1rotR Fraction of totale single bonds
b ar Number of aromatic bonds
b count Number of bonds
b double Number of double bonds
b heavy Number of bonds between heavy atoms
b rotN Number of rotatable bonds
b rotR Fraction of rotatable bonds
b single Number of single bonds
b triple Number of triple bonds
VAdjMa Vertex adjacency informations (magnitude)
VAdjEq Vertex adjacency informations (equality)
The atom counts and bond count descriptors describe the number of particular atom
type and bound type in a molecule or properties directly connected with them. The
atom counts and bond count descriptors calculated with MOE are reported in table
2.2.
22
2.1 Descriptors
Kier and Hall Connectivity and Kappa Shape Indices
The Kier-Hall connectivity indices calculated with MOE are divided in:
• Atomic connectivity indices (order 0 and 1)
• Carbon connectivity indices (order 0 and 1)
• Atomic valence connectivity indices (order 0 and 1)
• Carbon valence connectivity indices (order 0 and 1)
They consider each heavy atom (or only carbon atoms, in the case of carbon connec-
tivity indices) of a molecule as a vertex. The connectivity δ for each vertex represents
the number of direct connections of this vertex with the others. The connectivity index
is then defined as:
0χ =
∑
i
δ
−1/2
i
For connectivity indices of zero order and:
1χ =
∑
i
(δi · δj)−1/2
For connectivity indices of first order. In the second case, δi and δj are connectivity
values of vertices with topological distance equal to 1. The atomic (or carbon) valence
connectivity indices are obtained by replacing the vertex degree δ with the valence
vertex degree δv in the formulas reported above. The valence vertex degree is defined
as:
δv =
pi − hi
zi − pi − 1
where pi is the number of valence electrons in the i atom, hi is the number of hydro-
gens attached to the i heavy atom and zi is the total number of electrons in the i atom.
The Kappa shape indices compare the molecular graph with the minimal and max-
imal molecular graphs that are possible to be obtained with the same atoms number.
The first, second and third order κ shape indices are calculated as:
1κ = 2 ·
1Pmax ·1 Pmin
(1P )2
=
A(A− 1)2
(1P )2
2κ = 2 ·
2Pmax ·2 Pmin
(2P )2
=
(A− 1)(A− 2)2
(2P )2
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3κ = 4 ·
3Pmax ·3 Pmin
(3P )2
=

(A−3)(A−2)2
(3P )2
if A is even
(A−1)(A−3)2
(3P )2
if A is odd
where Pmin and Pmax are the minimal and maximal molecular graphs and A is the
number of atoms in the molecule. The Kier alpha-modified shape indices take also the
covalent radius of atoms and their hybridization state into account. It can be insert
into the original calculation a value α defined as:
α =
ri
rC
− 1
where ri is the covalent radius of atom i and rC is the covalent radius of a carbon
atom. The first, second and third order of Kier alpha-modified shape indices are
calculated as:
1κ =
(A+ α)(A+ α− 1)2
(1P + α)2
2κ =
(A+ α− 1)(A+ α− 2)2
(2P + α)2
3κ =

(A+α−3)(A+α−2)2
(3P+α)2
if A is even
(A+α−1)(A+α−3)2
(3P+α)2
if A is odd
The Kier molecular flexibility index KierFlex is calculated as:
KierF lex =
(KierA1)(KierA2)
n
where n is the number of atoms in the molecule. The Zagreb index is defined as the
sum of the vertex degrees for all the heavy atoms of the molecule.
Adjacency and Distance Matrix Descriptors
The adjacency and distance matrix descriptors are based on the adjacency matrix and
the distance matrix of a chemical structure. If a molecule is represented as a graph,
the adjacency matrix shows which vertices (atoms) are adjacent (directly connected)
to each other. The distance matrix shows on the other hand the topological distance
between vertices in the graph representation of a molecule. The adjacency and distance
matrix descriptors are summarized in table 2.3.
BCUT and GCUT descriptors
The BCUT and GCUT descriptors [102] are two particular kinds of adjacency matrix
descriptors. Their calculation is based on a modified adjacency matrix, called Burden
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Table 2.3: Adjacency and distance matrix descriptors.
Code Descriptor name
balabanJ Balaban’s connectivity topological index
diameter Topological diameter
petitjean Graph-theoretical shape coefficient
radius Topological radius
VDistEq Vertex distance equality index
VDistMa Vertex distance magnitude index
wienerPath Wiener path number
wienerPol Wiener polarity number
matrix.[103] For BCUT descriptors, the Burden matrix is defined as an adjacency ma-
trix where the diagonal elements are selected atomic properties and the off-diagonal
elements Bij, only for adjacent atoms, take the value of pi
−1/2, where pi is the conven-
tional bond order. Remaining elements take the arbitrary value of 0.001. The matrix
eigenvalues are calculated and the smallest, second, third, and largest eigenvalues are
used as descriptors. The GCUT descriptors differ to BCUT descriptors only for the
definition of the used matrix. For calculation of GCUT descriptors, the values of off-
diagonal entries are calculated as d−1/2, where d is the graph distance between the
two atoms. MOE uses as atomic properties for the matrix diagonal the PEOE partial
charges, the atomic contribution to logP and the molar refractivity (both calculated
using the Wildman and Crippen SlogP/SMR methods).
Pharmacophore Feature Descriptors
The pharmacophore feature descriptors calculated with MOE can be divided into two
subgroups: Descriptors that simply count the number of atoms included in predefined
pharmacophoric groups in the molecule and descriptors calculated as the sum of the
van der Waals areas of atoms included in the considered pharmacophoric groups. The
feature sets used for descriptors calculation are:
• Number of hydrogen bond acceptor atoms
• Number of acid atoms
• Number of basic atoms
• Number of hydrogen bond donor atoms
• Number of hydrophobic atoms
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2.1.2 3D MOE descriptors
Potential Energy Descriptors
The potential energy descriptors are calculated using each single component of the
potential energy value of a molecular conformation. This class of descriptors com-
prises the value of the potential energy, descriptors based on bonded forces, and on
non-bonded forces. The value of the potential energy is the sum of all single energy
components of the force field. Descriptors based on bonded forces calculate the po-
tential energy component of atoms connected by covalent ligands only. They comprise
the bond stretching energy, the angle bending energy, the stretch-bend interaction
energy, the out-of-plane bending energy, and the torsion energy. Descriptors based on
non-bonded forces are the van der Waals energy and the electrostatic energy. [104]
Surface Area and Volume Descriptors
Table 2.4: Surface area and Volume descriptors.
Code Descriptor name
ASA Water accessible surface area
dens Mass density
glob Globularity
pmi Principal moment of inertia
pmi(XYZ) x,y,z components of the principal moment of inertia
rgyr Molecular weight
std dim1 Standard dimension1
std dim2 Standard dimension2
std dim3 Standard dimension3
vol van der Waals volume
VSA van der Waals surface area
These descriptors are correlated with the molecular conformation and are useful to
describe dimensional parameters (like volume and surface) of molecules. The water
accessible surface area (ASA) and the van der Waals surface area (VSA) quantify
the molecular surface using different approaches. The water accessible surface area
is calculated using a sphere with diameter of 1.4 A˚ that simulates a water molecule.
The van der Waals surface area is calculated as the sum of the atomic van der Waals
surface areas not included in other atoms. Analogously, the van der Waals volume
is calculated as the volume included in the van der Waals surface area. The mass
density is defined as the molecular weight divided by the van der Waals volume. The
value of globularity indicates how is the molecule in the bulk extended. [105] A value
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of globularity tending to 1 means that the molecule has a globular form while a value
of globularity tending to 0 is associated with linear structures. This descriptor is
obviously highly dependent on the molecular conformation. The principal moment of
inertia is defined as:
pmi =
A∑
i=1
mi · r2i
where A is the atom number, mi is the atomic mass and ri is the perpendicular
distance from the axis of the atom i. The three x, y, z components of the principal
moment of inertia are defined as:
pmiX =
A∑
i=1
mi · (y2i + z2i ) pmiY =
A∑
i=1
mi · (x2i + z2i ) pmiZ =
A∑
i=1
mi · (x2i + y2i )
where x, y and z are the atom coordinates.[98] The three standard dimensions
(std dim1, std dim2 and std dim3) calculated by MOE are the largest, second largest
and third largest eigenvalues of the covariance matrix of the atomic coordinates.
Conformation Dependent Charge Descriptors
These conformation dependent descriptors are calculated using the stored partial
charges of molecules. This class includes the dipole moment and its three separated
components, as well as several descriptors calculated combining the partial charges
with the water accessible surface area of the molecule.
Vsurf Descriptors
The Vsurf descriptors are the MOE implementation of the VolSurf descriptors devel-
oped by Cruciani et. al. [106]. These conformation dependent descriptors are able
to numerically represent molecular interaction field (MIFs) informations about the
molecular size, the molecular shape, the distribution of hydrophobic and hydrophilic
regions and their balance [98]. Interactions fields are calculated using a water probe,
a hydrophobic probe or other probes, like ionic probes [106].
MOPAC Descriptors
The MOPAC descriptors are conformation dependent descriptors calculated using the
MOPAC package implemented in MOE. The semiempirical Hamiltonians PM3, MNDO
or AM1 are used in the calculation to obtain the dipole moment (kcal/mol), the total
energy (kcal/mol), the electronic energy (kcal/mol), the heat of formation (kcal/mol),
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the ionization potential (kcal/mol), the energy (eV) of the Lowest Unoccupied Molec-
ular Orbital (LUMO), and the energy (eV) of the Highest Occupied Molecular Orbital
(HOMO).
2.1.3 RECON/TAE descriptors
Molecular electron density can be represented by quantum chemically derived descrip-
tors. These descriptors are useable with a wide kind of molecules and are easily ob-
tained by ab-initio calculations. However, an inconvenience of these descriptors is the
considerable computational effort expended to calculate them using quantum chemical
methods [107]. This problem can be bypassed using Transferable Atom Equivalents
(TAEs). TAEs are electron density fragments containing a charged nucleus and are
delimited by discrete boundaries. It is possible to assembly TAE fragments to repre-
sent molecular electron densities. The RECON algorithm firstly combines TAE atoms
together to generate the electron density distribution of molecules. The following step
is the adjustment of surface electronic properties used for generating QSAR descrip-
tors [107]. Finally, the light reflection algorithm is used to generate the TAE/Shape
descriptors [108].
2.1.4 RDF descriptors
Formally, the Radial Distribution Function (RDF) of an ensemble of N atoms can be
interpreted as the probability distribution to find an atom in a spherical volume of
radius r [109]. The general form of the radial distribution function is given in the
following equation:
g(r) = f
N−1∑
i
N∑
j>i
AiAje
−B(r−rij)2
where f is a scalar vector, A are atomic properties of the atoms i and j, rij is the
interatomic distance between the atoms i and j, and B is a smoothing parameter that
could be interpreted as a temperature factor that defines the movement of atoms.
The RDF descriptors calculated with MOE are divided into two groups, according
to the used distance: the 3D-RDF descriptors are calculated using the geometrical
distance, while the 2D-RDF descriptors are calculated using the topological distance.
Each molecule is codified by either an RDF vector of 30 values (if 3D-RDF descriptors
are used) or by a RDF vector of 15 values (if 2D-RDF descriptors are used). The step
size of r is equal to 0.5 A˚ for 3D-RDF descriptors, while the 2D-RDF descriptors use
a step size for r equal to 1 A˚. The B value is fixed to 100 A˚−2.
The used atom properties for the calculation of RDF descriptors are the electroneg-
ativity (e), the atomic mass (m), the refractivity (p), and the atomic volume (v). RDF
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descriptors were also calculated without the use of atomic properties (unweighted, u).
2.1.5 Inductive descriptors
Inductive descriptors basically quantify inductive and steric interactions between sub-
stituents and reaction centers. Other parameters that can be quantified with the
same mathematical apparatus are the partial atomic charges, analogues of chemical
hardness-softness and electronegativity [110].
2.1.6 Dragon descriptors
The Dragon descriptors used in this work were calculated using the free version of the
program (E-Dragon), available at the internet address http://www.vcclab.org/lab/edra-
gon.
Autocorrelation descriptors (DRAGON)
The Autocorrelation of a Topological Structure (ATS) also known as Moreau-Broto
autocorrelation [111] is the most famous spatial autocorrelation, defined as:
ATSk =
1
2
A∑
i=1
A∑
j=1
wi · wj · δ(dij; k)
where w are atomic properties, A is the number of atoms of the molecule, k is the
lag, and dij is distance (geometrical or topological) between the atoms i and j. δ(dij; k)
is the Kronecker delta function: it is equal to 1 if dij = k, while it is equal to 0 if
dij 6= k.
The ATS descriptors are divided into topological and geometrical ATS descriptors
based on the used distance matrix (topological or geometrical, respectively). The δ
values range from 1 to 15 for the topological ATS descriptors, while the geometrical
ATS descriptors use δ values between 1.5 and 15.5 A˚, with a step size of 0.5 A˚. The
atomic properties used for the calculation of the ATS descriptors are the VSA values
(a), the electronegativity (e), the hydrogen bond acceptors (ha), the hydrogen bond
donors (hb), the SLogP increments (L), the atomic mass (m), the SMR increments
(s), and the atomic volume (v). Like the RDF descriptors, also the ATS descriptors
were calculated without the use of atomic properties (unweighted, u).
3D-MoRSE descriptors (DRAGON)
The 3d-MORSE (3d-MOlecule Representation of Structures based on Electron diffrac-
tion) descriptors represent the 3D structure of a molecule by a fixed number of variables
independed on the number of atoms of the molecule [112]. 3D-MoRSE descriptors
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are calculated using different atomic properties such as atomic mass, atomic volume,
atomic electronegativity, and atomic polarizability [113].
WHIM descriptors (DRAGON)
The WHIM (Weighted Holistic Invariant Molecular) descriptors codify important molec-
ular 3D informations regarding molecular size, shape, symmetry, and atom distribution
[114]. The algorithm performs a principal component analysis on the cartesian coordi-
nates of the molecule by using a weighted covariant matrix [98]. The atomic properties
used to calculate WHIM descriptors are atomic mass, the van der Waals volume, the
atomic electronegativity (e), the atomic polarizability and the electrotopological state
indices of Kier and Hall [113].
GETAWAY descriptors (DRAGON)
The GETAWAY descriptors are calculated from the Molecular Influence Matrix (MIM)
defined as:
H = M · (MT ·M)−1 ·MT
where H is the MIM and M is the molecular matrix (the centered cartesian coordi-
nates of the atoms in the molecule). The superscript T refers to the transposed matrix
[98, 115].
2.2 Machine learning methods
2.2.1 Self-Organizing Maps (SOMs)
Self-organizing Maps (SOMs), discovered by Teuvo Kohonen 30 years ago, are un-
supervised neural networks able to project a multidimensional chemical space to a
one- or two-dimensional layer of neurons [116, 117]. Self-organizing Maps are able to
solve a wide variety of classification problems as such as speech recognition (Kohonen,
1990) or can be used in rational Drug Design [118]. Basically, a SOM consists of a
group of neurons arranged in a one-dimensional array of neurons or, more frequently, a
two-dimensional plane. Each neuron is in relationship with a defined number of other
neurons of the SOM, named neighbors [117]. According to the topological distance
between a neighbor and the considered neuron, the neighbor will be classified as near-
est neighbor, second-nearest neighbor, etc. The arrangement of the neighborhood of
a neuron is normally squared, rectangular or hexagonal [119]. These three kinds of
two-dimensional arrangement have the problem that neurons on the border of the map
have fewer neighbors as compared to neurons on the center of the map. This problem
30
2.2 Machine learning methods
has been solved using a toroidal topology [120]. This solution has been used in the
present work. In case of a square SOM, each neuron is codified as a vector:
mi = (mi1,mi2,mi3, . . . ,min)
Each neuron of a SOM is initialized with a random vector. The input information
(in this work, a chemical compound) is also codified as a vector:
xi = (xi1,xi2,xi3, . . . ,xin)
Where vector elements consist of molecular descriptors. Now the task of the SOM
now is to find the Best-Matching Cell or, in other words, the most similar neuron to
the chosen input vector. The similarity between the input vector and the neurons of
a SOM is based on the Euclidian distance:
d(p,q) =
√√√√ n∑
i=l
(qi − pi)2
The neuron with minimal distance to the input vector is defined as the winning
neuron. Once that the winning neuron has been found, the algorithm modifies the
neuron vector according to the equation:
mi(t+ 1) = mi(t) + hci(t)[x(t)–mi(t)]
Where mi represent the winning neuron, x is the input vector, t is the training
iteration and hci(t) is the Gaussian kernel, that defines the neighborhood of the winning
neuron and how these neurons must be modified. Mathematically, hci(t) is defined as:
hci = α(t)exp
(
−||rc − ri||
2
2σ2(t)
)
Where α(t) is the scalar-valued adaptation gain, that monotonically decreases from 1
to 0, ||ri−rc|| is the Euclidian distance between the winning neuron and the neighboring
neuron and σ(t) is the radius of the neighborhood. The self-organizing maps calculated
with the Kohonen package implemented in R, start as default with a value of radius
that covers 2/3 of all unit-to-unit distances. Thus, in the early iteration steps the
SOM is globally modified. Modifications will be more restricted with progressing of
the training and, nearly to the end of the training, they will affect only the winning
neurons [119, 121]. On the end of the training process, objects with similar input
vectors (molecular descriptors, in our case) will be mapped into the same neuron or in
closely adjacent neurons [120]. Finally, the algorithm assigns the class of the neurons
in the SOM by looking which element in the training set has the closest Euclidian
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distance to the considered neuron. If more than one element is associated with the
same neuron, the class is calculated by the amount of the training elements of the
two classes: the most represented class, in term of training elements on the neuron,
also will become the class associated to that neuron. A trained SOM can be used
to classify an external (test) dataset. The test dataset has to be projected to the
map. The best matching neuron assigns the class label to the object, according to the
Euclidian distance between the input vector and the vector associated to the neuron.
2.2.2 Support vector Machine (SVM)
Support vector machines (SVMs) are kernel-based classification methods, proposed by
Vapnik in the beginning of 80s and improved in 1995 [122, 123]. SVMs are widely used
to solve classification problems in many research fields as computational biology and
drug discovery [124, 125, 126, 127]. Like other classification methods, SVMs separate
two or more classes of objects with different labels in a multidimensional space through
a hyperplane. What distinguishes a SVM from other classification methods is how it
choses the hyperplane. As shown in figure 2.1a, more lines (or hyperplanes) are able to
separate two populations of vectors in the training set, but which one will generalize
well? The problem to find optimal hyperplanes for separating classes of vectors has
been solved using support vectors: If two vector populations are separated without
errors by a hyperplane, it is possible to take into account only the nearest training
vectors to the hyperplane and to maximize the distance between the hyperplane and
these vectors. The hyperplane with the maximized margins is also the hyperplane that
provides the best classifier (figure 2.1b) [122, 128]. If we assume that the class labels
are 1 and -1, xi is the i
th vector in a dataset and yi is the label of xi. The dataset
is linearly separable if there exists a vector w (called weight vector) and a scalar b
(called bias) such that the inequities
w · xi + b ≥ 1 if yi = 1
w · xi + b ≤ −1 if yi = 0
are valid for all dataset elements. The optimal hyperplane, which minimizes the
margins, is defined as [122]:
w0 · x+ b = 0
Unfortunately, data coming from biological assays are not ideal, they contain er-
rors. In this case it is impossible to cleanly separate two clusters using a line or a
hyperplane. The SVM algorithm has to be modified to consider this problem and to
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(a) Two classes of points in a two-
dimensional plane
(b) The maximum-margin decision
boundary implemented by the
SVMs
Figure 2.1: Linear separation with hyperplanes (reproduced from Tarca et. al., 2007)
be able to separate the dataset with the minimal number of errors. The presence of
errors can be allowed by introduction of a positive variable ξ called slack variable that
permits to exclude the elements in the training dataset that seem to be experimental
errors. In other words, the hard margin in the original form of the algorithm has been
substituted with a soft margin. This idea can be expressed in mathematical form as
the minimization of the function:
1
2
w2 + CF
(
l∑
i=1
ξi
)
where C is a constant parameter which sets the weight of the slack variables and
F is a monotonic convex function. Large values of C mean that a large penalty is
assigned to errors [124].
In many practical cases, nonlinear classifiers generate better accuracy than linear
classifiers. It is possible to extend the linear SVMs to nonlinear SVMs, if it is required
by the analyzed problem. This extension is provided by using a kernel transformation,
which adds an additional dimension to the dataset. In the transformed feature space,
the kernel transformation enables to linearly separate a dataset that was not separable
in the original feature space [129]. Two examples of kernels, implemented in R and
used in the present work are the polynomial:
k(x,z) = (xzT + 1)d
And the radial basis function (RBF):
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k(x,z) = exp(−γ||x− z||2)
2.2.3 k-Nearest Neinghbors (k-NN)
k-Nearest Neighbors (k-NN) is a simple and fast algorithm that assigns the class label
of an input vector according to the majority class of its closest k-nearest neighbors.
The distance between the input vector and the neighborhood is generally the Euclidian
distance, defined as:
d(p,q) =
√√√√ n∑
i=l
(qi − pi)2
The parameter k is the number of neighbors considered for assigning the class label.
Normally this value is odd, to avoid undecideds.
2.3 Analysis of data
In the two class case with classes 1 (positive) or 0 (negative), the single prediction has
four different outcomes. The true positive (TP) and true negative (TN) are the two
cases of correct classification, while the false positive (FP) and the false negative (FN)
are not. The false positive occurs when the outcome is predicted as positive but it is
actually negative. Otherwise, the false negative occurs when the positive outcome is
incorrectly predicted as negative. The true positive rate is given by [130]:
TP rate =
TP
TP + TN
The true negative rate is otherwise given by:
TN rate =
TN
TP + TN
The overall quality of the prediction is given by the accuracy, expressed as follows:
ACC =
TP + TN
TP + FP + TN + FN
The confusion matrix, an easy representation of the results of a two classes predic-
tion, is given as shown below:
34
2.4 3D QSAR
Positive
predicted
Negative
predicted
Positive observed
(active)
TP FN
Negative observed
(inactive)
FP TN
2.4 3D QSAR
While the classical QSAR methods relate the biological activity of compounds to
their physicochemical parameters, the 3D QSAR methods, particularly comparative
molecular field analysis, take in to consideration also the three-dimensional structures
and the binding modes of protein ligands [131]. One of the first developed 3D QSAR
methods is the Comparative Molecular Field Analysis (CoMFA). This method was
described for the first time by Cramer et. al [132].
The compounds used for CoMFA should be structurally related and should have the
same kind of interaction with the target protein. In contrast to classical QSAR, it is
sufficient that they conserve a common pharmacophore and not necessarily the same
skeleton, as required for classical QSAR.
The first step on performing a CoMFA analysis consists to generate the low energy
3D structure of the most active compound in the chosen molecules set. In the next
step, the other molecules of the dataset are superimposed on to the template structure,
according to the common pharmacophore. The superimposed molecules are finally
placed into a three-dimensional box that is several A˚ larger than the combined volumes
of all molecules. The box is then divided into a regular lattice with a default distance
of 2 A˚ between the grid points (Figure 2.2).
The neutral carbon atom, charged atoms or hydrogen bond donor or acceptors are
used as probe atoms to measure the interaction energies at each grid point (the van
der Waals, the Coulomb and the hydrogen bond interactions, respectively). The van
der Waals interactions are calculated using the Lennard-Jones potential equation:
EvdW =
n∑
i=1
(Aijr
−12
ij − Cijr−6ij )
where EvdW is the sum of the van der Waals interaction energies, rij is the distance
between the atom i and the grid point j, where the probe atom is localized, and Aij
and Cij are constants related to the van der Waals radii of the corresponding atoms.
The Coulomb interactions are calculated using the Coulomb potential equation:
35
2 Materials and Methods (Molecular Modelling)
Figure 2.2: Schematic representation of the CoMFA grid. For clearer representation, only
one molecule is shown and only the outer lines of the grid are drawn.
Ec =
n∑
i=1
qiqj
Erij
where Ec is the Coulomb interaction energy, qi is the partial charge of the atom i, qj
is the charge of the probe atom j, E is the dielectric constant, and rij is the distance
between the atom i and the grid point j, where the positive charge is localized.
As shown in figure 2.3, the Lennard-Jones and the Coulomb potentials can change
their values from very small to very large numbers within an A˚ngstrom fraction. In
order to prevent the presence of too small and too large values in the CoMFA fields,
cut-off values were defined. However, small changes of the molecule orientation could
result in very different results of the CoMFA analysis [134].
In contrast to CoMFA, the comparative molecular similarity indices analysis (CoM-
SIA) [135] does not calculate interaction energies but ’similarity indices’ to probe
atoms. These similarity indices are calculated at the intersections of a regular lattice
[136]. The similarity indices are calculated using the following equation:
AqF,k(j) =
n∑
i=1
Wprobe,kwike
−αr2iq
where AF,k is the similarity index between the molecule and a probe atom placed
at the intersections of the lattice, i is the summation index over all atoms of the
investigated molecule j, wprobe,k is the probe atom with charge +1, radius equal to
1 A˚, and hydrophobicity equal of +1, wik is the actual value of the physicochemical
property k of atom i, α is the attenuation factor, and riq is the mutual distance between
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Figure 2.3: The Lennard-Jones and Coulomb functions used in CoMFA studies compared
to the Gaussian approximation used in CoMSIA studies [131, 133].
the probe atom at the grid point q and the atom i of the molecule.
The use of the Gaussian potential instead of the Lennard-Jones and the Coulomb
potentials leads also to limited energy values also short distances between the atom
and the probe. For this reason, cut-off values are not needed in CoMSIA analysis
(Figure 2.3). The better uniformity of the potential values in the CoMSIA analysis
with respect to the CoMFA analysis allows the calculation of interactions inside the
molecule as well as on the molecular surface. Furthermore, the CoMSIA analysis is not
highly influenced by the orientation of the molecule in the lattice as in CoMFA analysis.
These advantages of the CoMSIA analysis lead generally to better predictivity values
in comparison to the CoMFA analysis.
2.4.1 PLS analysis
The matrix obtained from a CoMFA or a CoMSIA analysis consists of several thousand
columns, while the number of rows (given by the number of molecules in the analysis) is
generally lower than one hundred. For this reason, a normal multiple linear regression
is not possible. The Partial Least Squares (PLS) analysis is the method of choice
for deriving a linear relationship between the activity column (the Y vector) and the
field variables (the X matrix) of CoMSIA and CoMFA analysis. Analogously to PCA,
in the PLS analysis the X matrix (the CoMFA and CoMSIA fields) is decomposed
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into the product of a score matrix and a loading matrix. The columns of the score
matrix are called latent vectors. The latent variables can be considered as linear
combination of the original field variables. The number of components to use for the
analysis is chosen in order to find the maximal correlation between the X and Y values.
The sequential extraction of the components is performed by trying to maximize the
variance of the independent variables an the correlation with the Y vector. The next
extracted component is orthogonal to the previous one and explains a part of the
remaining variance. The extraction of the components is performed until reaching a
maximal number of component or until complete explanation of the variance. The use
of high numbers of components leads to overfitting by the model: In order to prevent
this, the generated 3D QSAR models must be statistically validated.
2.4.2 Validation of 3D QSAR models
The quality of 3D QSAR models is mainly evaluated by using two parameters: the r2
value (the fraction of explained variance) and the q2 value (the cross-validated r2). R2
measures the ability of the 3D QSAR model to describe the variance of the data, or
rather it estimates the fit’s quality of the regression model obtained from the training
set. R2 is calculated as:
r2 = 1−
n∑
i=1
(yi − yˆi)2
n∑
i=1
(yi − y¯)2
where yi is the actual value, yˆi is the value predicted by the model and y¯ is the mean
of the y values.
The q2 value expresses the robustness of the 3D-QSAR model. It is calculated
according to the following equation:
q2 = 1− PRESS
SD
= 1−
n∑
i=1
(Ya − Yp)2
n∑
i=1
(Ya − Ym)2
where PRESS is the predictive sum of squares, SD is the sum of squared deviations,
and Yp is a predictive value. The values of q
2 can be between −∞ and 1. If the
value of q2 is equal to 1, the model is perfect and each point of the model can be
calculated without errors. A value of q2 equal to 0 means that the model is not more
predictive than a model where to each element of the dataset was assigned the average
of the observed activity values as predicted value. A negative q2 value means that the
predicted values are worse than the average of the activity values of the dataset.
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3 Materials and Methods (Biological
testing)
3.1 Materials
3.1.1 Chemicals
Table 3.1: Chemicals used in this work.
Chemicals Manufacturer Article number
Calcein AM Sigma 17783
Calcium chloride dihydrate Merck P 4901
Cyclosporine A Sigma C 3662
D-glucosemonohydrate Merck 1040740500
Dimethylsulfoxide (DMSO) Acros AC 19773
Disodium hydrogenphosphate Applichem A 4732
HEPES (free acid) Appluchem A 3707
Hoechst 33342 Sigma B 2261
Hydrochloric acid (0.5 M) Gru¨ssing 24204
Ko143 Tocris 3241
Magnesium sulfate heptahydrate Applichem A 4101
Melsept SF Braun 18907
Methanol Merck 107018
Mitoxantrone Sigma M 6545
Potassium chloride Merck 104936
Potassium dihydrogenphosphate Applichem A 3095
SN-38 TCI Europe N.V. E 0748
Sodium bicarbonate Merck 106329
Sodium chloride Merck 106404
Sodium hydroxide solution (1 M) Gru¨ssing 22195
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3.1.2 Materials
Table 3.2: Materials for assays and cell culture.
Material Manufacturer Article number
1.0-5.0 mL Bulk, Natural pipette
tips
Starlab 11009-5000
1.5 mL Amber microtubes with
attached pp cap
Sarstedt 72690004
1.5 mL Neutral microtubes with
attached pp cap
Sarstedt 72690001
2.0 mL MaxyClear microtubes Axygen scientific MCT-200-C
96 Well, clear PS microplate, flat
bottom
Greiner bio-one 655098
96F untreated black micro well
SH plate
Nunc 237108
96-Well tissue culture plate, flat
bottom with lid, sterile
Sarstedt 831835
CASYton solution Scha¨rfe System 43001
Conical test tube PP 15 mL, ster-
ile
Nerbeplus GmbH 25027001
Conical test tube PP 50 mL, ster-
ile
Nerbeplus GmbH 25007001
Cryos PP with screw cap, sterile Greiner bio-one 123263
Fetal bovine serum Sigma F 7524
Glas pasteur pipettes (230 mm) VWR international 612-1702
Growth medium D-MEM 5671 Sigma M 5650
Growth medium RPMI-1640 PAN Biotech GmbH P 0416500
Membrane filter 0.2 µm, sterile Whatman 10462200
Norm-Ject 10 mL syringe Henke Sass Wolf 4100-000V0
Norm-Ject 20 mL syringe Henke Sass Wolf 4200-000V0
Penicillin-Streptomycin solution Sigma P 0781
Serological pipette 10 mL, sterile Sarstedt 86.1254.001
Serological pipette 25 mL, sterile Sarstedt 86.1685.001
TipOne 0.1-10.0 µL natural
pipette tips
Starlab S 1111-3000
TipOne 1-200 µL yellow pipette
tips
Starlab S 1111-0006
TipOne 101-1000 µL natural
pipette tips
Starlab S 1111-2020
42
3.1 Materials
Table 3.2: Materials for assays and cell culture.
Material Manufacturer Article number
Tissue culture flasks, 25 cm2,
sterile, filter cap
Greiner bio-one 690175
Tissue culture flasks, 75 cm2,
sterile, filter cap
Greiner bio-one 658175
Tissue culture flasks, 175 cm2,
sterile, filter cap
Greiner bio-one 660175
Trypsin-EDTA solution PAN Biotech GmgH P100231SP
3.1.3 Instruments
Table 3.3: Instruments used in this work.
Instruments Manufacturer Serial number
Accu-Jet suction pump Brand 441938
Avanti centrifuge J-25 Beckman JHY97G35
Axiovert 25 microscope Zeiss 660197
CASY1 model TT Scha¨rfe System SC1 TT
CO2 cell MMM Group -
CO2 water jacket incubator Forma scientific -
FLUOstar Optima fluorescence
plate reader
BMG Lab Technolo-
gies
4131164, 4132279
Laminar flow cabinet (model:
Antares 48)
Steril S.p.A. 10155/1996
pH-Meter 744 Metrohm 20506
Pipette 0.1-2.5 µL Eppendorf 3638475
Pipette 2-20 µL Eppendorf 33407866
Pipette 20-200 µL Eppendorf 3534296
Pipette 100-1000 µL Eppendorf 4741196
Pipette 500-5000 µL Eppendorf 3615095
POLARstar Galaxy fluorescence
plate reader
BMG Lab Technolo-
gies
4030639
RH basic magnetic stirrer IKA Labortechnik 3061661
Vacuum pump BVC21 Brand 08E12592
Vortex stirrer Minishaker Vacuubrand 2.88069E+13
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Table 3.3: Instruments used in this work.
Instruments Manufacturer Serial number
Waterbad type 1083 GFL 11530203
3.2 Cell culture
In this work, cells were aseptically cultivated in T75 flasks (or T175 flasks in case of
cultures used for a backup) and conserved in humidified atmosphere containing 5%
CO2 at 37
◦C. The used culture medium is specific for each cell line. The composition
of each used culture medium will be described in chapter 3.3. To prevent cell stress,
the culture medium was preventively warmed up in warm water at 37 ◦C. The culture
medium contained phenol red, a pH indicator. If the color of the medium (due to
phenol red) changes from red to yellow, the culture medium has to be changed. If the
culture medium had to be changed, the old medium was drawn, using a vacuum pump.
After removing the old culture medium, 15-20 mL of fresh medium was added to a T75
flask and 25-30 mL to a T175 flask. When the cell culture reaches a confluence value
of about 90 %, the cells must be harvested. If cell harvesting was required, first the old
culture medium was removed. In order to detach the cells from the flask surface, 3 mL
of trypsin-EDTA (0.05-% trypsin/0.02-% EDTA) were added to the culture. After 3-5
minutes of incubation at 37 ◦C (15 minutes at 37 ◦C for MDCK cells), 7 mL of fresh
culture medium were added to the culture and the suspension was centrifuged (266 xg,
4 ◦C, 4 min). The supernatant was removed and the cell pellet was then resuspended
in 4-5 mL of fresh culture medium.
3.2.1 Thawing of cells
The vial containing frozen cells was taken from the liquid nitrogen tank and put in
warm water (37 ◦C) under moderate agitation, until ice was no longer visible. The
suspension was transferred under sterile conditions into a T75 flask containing 15-20
mL culture medium and incubated in humidified atmosphere containing 5-% CO2 at
37 ◦C. After 6 h the old medium was removed and new warm (37 ◦C) medium was
added.
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3.2.2 Freezing of cells
Cells were cultivated in a T175 flask until reaching a confluence of about 90 %. When
the ideal confluence was reached, cells were harvested as described in chapter 3.2. The
obtained cell pellet was suspended in 2.7 mL fresh medium. Each vial was then filled
with about 900 µL of the obtained cell suspension and 100 µL of DMSO. The vials
were firstly stored at a temperature of -80 ◦C and than in liquid nitrogen.
3.3 Cell lines
3.3.1 MCF-7 and MCF-7 MX cell lines
The human breast cancer cell line MCF-7 (ECACC No. 86012803) and the mitox-
antrone resistant cell line MCF-7 MX, kindly provided by Dr. E. Schneider (Wadsworth
Center, Albany, NY, USA), were cultivated in RPMI-1640 medium supplemented with
20-% fetal bovine serum, 50 µg/mL streptomycin and 50 U/mL penicillin G. The cells
were incubated in a humidified atmosphere containing 5-% CO2 at 37
◦C.
3.3.2 A2780 and A2780 Adr cell lines
The A2780 and A2780 Adr cell lines were purchased from the European collection of
animal cell cultures (ECACC, Salisbury, Wiltshire, UK). The A2780 cell line (ECACC,
No.93112519, UK) was obtained from a human epithelial ovarian carcinoma. The
A2780 Adr cell line (ECACC, No.93112520, UK) was selected by treating the A2780
cell line with doxorubicine several times. The A2780 and A2780 Adr cell lines were
cultivated in RPMI-1640 medium supplemented with 10-% fetal bovine serum, 50
µg/mL streptomycin and 50 U/mL penicillin G. Cells were incubated in a humidified
atmosphere containing 5-% CO2 at 37
◦C.
3.3.3 MDCK II and MDCK II-BCRP cell lines
The canine kidney cell line MDCK was purchased from the European collection of
animal cell cultures (ECACC No. 84121903). The cell line MDCK II-BCRP was a
kind gif from Dr. A. Schinkel (The Netherlands Cancer Institute, Amsterdam, The
Netherlands). Both cell lines were cultivated in DMEM medium supplemented with
10 % fetal bovine serum and 50 µg/mL streptomycin and 50 U/mL penicillin G.
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3.4 Preparation of the buffer solutions
3.4.1 Preparation of a 5x concentrated Krebs HEPES buffer
Table 3.4: Composition of the Krebs HEPES buffer.
Chemical name Chemical
formula
Molecular
weight (g/mol)
Taken weight
(g)
Sodium chloride NaCl 58.4 17.330
Potassium chloride KCl 74.6 0.876
Potassium dihydrogen
phosphate KH2PO4 136.1 0.408
Sodium hydrogen
carbonate NaHCO3 84.0 0.882
D-glucose monohydrate C6H12O6 · H2O 198.2 5.796
HEPES (free acid) C8H18N2O4S 238.3 5.958
The 5x stock Krebs HEPES buffer was prepared by mixing the substances indicated
in table 3.4 into a 500 mL volumetric flask. The used mass of each substance is
reported on the last column of the table. Distilled water was added to reach a volume
of 450 mL and the pH of the solution was adjusted to 7.4 using 1 M sodium hydroxide.
Finally, distilled water was added until the final volume of 500 mL was reached. The
5x stock Krebs HERPES buffer solution was stored at a temperature of -20 ◦C. The
1x Krebs HEPES buffer was prepared using 100 mL of the 5x stock solution. This
solution was diluted to a volume of 400 mL with distilled water. 650 µL of 1 M calcium
chloride solution and 600 µL of 1 M magnesium sulfate solution were added to the
buffer solution. The final volume of 500 mL was reached adding distilled water. The
1x Krebs HERPES buffer solution was stored at a temperature of -20 ◦C.
3.4.2 Preparation a the PBS buffer
Table 3.5: Composition of the phosphate buffered saline (PBS) buffer.
Chemical name Chemical
formula
Molecular
weight (g/mol)
Taken weight
(g)
Sodium chloride NaCl 58.4 8.0
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Table 3.5: Composition of the phosphate buffered saline (PBS) buffer.
Chemical name Chemical
formula
Molecular
weight (g/mol)
Taken weight
(g)
Potassium chloride KCl 74.6 0.2
Potassium dihydrogen
phosphate KH2PO4 136.1 0.2
Disodium hydrogen
phosphate Na2HPO4 141.9 1.44
The phosphate buffered saline (PBS) buffer was prepared by mixing in a flask the
substances indicated in table 3.5 with about 900 mL distilled water. Afterwards, the
pH was adjusted to 7.4. Finally, the volume of 1000 mL was reached, adding distilled
water. This solution was sterilized by autoclaving (20 min, 121 ◦C, liquid cycle) and
stored at a temperature of 4 ◦C.
3.5 Cell counting using the CASY R© model TT
In order to count the cell number in a cell suspension and to test their viability, 20 µL
of the suspension of cells and culture medium were taken and put into 10 mL of sterile
CASY R©ton solution, an isotonic and iso-osmotic electrolyte (Schaerfe System Ltd.).
The obtained diluted suspension was measured using a CASY R© 1 Modell TT. This
instrument uses two methods: the Electrical Current Exclusion (ECE) and the Pulse
Area Analysis. The Electrical Current Exclusion method is based on the principle
that viable and dead cells suspended in CASY R©ton have different permeability to the
electrical current: Viable cells have an intact membrane that is an electrical insulator,
whereas dead cells posses pores in the membrane that allow the current passage. The
cells in the suspension are drawn one by one trough a capillary with defined diameter
(150 µm). The suspension is than exposed to a low and cycled electrical current.
A decreasing of the electrical signal is correlated with the passage of a cell and is
proportional to the cell volume. Each cell is measured several hundred times by the
machine. The results related to each cell were analyzed by Pulse Area Analysis, a
digital pulse processing technique developed by Schaerfe System Ltd [137]. In the
present work, the dimension limits for viable cells were set between 8 or 10 µm and 40
µm. Particles with diameter bigger than 40 µm were associated with cell agglomerates.
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3.6 Accumulation Assays
3.6.1 Hoechst 33342 assay
NBD NBD
TMD TMD
BCRP
Intracellular
Extracellular
Hoechst Inhibitor
Hoechst
Hoechst
Hoechst 33342
Hoechst 33342
Hoechst 33342
Figure 3.1: Hoechst Assay
Principles of the method
The Hoechst 33342 assay is based on two main aspects: First, the bisbenzimidazole
Hoechst 33342, used in this assay, is a well-known BCRP and P-gp substrate [55].
Second, Hoechst 33342 forms strong and non-covalent complexes with DNA, binding
to the minor groove of DNA [138]. Both, binding to DNA and a lipophilic environ-
ment, like the cell membrane, lead to a several hundred fold increase of the intrinsic
fluorescence of the dye. [139, 140]. In cells not expressing BCRP or P-gp, Hoechst
33342 accumulation gives increasing fluorescence, while in cells expressing one of these
two transporters the Hoechst 33342 accumulation is decreased, due to active efflux of
the dye. In cells expressing BCRP or P-gp ,accumulation of Hoechst 33342 is increased
if a modulator is added. In this case, the accumulation of Hoechst 33342 depends to
the concentration of the modulator and its potency.
Assay execution
Cells were harvested after reaching a confluence of 80-90-% with trypsin-EDTA (0.05-
% trypsin/0.02-% EDTA), centrifuged (266 g, 4 ◦C, 4 min) and than resuspended in
fresh culture medium. The cell density was measured using the Casy I Modell TT cell
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counter device. Later, cells were again centrifuged and the medium eliminated. The
pellet was than resuspended in Krebs-Hepes buffer. 90 µL of this final suspension,
containing 27,000 cells, were seeded into each well of a black 96-well plate and 10
µL of different inhibitor concentrations was added. Finally, the prepared plates were
incubated under 5-% CO2 atmosphere and 37
◦C for 30 minutes. 20 µL of a 6 µM
Hoechst 33342 solution was added to each well. The fluorescence of each well was
measured at constant intervals of 60 seconds, at excitation wavelength of 355 nm
and an emission wavelength of 460 nm, using a BMG POLARstar microplate reader
tempered at 37 ◦C. The data was analyzed considering the fluorescence kinetic as not
linear. With the use of the program Graph Pad Prism (version 5.1) R© it was possible
to fit the kinetic curve as a one-phase exponential association function. For each
modulator concentration, the top of this function was used to build the dose response
curve.
3.6.2 Calcein AM assay
NBD NBD
TMD TMD
P-gp
Intracellular
Extracellular
Calcein Inhibitor
Calcein-AM
Calcein-AM
Esterase
Calcein
Figure 3.2: Calcein Assay
Principles of the method
Calcein acetoxymethyl ester (AM) is a non-fluorescent lipophilic P-gp substrate. Cal-
cein AM is rapidly hydrolyzed by intracellular esterases to the free acid calcein, which
is not a P-gp substrate. Calcein is a fluorescent non-cytotoxic compound with a high
molar emission coefficient. The fluorescence excitation maximum of calcein is 496
nm and its emission maximum is at 517 nm. If calcein AM is administered to P-gp
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expressing cells, the intracellular concentration of calcein AM remains low and conse-
quentially also the total amount of calcein, resulting in low fluorescence. In presence of
P-gp modulators the transport of calcein AM to outside the cells is inhibited, causing
accumulation of calcein in the cells and increasing fluorescence.[141, 142]
Assay execution
The doxorubicin resistant cell line A2780 Adr and the parental cell line A2780 were
grown in RPMI-1640 medium supplemented with 10-% fetal bovine serum, 50 µg/mL
streptomycin, and 50 U/mL penicillin G, in a 5-% CO2 atmosphere at 37
◦C. After
reaching a confluence of about 90-%, the cells were harvested using trypsin-EDTA
solution (0.05-% trypsin/0.02-% EDTA). The cells were centrifuged (266 g, 4 ◦C, 4
min) and than resuspended in fresh culture medium. The cell density was measured
with the Casy I Modell TT cell counter device. Cells were again centrifuged and
the medium eliminated. The pellet was than resuspended in Krebs-Hepes buffer. 90
µL of this final suspension, containing 30,000 cells, were seeded into each well of a
black 96-well plate and 10 µL of different inhibitor concentrations were added. The
prepared plates were than incubated under 5-% CO2 atmosphere and 37
◦C for 30
minutes. Finally, 33 µL of a 1.25 µM calcein-AM solution were added to each well.
The fluorescence of each well was detected at constant intervals of 60 seconds up to 60
min using an excitation wavelength of 485 nm and an emission wavelength of 520 nm
at a temperature of 37 ◦C in a BMG POLARstar microplate reader. The slope of the
initial linear part of each fluorescence-time curve was calculated by linear regression.
Concentration-response curves were generated from the slopes by nonlinear regression
using the 3- or 4-parameter logistic equation (with or without variable Hill slope)
implemented in GraphPad Prism R©.
3.7 MTT assay
N N
NN N
S
CH3
CH3
Br Dehydrogenase
+2e-, +2H+ N
NS
H3C CH3
NH
N N
+ HBr
Figure 3.3: Reduction of the yellow compound MTT to the violet compound Formazan
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Principles of the method
The toxicity of cytotoxic drugs or new substances against several cell lines can be mea-
sured using MTT assay, as described for the first time by Mosmann et. al. [143]. The
method is based on the reduction of the yellow substance 3-(4,5-dimethylthiazole-2-
yl)-2,5-diphenyl tetrazolium bromide, MTT, Thiazolylblau) to violet-colored formazan
precipitate. This reaction is catalyzed by mitochondrial dehydrogenases and it is pos-
sible only in living cells. The absorption of the formazan solution is linearly correlated
with cell viability.
Shift of the dose-response curve of cytotoxic drugs
Cells were seeded into a 96-well tissue culture plates with a density of 10,000 cells
per well (for MCF-7 and MCF-7 MX cells) or 1,250 cells per well (for MDCK cells)
in a total volume of 160 µL and kept at 37 ◦C under 5-% CO2 for 6 h. After the
cells had attached to the well bottom, 20 µL of test compound and 20 µL of cy-
tostatic solution were added. Cells were than incubated for 72 hours and then the
MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) reagent (40 µL
of a 5mg/mL solution) was added to each well. After 90 minutes of incubation with
MTT, the supernatant was removed and cells were lysed with 100 µL DMSO per well.
Viability of the cells was measured with spectrophotometry by absorbance at 544 nm
and background corrected at 710 nm using a BMG POLARstar microplate reader.
Determination of cytotoxicity of the studied compounds
MCF-7 and MCF-7 MX cells were seeded into 96-well tissue culture plates with density
of 10,000 cells per well in a total volume of 90 µL and kept at 37 ◦C under 5 % CO2
for 6 h. After the cells had attached to the bottom of the well, 10 µL of test com-
pound at four different concentrations was added. 10 µL of PBS and 10 µL of DMSO
were used as negative and positive controls respectively. Cells were incubated for 72
h and then the MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide)
reagent (40 µL of a 5mg/mL solution) was added. After 90 minutes of incubation with
MTT, the supernatant was removed and cells were lysed with 100 µL DMSO per well.
Viability of the cells was measured with spectrophotometry by absorbance at 544 nm
and background corrected at 710 nm using a BMG POLARstar microplate reader.
3.7.1 Analysis of the data using GraphPad Prism R©
In this work, the potency of the studied compounds against BCRP and P-gp was
reported as IC50 ± SD values. The fluorescence values obtained by Hoechst 33342
assay and calcein-AM assay were analyzed using the statistics software GraphPad
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Prism R© (version 5.1). In order to calculate the IC50 value of each single dose-response
curve, both the 4-parametric logistic equation and the 3-parametric logistic equation
(with Hillslop equal to 1) were calculated and compared. In case of not complete
inhibition of the transporters at the highest used compound concentrations, the top
values of the test compounds were fixed to the top value of the standard compound.
All assays were performed at least three times and the reported IC50 values are the
reported as mean ± SD.
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4 Investigation of the inhibitory
activity of a new class of tariquidar
analogues.
4.1 Optimization of the Hoechst 33342-assay
The fluorescent compound Hoechst 33342 has been recognized to be a P-gp [32] and
BCRP [144, 145] substrate. Therefore, Hoechst 33342 can be used to investigate
the inhibitory activity of small molecules against those two ABC-transporters. The
Hoechst 33342-assay has been developed by Dr. Henrik Mueller and was used as HTS
(High Throughput Screenig) assay [146].
A goal of this work is the determination of the BCRP inhibitory potency of a new
class of BCRP inhibitors. The determination of the potency of these compounds was
determined using the Hoechst-assay in MCF-7 MX cells. In order to optimize the
quality of the results, parameters of the Hoechst 33342-assay in MCF-7 MX cells, like
the Hoechst 33342 concentration and the used cells number, were optimized.
4.1.1 Optimization of the used Hoechst 33342 concentration
To date, only a relatively small number of BCRP-inhibitors are known. One of these
compounds is the potent P-gp inhibitor XR9577, used in this work as reference com-
pound for the validation of the Hoechst-Assay. The standard protocol developed in
our laboratory by Dr. Henrik Mueller used an Hoechst 33342 final concentration of 5
µM and 27,000 cells in each vial. The relationship between fluorescence and Hoechst
33342 was investigated in MCF-7 cells, MCF-7 MX cells and MCF-7 MX cells to which
the modulator XR9577 was added at a final concentration of 10 µM. The fluorescence
values reported are the difference of the fluorescence measured in the vials containing
buffer, cells and fluorescent substate minus the fluorescence of the vials containing
only buffer and fluorescent substrate.
As shown in figure 4.1, the fluorescence of a 5 µM Hoechst 33342 solution is not in the
linear region of the concentration-fluorescence relationship and is already in a plateau
region. This deviation from linearity is observed in MCF-7 cells and in MCF-7 MX
cells with and without modulator. In all these three cases, the fluorescence increases
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Figure 4.1: Fluorescence of Hoechst 33342 by increasing the substrate concentration (MCF-
7 and MCF-7 MX cells).
with the substrate concentration only until a substrate concentration of about 2 µM.
However, the relationship is linear only until a Hoechst 33342 concentration of about
1.5 µM.
The plateau in the fluorescence of Hoechst 33342 could be due to saturation of the
binding of Hoechst 33342 to the membrane or to the DNA. Another explanation could
be that the relatively high concentration of fluorescent substrate causes quenching
effects. In figure 4.2, the concentration-fluorescence relationship for lower concentra-
tion of Hoechst 33342 up to 1 µM is shown. In this interval of concentrations, the
fluorescence of the cells increases linearly with the concentration of Hoechst 33342.
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Figure 4.2: Fluorescence of Hoechst 33342 versus substrate concentration. The concentra-
tions of Hoechst 33342 were between 0.1 and 1.0 µM(MCF-7 cells at 27,000
cells/well.).
In order to investigate which concentration of Hoechst 33342 should be used to
obtain good quality dose response curves and, several dose response curves for the
modulator XR9577 at different concentrations of Hoechst 33342 were determined. In
figure 4.3a is shown that for concentrations of Hoechst 33342 between 1 and 5 µM,
there is no difference in the span of the obtained dose response curves. The curves
obtained with concentrations of Hoechst 33342 of 3 µM and 5 µM also show very
similar bottom and top values, in agreement with the findings presented in fig 4.1.
The dose response curves obtained using an Hoechst 33342 concentration of 1 µM has
a similar span value as the other two curves, but has lower bottom and top values. The
dose response curves obtained using an Hoechst 33342 concentration of 0.5 µM showed
a further decrease of its bottom and top values and also a considerable reduction of
the span.
As shown in figure 4.3b, all the dose response curves of the modulator XR9577
obtained with Hoechst 33342 concentration between 0.2 and 1 µM gradually present
lower values of bottom, top and span. Those results are consistent with the experiment
on the linearity of the relationship between fluorescence and concentration of Hoechst
33342. Considering the results of the experiments, it was decided to set the Hoechst
33342 concentration for the Hoechst 33342 assay to the value of 1 µM.
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(a) Dose-response curves obtained using
concentrations of XR9577 between
0.5 and 5 µM.
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concentrations of XR9577 between
0.2 and 1 µM.
Figure 4.3: Dependence of the Dose response curve of the modulator XR9577 on the con-
centration of Hoechst 33342 .
4.1.2 Optimization of the cell number.
In order to find the optimal number of cells for each well, the influence of the cell num-
ber on the fluorescence was investigated. The experiment was performed on the same
96-well plate, using MCF-7 cells from the same culture and different concentration of
Hoechst 33342. The results reported in figure 4.4 show that for concentrations lower
than 1 µM the correlation between the Hoechst 33342 concentration and the fluores-
cence remains linear for all used cell numbers. The quality of the linear correlation
also increases with the number of cells, reaching a linear correlation for values higher
than 20,000 cells/well. Also in figure 4.4 it is shown that for values of a cell number up
to 40,000 the fluorescence increases for each Hoechst 33342 concentration with the cell
number. Increasing the cell number in the well to 50,000 cells/well does not increase
the fluorescence further. In figure 4.5 the correlation between the fluorescence and the
number of MCF-7 and MCF-7 MX cells is represented. The relationship was inves-
tigated using cell suspensions with different concentrations of cells and with 10 µM
final concentration of the modulator XR9755 and MCF-7 MX cells without modulator.
In this experiment, the fluorescence of the buffer solution containing Hoechst 33342
at the same concentration was subtracted from the fluorescence in presence of cells.
The results show that the fluorescence increases linearly for cells with and without
modulator.
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(a) 10,000 cells.
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(b) 20,000 cells.
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(c) 40,000 cells.
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(d) 50,000 cells.
Figure 4.4: Linearity of the fluorescence for Hoechst 33342 in relation with the number of
cells in each vial (MCF-7 cells).
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Figure 4.5: Dependence of cell number on the fluorescence in presence or absence of the
modulator XR9577 at a concentration of 10 µM (MCF-7 MX cells). The
Hoechst 33342 concentration is equal to 1 µM.
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Figure 4.6: Dependence of the dose-response curve of the modulator XR9577 on the number
of cells (MCF-7 MX cells). The used Hoechst 33342 concentration is equal to
1 µM.
For cells numbers higher than 36,000 cells/well the fluorescence of the MCF-7 MX
cells treated with Hoechst 33342 at a final concentration of 10 µM does not increase
anymore with the cell number, but reaches a plateau. In figure 4.6 is shown how the
cell number influences the dose response curve parameters. If the concentration of cells
is higher than 36,000 cells/well, the top of the dose response curve does not change
anymore with the cell number. A notable decrease of the top value of the dose response
curve with respect to the curves obtained using 45,000 and 36,000 cells/well is seen for
27,000 cells/well. A further decrease of the span of the dose response curve is observed
if only 18,000 cells/well are used. In conclusion, the use of a cell concentration higher
than 36,000 cells/well leads to the saturation of the fluorescence values of the curve. In
figure 4.5 is also shown that the quality of the curve obtained using 27,000 cells/well is
better than that obtained using higher cells numbers. The use of cells concentrations
lower than 36,000 cells/well is also to prefer considering the cost that the use of high
cells concentrations implies in terms of laboratory materials.
On the other hand, cell concentrations lower than 20,000 cells/well lead to dose
response curves with lower span, what complicates the use of this assay. For those two
reasons, it was decided to use for the next assays a cell concentrations equal to 27,000
cells/well.
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4.1.3 Analysis of the raw data obtained from the Hoechst 33342
assay
0 2000 4000 6000
0
5000
10000
15000
20000
control
0.1 µM
0.2 µM
0.6 µM
1.0 µM
5.6 µM
10 µM
Time (s)
Fl
uo
re
sc
en
ce
 a
. u
.
(a)
-9 -8 -7 -6 -5
0
50
100
WK-X-24 (log M)
Ef
fe
ct
, r
el
at
iv
e 
un
its
(b)
Figure 4.7: (a) Fluorescence against time curves for different concentrations of the modu-
lator Hoechst 33342, generated with the Hoechst 33342 assay in MCF-7 MX
cells. The fluorescence-time curves were analyzed using the one-phase associa-
tion model. (b) Dose-response curve of XR9577 (WK-X-24) in MCF-7 MX cells
obtained from the plateau values of the one-phase association model (pIC50 =
6.30, Hill Slope = 1.24).
In order to determinate if XR9577 (WK-X-24) is able to increase the intracellular
fluorescence of Hoechst 33342, different concentrations of this modulator were added
to MCF-7 MX cells at a concentration of 27,000 cells/well. Afterwards, Hoechst 33342
was added to obtain a final concentration of 1 µM in each well. The fluorescence-
time diagram was registered and analyzed. In figure 4.7a a typical fluorescence-time
curves are shown, obtained with XR9577 as modulator and MCF-7 MX cells. In-
creasing concentrations of the modulator XR9577 also increase the fluorescence and
the fluorescence reaches a maximum after 5000 seconds. The fluorescence-time curves
were approximated by one-phase association functions. Their plateau values were
plotted against the corresponding logarithmic concentrations in order to obtain the
dose-response curve of the modulator. Alternatively, the last fluorescence values of
the fluorescence-time curve (7200 s) can be used and plotted against the logarithmic
concentration of the modulator. In figure 4.7b the obtained sigmoidal dose-response
curve is reported.
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4.2 Determination of the activity of a new class of
BCRP-inhibitors.
4.2.1 Tariquidar analogues with modified anthranilic acid partial
structure
Tariquidar (XR9576) is a potent third generation P-gp inhibitor and also a BCRP-
inhibitor [147, 148]. Several Tariquidar analogues were synthesized in our laboratory
by Dr. Werner Klinkhammer [149]. The structure of Tariquidar can be divided in six
substructures, as illustrated in figure 4.8:
• The tetrahydroisoquinoline residue
• The first aromatic ring
• The first linker
• The second aromatic ring
• The second linker
• The third aromatic ring
N
H
NH
N
O
NO
O
O
O
O
First linker 
Tetrahydroisoquinoline 
residue 
Second linker 
First aromatic 
ring 
Second aromatic 
ring 
Third aromatic 
ring 
Figure 4.8: Elements of the Tariquidar structure.
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N
H
NH
RO
OHO
Figure 4.9: General structure of the selective BCRP-inhibitors synthesized by Werner
Klinkhammer. R = phenyl (WK-X-7), R = 3-chinolinyl (WK-X-8), R =
2-nitrophenyl (WK-X-9), R = 2-aminophenyl (WK-X-20), R= 4-nitrophenyl
(WK-X-27, also known as KS-176), R = 4-methylphenyl (WK-X-28).
Dr. Werner Klinkhammer synthesized six compounds without the tetrahydroiso-
quinolin residue, that was replaced by a hydroxyl group. The biological results showed
that these compounds were BCRP-inhibitors but not P-gp or MRP inhibitors [150].
The loss of P-pg inhibitory activity is probably due to the absence of the basic ni-
trogen of the tetrahydroisoquinoline moiety in these compounds. That seems to be
important for the P-gp inhibitory activity of different classes of compounds [151]. At
a later stage, Dr. Kerstin Steggeman synthesized more compounds of this new class of
anthranile amide derivates, with modifications of the above named substructures into
which the structure of Tariquidar can be divided.
A goal of this work was the characterization of the BCRP-inhibitory activity of
these compounds, using the Hoechst 33342 assay. The inhibitory activity against P-gp
was also measured using the calcein-AM assay, in order to determinate the selectivity
of the compounds for BCRP. For selected compounds the capacity to reverse the
resistance against cytostatic compounds of cells expressing BCRP was evaluated using
the MTT assay. The MTT assay was also used to determinate the cytotoxicity of
selected compounds.
4.2.2 Characterization of the inhibitory activity of the compound
WK-X-27
Between the selective inhibitors synthesized by Werner Klinkhammer, the most active
is the compound WK-X-27 (KS-176). It shows an IC50 value of 1.58 µM and does not
has an inhibitory effect on P-gp.
The inhibitory activity against BCRP of compound KS-176 was tested using the
Hoechst 33342 assay, while the the inhibitory activity for P-gp was tested using the
calcein AM assay. As shown in figure 4.10, KS-176 is able to increase the accumulation
of Hoechst 33342 in MCF-7 MX cells with increasing concentrations.
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Figure 4.10: Dose-response curve of WK-X-27 (KS-176). The BCRP inhibitory activity
was tested using the Hoechst 33342 assay and MCF-7 MX cells.
To investigate the reversal of BCRP-mediated resistance by KS-176, the toxicity of
mitoxantrone and Hoechst 33342 were determined in the presence and absence of this
compound. Cell viability was determined by the MTT assay. The cytotoxicity of mi-
toxantrone was determined in parenteral MCF-7 and resistant MCF-7 MX cells, while
the cytotoxicity of Hoechst 33342 was determined in parenteral MDCK and resistant
MDCK BCRP cells. MDCK BCRP cells were included because in this transfected cell
line the resistance can be solely attributed to the presence of BCRP. The IC50 values
of mitoxantrone were determined for parenteral MCF-7 cells and resistant MCF-7 MX
cells without the addition of inhibitor and in the presence of two different inhibitor
concentrations. Figure 4.11a shows the effect of compound KS-176 on the EC50 value
of mitoxantrone in MCF-7 cells. In the presence of an inhibitor concentration of 5 µM,
a significant decrease in resistance is observed, and in presence of compound KS-176
at 10 µM the resistance is fully reversed and the cytotoxicity of mitoxantrone is re-
stored, leading to a sensitivity of the MCF-7 MX cell line almost identical to that of
the parental MCF-7 cells. This result shows that this compound is able to reverse the
resistance of MCF-7 MX cells against mitoxantrone completely. Figure 4.11b shows
the dose-response curve of Hoechst 33342 in the presence of compound KS-176. The
shift in the dose-response curves of MDCK BCRP cells caused by progressively higher
inhibitor concentrations of compound KS-176 indicates that this compound also dose-
dependently inhibits BCRP-mediated resistance to Hoechst 33342. The results prove
the conclusions that the inhibitory effect of compound KS-176 is not substrate depen-
dent.
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Figure 4.11: (a) The effect of compound KS-176 on the EC50 value of mitoxantrone in
MCF-7 cells (green) and MCF-7 MX cells (red) investigated at a concentra-
tion of 5 and 10 µM. Cells in absence of the inhibitor were used as control.
Data is the average ±SD from three independent experiments. (b) Shift of
the dose-response curve of Hoechst 33342 caused by increasing inhibitor con-
centration. MDCK BCRP cells (empty square), MDCK BCRP cells + 5 µM
KS-176 (black square), MDCK BCRP cells + 10 µM KS-176 (empty triangle),
parental MDCK cells (red down triangle)
4.2.3 Variations of the first linker
The first linker of the structure of this new class of BCRP inhibitors was modified
in order to understand and clarify the structure activity relationship for this class
of compounds. Compound KS-176 is used as reference. As reported in table 4.1, the
variations of the first linker generally lead to low active or inactive compounds and only
in one case enhancement of activity is observed. All compounds having modifications
of the first linker, with exception of the compound KS-311, have also exclusion or
substitution of the carboxylic group in the anthranilic acid substructure or insertion
of one or more atoms between the carboxylc group and the aromatic ring. The direct
binding of carbonyl group of the amide to the aromatic ring seems to be important
for the activity of these compounds, probably because of the hydrogen bridge that
forms between the nitrogen of the anthranile amide substructure and the oxygen of
the carbonyl group. This intramolecular interaction could be important to maintain
the correct conformation of the molecule in the binding site of the protein. The results
showed also that for the modified compounds, the presence of rotatable linkers leads to
active compounds, in respect to the not rotatable homologue. For example, compound
KS-360, with the insertion of an ethenyl group between the second aromatic ring and
the carboxylic group does not show any inhibitory activity at a concentration up to 10
µM. KS-366 is structurally similar to KS-360, but it possesses an ethyl group instead
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of the ethenyl group. The cellular testing revealed that compound KS-366 is a BCRP
inhibitor with an IC50 value of 7.58 µM. An other example involves the compounds KS-
364 and KS-357, which differ only by the presence of an amide nitrogen in the linker
(compound KS-357). The presence of this amide nitrogen leads to loss of activity, with
respect to compound KS-364 (IC50 = 9.69 µM). This amide nitrogen probably confers
a higher rigidity to the linker as compared to compound KS-364 due to the mesomeric
effect of the urea linker. The length of the linker also influences the activity of the
compounds. Comparing compounds KS-366 and KS-364, which have an alkyl linker
between the central aromatic ring and the carbonyl group of the amide, the inhibitory
activity against BCRP increases with the length of the linker (IC50 = 7.58 µM for KS-
366 and IC50 = 9.69 µM for KS-364). The presence of heteroatoms directly connected
to the second aromatic ring, as for example in compounds KS-351 and KS-392 leads to
a loss of activity. The best compound with a modified first linker is compound KS-311,
with an ethyl group between the amide and the first aromatic group. This compound
shows an IC50 value of 0.64 µM, also lower than compound KS-176. In conclusion, the
carbonyl group of the first linker is important for the activity of this class of compounds
and must be directly connected to the second aromatic ring. The inhibitory activity
against BCRP is also increased by insertion of an alkyl linker between the amide linker
and the first aromatic ring, as in compound KS-311.
Figure 4.12: Summary of structural features of the investigated compounds influencing
BCRP inhibitory activity.The symbols + and - are used to indicate if the
considered feature plays a favorable or an unfavorable role for the activity of
the compounds.
Additionally, the inhibitory activity against P-gp was investigated for those com-
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pounds. The results showed that the insertion of the alkyl group after (compound
KS-311) or before (compound KS-366) the amide group of the linker leads to a weak
P-gp inhibition. In case of compound KS-366, the IC50 is 14.5 µM, slightly lower than
of compound KS-311, that has an IC50 value of 25.4 µM. Also compound KS-392, with
sulfonamide group as first linker is a weak P-gp inhibitor, with an IC50 value of 20.8
µM.
Table 4.1: Inhibitory activity of compounds with variations of the first linker. Activ-
ities were measured using Hoechst 33342 assay and MCF-7 MX cells for
BCRP (reference substance WK-X-24: IC50 = 0.90± 0.07 µM) and calcein
AM assay and A2780 Adr cells for P-gp (reference substance WK-X-24:
IC50 = 0.41± 0.08 µM). n.a. = no activity for concentration up to 10 µM.
Formula Compound
IC50 BCRP µM ±
SD
IC50 P-gp µM ±
SD
N
H
NH
O
OH
NO2
O
KS-176 1.58 ± 0.36 n.a.
NH
O
NO2
N
H
O OH
KS-360 n.a. n.a.
NH
O
NO2
N
H
O OH
KS-366 7.58 ± 1.20 14.5 ± 3.9
O
NH
O
CF3
N
H
O OH
KS-351 n.a. n.a.
NH
O
NO2
H
NO
OH
KS-364 9.69 ± 2.65 n.a.
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Formula Compounds
IC50 BCRP µM ±
SD
IC50 P-gp µM ±
SD
NH
NH
O
NO2
H
NO
OH
KS-357 n.a. n.a.
N
H
O2
S
NH
O
OH
NO2
KS-392 n.a. 20.8 ± 5.9
N
H
NH
O
NO2
O OH
KS-311 0.644 ± 0.149 25.4 ± 7.7
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4.2.4 Variations of the second linker
The modification of the second linker of this class of compounds does not strongly
decrease their activity, as observed with the modification of the first linker. As shown
in table 4.2, the insertion of an alkyl group between the amide and the third aromatic
ring leads to loss of activity (compound KS-181). The structurally related compound
KS-094, with an urea linker instead of the amide group, is a BCRP inhibitor with a
IC50 value equal of 4.04 µM. Compound KS-367 differs from compound KS-094 only by
the presence of a trifluoromethyl group instead of the nitro group on the third aromatic
ring. Its BCRP inhibitory activity is slightly lower than of compound KS-094 (IC50
= 7.21 µM). The difference of the activity between compounds KS-181 and KS-094
could be explained with the different orientation which the nitrogen of the urea linker
confers to the third aromatic group.
Figure 4.13: Superposition of the compound KS-176 (reference compound) with com-
pounds KS-181 and KS-094. The orange substructure belongs to compound
KS-181, while the green substructure belongs to compound KS-094.
To explain the remarkable difference in the activity of these three compounds, the
three molecular structures of compounds KS-176, KS-181 and KS-094 were aligned
first. Then, the common parts of the three compounds (the first aromatic ring, the
first linker and the second aromatic ring) were fixed. Next, the unfixed parts of the
structures (the second linker and the third aromatic ring) were minimized using PM3
(MOPAC) calculation. The flexible alignment, and the structure minimizations were
performed using the program MOE [97]. The results of this calculation showed that
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the compounds KS-176 and KS-094 have the same orientation of the third aromatic
ring, while the orientation of the third aromatic ring for compound KS-181 is rotated
by about 45◦ with respect to the axis of the other two compounds. This difference
of orientation is due to the tetrahedral geometry of the alkyl linker, while the ge-
ometry of the amide and urea linkers is quite planar. This different ring orientation
for compound KS-181 could cause loss of important non-covalent interactions of the
compound with the binding site and consequently loss of the inhibitory activity. In
support of this assumption, the introduction of an oxygen between the alkyl linker and
the third aromatic ring, as in case of compound KS-187, restores the inhibitory po-
tency against BCRP and the IC50 value of this compound (7.69 µM) is comparable to
that of compound KS-094. The BCRP inhibitory activity of compound KS-187 could
be explained by the change of the orientation of the third aromatic ring with respect
to compound KS-181. This new orientation is similar to that of compound KS-094.
This hypothesis was confirmed by the superposition of the minimized structures of
compound KS-187 and compound KS-094.
The three compounds with an ethenyl group between the amide and the third aro-
matic ring were found to be BCRP inhibitors. Compound KS-186, with a nitro group
at para position on the third aromatic ring, is a good BCRP inhibitor, with an IC50
value equal of 2.93 µM. Compound KS-257, with a chlorine as substituent at para po-
sition on the third aromatic ring is slightly more active than compound KS-186, with
an IC50 value of 1.85 µM, comparable to that of the reference compound KS-176. The
last compound of this series with an ethenyl group in the second linker, compound
KS-246, possesses an IC50 value of 0.52 µM and is the most active compound in this
group. This high inhibitory activity could be explained by the electronic effect of the
two chlorine substituents at ortho positions on the third aromatic ring. This effect
could modify the electronic density of the aromatic ring and the interactions of this
ring with the binding site of BCRP.
The last compound of this series is KS-290, has an amino group as linker between
the second and the third aromatic ring. This compounds is not a BCRP inhibitor,
probably due to the disadvantageous orientation of the third aromatic ring or to the
too low distance between the two aromatic rings.
Regarding the inhibitory activity of these compounds against P-gp, only two of them
have a detectable capacity to inhibit this protein. Both of these compounds have an
ethenyl group in the second linker, between the amide and the third aromatic ring.
The best P-gp inhibitor in this series is compound KS-186, with an IC50 value equal
of 6.62 µM. Compound KS-246 is also able to inhibit P-gp, but with an IC50 value
of only 11.0 µM. The third compound with an ethenyl group in the linker does not
inhibit the transport mediated by P-gp.
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Table 4.2: Activity of compounds with variations in the first linker. Activities were
measured using Hoechst 33342 assay and MCF-7 MX cells for BCRP (refer-
ence substance WK-X-24: IC50 = 0.90±0.07 µM) and calcein AM assay and
A2780 Adr cells for P-gp (reference substance WK-X-24: IC50 = 0.41±0.08
µM). n.a. = no activity for concentration up to 10 µM.
Formula Compound
IC50 BCRP µM ±
SD
IC50 P-gp µM ±
SD
N
H
NH
O
OH
NO2
O
KS-176 1.58 ± 0.36 n.a.
N
H
NH
O
OHO
NO2
KS-181 n.a. n.a.
N
H
NH
NHO
OHO
NO2
KS-094 4.04 ± 0.48 n.a.
N
H
NH
NHO
OHO
CF3
KS-367 7.21 ± 4.88 n.a.
N
H
NH
OO
OHO
NO2
KS-187 7.69 ± 0.55 n.a.
N
H
NH
O
OHO
NO2
KS-186 2.93 ± 0.59 6.62 ± 0.98
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Formula Compounds
IC50 BCRP µM ±
SD
IC50 P-gp µM ±
SD
N
H
NH
O
OHO
Cl
KS-257 1.85 ± 0.75 n.a.
N
H
NH
O
OHO
Cl
Cl
KS-246 0.52 ± 0.10 11.03 ± 4.24
N
H
NH
OHO
KS-290 n.a. n.a.
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4.2.5 Reduction of the scaffold size
Figure 4.14: Diagram of the scaffold reduction for the antranile amide derivates.
In order to verify if is possible to further reduce the size of the scaffold of this class of
BCRP inhibitors, a series of compounds without the first or third aromatic ring or with
other substituents instead of the aromatic rings were synthesized by Dr. Steggemann.
The reduction process could be summarized in three phases and it is shown in figure
4.14. In the first phase the substituent on the first aromatic ring (highlighted in blue)
was replaced by a hydroxy group directly bound to the aromatic ring. In the second
phase the first and third aromatic rings (the green points in the figure) were replaced
by aliphatic rings, in order to test if aromaticity at this position is really necessary for
activity. In the third phase the first or third aromatic ring was deleted (highlighted in
orange).
As shown in table 4.3, the cellular testing results showed that the replacement of
hydroxyethyl group by a phenolic hydroxy group (compound KS-251) leads to high
BCRP inhibitory activity, with an IC50 value for this compound equal of 1.76 µM. This
result suggests that the hydroxyethyl group is not necessary for the BCRP inhibitory
activity of these compounds and could be simplified.
The deletion of the third aromatic ring or its replacement by an aliphatic cyclohexyl
ring leads to loss of the inhibitory activity against BCRP. In particular, the complete
deletion of the second linker with deletion of the third aromatic ring, as for compound
KS-092, leads to loss of the BCRP inhibitory activity. The replacement of the third
aromatic ring by a methyl group (compound KS-293) as well as by a cyclohexyl ring
(compound KS-170) leads also to loss of the inhibitory activity for BCRP. In the light
of these results, the third aromatic ring seems to be essential for the BCRP inhibitory
activity of this class of compounds.
When the first aromatic ring is replaced by a 4-hydroxycyclohexyl group, the BCRP
inhibitory activity decreases but does not disappear. This is the case for compounds
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KS-305 and KS-304, with IC50 values of 6.11 µM and 3.35 µM respectively. Otherwise,
the complete deletion and its replacement by an ethyl group, as for compound KS-
328, leads to a loss of BCRP inhibitory activity. These results indicate that the first
aromatic ring increases the BCRP inhibitory activity of this class of compounds but
is not inherently essential for the activity of these inhibitors as it can be changed to a
cyclic aliphatic group.
The calcein-AM assay results show that the last three compounds KS-305, KS-304
and KS-251 are also weak inhibitors of P-gp with IC50 values higher than 20 µM. This
result suggests that probably the hydroxyl group directly bound to the ring system
leads to an increase of the P-gp inhibitory activity.
Table 4.3: Activity of compounds with reduction of the scaffold. Activities were mea-
sured using Hoechst 33342 assay and MCF-7 MX cells for BCRP (reference
substance WK-X-24: IC50 = 0.90 ± 0.07 µM) and calcein AM assay and
A2780 Adr cells for P-gp (reference substance WK-X-24: IC50 = 0.41±0.08
µM). n.a. = no activity for concentration up to 10 µM.
Formula Compound
IC50 BCRP µM ±
SD
IC50 P-gp µM ±
SD
N
H
NH
O
OH
NO2
O
KS-176 1.58 ± 0.36 n.a.
N
H
NH2
OHO
KS-092 n.a. n.a.
N
H
NH
CH3O
OHO
KS-293 n.a. n.a.
N
H
NH
O
OHO
KS-170 n.a. n.a.
N
H
NH
O
NO2
O
CH3
KS-328 n.a. n.a.
74
4.2 Determination of the activity of a new class of BCRP-inhibitors.
Formula Compounds
IC50 BCRP µM ±
SD
IC50 P-gp µM ±
SD
N
H
NH
O
OH
NO2
O
KS-305 6.11 ± 2.58 51.8 ± 12.1
N
H
NH
O
OH
CF3
O
KS-304 3.35 ± 1.06 20.8 ± 4.4
N
H
NH
O
OH
NO2
O
KS-251 1.76 ± 0.18 27.5 ± 1.9
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4.2.6 Variations on the second aromatic ring
The variations on the second aromatic ring involved the positions 4 (R1) and 5 (R2) of
the ring, with insertion of substituents such as chlorine, methyl and methoxyl groups on
those positions. The third aromatic ring is substituted with 4-nitro, 4-trifluoromethyl
or chlorine groups. Compound KS-274 has a naphthyl group instead.
N
H
NH
O
OH
X
O
R1
R2
Figure 4.15: Positions of the substituents on the second aromatic ring.
As reported in table 4.4, in compounds with a 4-nitro substituent on the third aro-
matic ring, the presence of any substituent on the second ring decreases the inhibitory
potency of these compounds relative to that of the reference compound, KS-176. The
substitution at position R2 causes a slight decrease in activity (compounds KS-191,
KS-401, and KS-282), whereas substitution at R1 leads to a more remarkable decrease
in activity (compounds KS-206, KS-399, and KS-249).
The presence of a methoxy group at position R2 (compound KS-191) results in a
slight decrease in activity (IC50 = 3.93 µM), but at position R
1 the presence of the
same substituent (in KS-206) decreases the inhibitory activity by about 5 fold (IC50
= 8.43 µM).
The same trend is observed with methyl substituents: A methyl group at position
R2 (compound KS-401) decreases the activity (with respect to compound KS-176) to
an IC50 value of 2.69 µM, whereas the same substitution at position R
1 (compound
KS-399) gives an even less active compound, with an IC50 of 4.08 µM. Compounds with
chlorine substituents at positions R1 (KS-249) or R2 (KS-282) have similar inhibitory
effects against BCRP (IC50 values of 3.09 and 2.59 µM, respectively).
As shown in figure 4.16 the activity of the substituted compounds decreases linearly
with increasing van der Waals volume of the substituted aromatic ring, as calculated
with the software MOE [97]. This unfavorable steric effect is more evident at position
R1 than at position R2.
Compound KS-196, which has methyl groups at both positions and compound KS-
274 with a naphthol group instead are slightly more active than expected. In case of
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Figure 4.16: Plot of the van der Waals volumes of the substituted second aromatic ring
versus pIC50 values for compounds with a substituent on the second aromatic
ring at position R1 (circles) and with substitution at position R2 (triangles).
compound KS-196, this effect could be explained by the predominance of the steric
effect at position R1 over the effect at position R2 or by additional interaction of the
compound with the protein. The activity of compound KS-274 could be explained with
an extra interaction of the additional aromatic ring with the binding site. Compounds
KS-308, and KS-294 and KS-255 possess IC50 values lower than expected and they do
not follow the QSAR observed for the nitro series of compounds. These exceptions
could be explained from the plot of the three principal components of the 2D and
3D molecular descriptors calculated for the compounds containing substituents on the
second aromatic ring. It is seen that the compounds included in the QSAR are grouped
into a cluster, while the molecules that do not follow the QSAR, including compounds
KS-196 and KS-274, are outside the cluster.
Regarding the principal component analysis, the first component is high correlated
with the van der Waals surface area, while the second component is high correlated
with the lipophily. For the other compounds, the relevant modification of those two
parameters in respect to the reference compound could lead to a different kind of
interaction with the transporter or with the membrane and resulting to a consequential
effect on the IC50 values.
All together, the SAR of the second aromatic ring may be explained by a disad-
vantageous steric interaction of the substituents with the binding site of the protein.
This explanation of the activity differences is possible only for compounds with similar
global dimension and lipophily values.
The only two compounds of this group possessing an inhibitory activity against P-
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Figure 4.17: The chemical space of the compounds with a substituent on the second aro-
matic ring, obtained by plotting the three principal components of the 2D
and 3D molecular descriptors calculated using MOE. The green spheres are
associated with the compounds included in the QSAR, while the red spheres
are associated with the compounds not included in the QSAR.
gp are the compounds KS-294 and KS-255, with IC50 values of 18.1 µM and 2.54 µM
respectively. This effect could be related to the high lipophily of the compounds.
Table 4.4: Activity of compounds with variations on the second aromatic ring. Ac-
tivities were measured using Hoechst 33342 assay and MCF-7 MX cells for
BCRP (reference substance WK-X-24: IC50 = 0.90± 0.07 µM) and calcein
AM assay and A2780 Adr cells for P-gp (reference substance WK-X-24:
IC50 = 0.41± 0.08 µM). n.a. = no activity for concentration up to 10 µM.
Formula Compound
IC50 BCRP µM ±
SD
IC50 P-gp µM ±
SD
N
H
NH
O
OH
NO2
O
KS-176 1.58 ± 0.36 n.a.
N
H
NH
O
OH
NO2
O
H3CO
H3CO
KS-196 6.96 ± 2.20 n.a.
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Formula Compounds
IC50 BCRP µM ±
SD
IC50 P-gp µM ±
SD
N
H
NH
O
OH
NO2
O
H3CO
KS-206 8.43 ± 1.63 n.a.
N
H
NH
O
OH
CF3
O
H3CO
KS-308 0.928 ± 0.308 n.a.
N
H
NH
O
OH
NO2
O
H3CO
KS-191 3.93 ± 0.11 n.a.
N
H
NH
O
OH
CF3
O
H3CO
KS-294 4.02 ± 1.48 18.1 ± 3.1
N
H
NH
O
OH
NO2
O
H3C
KS-399 4.08 ± 0.48 n.a.
N
H
NH
O
OH
NO2
O
H3C
KS-401 2.69 ± 0.86 n.a.
N
H
NH
O
OH
NO2
O
Cl
KS-249 3.09 ± 0.22 n.a.
N
H
NH
O
OH
Cl
O
Cl
KS-255 1.54 ± 0.22 2.54 ± 0.29
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Formula Compounds
IC50 BCRP µM ±
SD
IC50 P-gp µM ±
SD
N
H
NH
O
OH
NO2
O
Cl KS-282 2.59 ± 0.87 n.a.
N
H
NH
O
OH
NO2
O
KS-274 4.58 ± 0.35 n.a.
4.2.7 Variations on the third aromatic ring
The activity of the compounds with modifications on the third aromatic ring (reported
in table 4.5) is correlated with the electronic effect of the substituents present on this
ring and with the lipophilicity of the aromatic system. The best correlation uses the σ-
Hammet parameter and the hydrophobic surface area of the substituted ring (equation
4.1). The σ values were selected with the amide group as reference position. Vsurf S
is the interaction surface area of the substituted aromatic ring calculated with MOE
[97]. The relative importance of the two descriptors is 1 for σ and 0.963 for Vsurf S.
Figure 4.18 shows the plot of observed versus calculated pIC50 values.
pIC50 = 0.503× σp+m + 0.00932× Vsurf S + 3.010 (4.1)
n = 13, r2 = 0.81, s = 0.156, F = 45.9
A possible explanation for this trend could be given by the interaction of the aro-
matic ring system at position R2 with aromatic residues of the protein binding site and
the consequential pi-pi stacking. Furthermore, the presence of bulky substituents with
a large contact surface area on this ring increases the affinity of the ligands and hence
the inhibitory activity. However, two compounds were excluded from the correlation.
The first of these excluded compounds, KS-405, is less active than calculated from the
equation. A hypothesis suggested by the similar activity values of compounds KS-405
and KS-406 is the possible hydrolysis of the ester group to a phenolic hydroxy group
under the assay conditions. To test this hypothesis, TLC was performed with com-
pound KS-405 after various incubation times in assay buffer at 37◦C. After 10 minutes
80
4.2 Determination of the activity of a new class of BCRP-inhibitors.
4.5 5.0 5.5 6.0
4.5
5.0
5.5
6.0
KS-406
KS-159
KS-371
KS-190
KS-169
KS-238
KS-157
KS-162
KS-144
KS-242KS-176
KS-150
KS-407
pIC50  measured
pI
C
50
 c
al
cu
la
te
d
Figure 4.18: Plot of measured versus calculated potencies for inhibition of BCRP in MCF-7
MX cells according to equation 6.1 for compounds with variation on the third
aromatic ring.
incubation, the original spot disappeared and a new spot was observed with the same
Rf value as that of compound KS-406. Thus it can be concluded that compound KS-
405 is not stable under the assay conditions. The second outlier from the correlation is
compound KS-237, with a chlorine group in ortho position of the third aromatic ring.
This compound was found to be not active against BCRP. A possible explanation
could be an interaction (steric and electrostatic) of the chlorine group with the oxygen
of the amide of the second linker. This interaction would changes the orientation of
the aromatic ring.
Regarding the selectivity of these compounds, most of them were not able to inhibit
P-gp. However, some exceptions were observed. The highest inhibitory activity against
P-gp was measured for compound KS-157, which contains a dimethoxy substituent.
This is in agreement with P-gp inhibitors from different structural classes, for which
this substitution pattern was found to be advantageous [152].
The presence of a voluminous lipophilic group on the third aromatic ring, as in
compounds KS-162 and KS-407, results in a weak inhibitory activity against P-gp.
The amino derivates KS-159 and KS-371 also show some inhibition of P-gp, while
from the corresponding nitro compounds only the 3-nitro derivative showed some,
albeit low inhibitory activity against P-gp. Very low inhibitory activity against P-gp
was also observed for compound KS-237 (IC50 = 18.8).
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Table 4.5: Activity of compounds with variations on the third aromatic ring. Activities
were measured using Hoechst 33342 assay and MCF-7 MX cells for BCRP
(reference substance WK-X-24: IC50 = 0.90 ± 0.07 µM) and calcein AM
assay and A2780 Adr cells for P-gp (reference substance WK-X-24: IC50 =
0.41± 0.08 µM). n.a. = no activity for concentration up to 10 µM.
Formula Compound
IC50 BCRP µM ±
SD
IC50 P-gp µM ±
SD
N
H
NH
O
OH
NO2
O
KS-176 1.58 ± 0.36 n.a.
N
H
NH
O
OHO
NO2
KS-150 1.31 ± 0.25 21.28 ± 0.29
N
H
NH
O
OHO
NH2
KS-159 8.65 ± 2.37 14.0 ± 4.2
N
H
NH
O
OH
CN
O
KS-144 2.54 ± 0.20 n.a.
N
H
NH
O
OH
Cl
O
KS-169 3.09 ± 1.32 n.a.
N
H
NH
O
OHO
Cl
KS-238 3.48 ± 0.54 n.a.
N
H
NH
O
OHO
Cl
KS-237 n.a. 18.8 ± 1.3
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Formula Compounds
IC50 BCRP µM ±
SD
IC50 P-gp µM ±
SD
N
H
NH
O
OH
CF3
O
KS-242 2.20 ± 0.57 n.a.
N
H
NH
O
OHO
KS-190 4.59 ± 0.57 n.a.
N
H
NH
O
OHO
OH
KS-406 21.2 ± 3.7 n.a.
N
H
NH
O
OHO
NH2
KS-371 8.12 ± 1.00 15.5 ± 2.1
N
H
NH
O
OHO
C(CH3)3
KS-162 2.95 ± 0.83 11.7 ± 3.9
N
H
NH
O
OH
O
O
CH3
CH3
KS-407 1.16 ± 0.29 8.42 ± 2.45
N
H
NH
O
OHO
O CH3
O
KS-405 12.8 ± 2.1 n.a.
N
H
NH
O
OHO
OCH3
OCH3
KS-157 3.61 ± 0.96 7.75 ± 1.19
83
4 Investigation of the inhibitory activity of a new class of tariquidar analogues.
4.2.8 Variations on the first aromatic ring
The ethyl alcohol on the first aromatic ring was modified especially for compounds
possessing 4-nitro, 4-trifluoromethyl and chlorine groups on the third aromatic ring.
The results are reported in table 4.6. The cellular test results showed that the substi-
tution of the hydroxyethyl group with a phenolic hydroxy group does not significantly
change the activity of the compound with respect to the reference compound KS-176
(compound KS-251, IC50 = 1.76 µM). The same effect was observed for the pair of
compounds containing a 4-trifluoromethyl substituent on the third aromatic ring. The
inhibitory activity of compound KS-342 (IC50 = 1.80 µM), with a hydroxy group on
the first aromatic ring is very similar to that of compound KS-242 (IC50 = 2.20 µM),
its homologue with the hydroxyethyl group at the same position. The same trend is
also observed for compounds possessing a chlorine group at position 4 on the third
aromatic ring: The inhibitory activity of the phenolic compound KS-252 (IC50 = 2.91
µM) is very similar to that of its homologue KS-169, with the hydroxyethyl group
(IC50 = 3.09 µM). Exceptions from this trend are compounds with 3,4-dimethoxy sub-
stituents on the third aromatic ring. For this subclass of compounds, the exchange
of the hydroxyethyl group by a phenolic hydroxy group leads to an increase of the
inhibitory activity against BCRP, as observed for compound KS-265 (IC50 = 1.16 µM,
three fold more potent than compound KS-157).
The methylation of the penolic hydroxy group in para position on the first aromatic
ring reduces the BCRP inhibitory activity to an IC50 value of 3.56 µM (compound
KS-267). For compounds with 3,4-dimethoxy substitution on the third aromatic ring,
the introduction of a methoxy group also on the first aromatic ring does not change the
inhibitory activity against BCRP (IC50 = 3.34 µM for compound KS-266 against IC50
= 3.61 µM for compound KS-157. The structure and activity of compound KS-157
are reported in table 4.1.). If the third aromatic ring is substituted with a 4-chlorine
group, the introduction of a methoxyl group on the first aromatic ring leads to loss of
activity.
The methylation of the hydroxyethyl group leads to opposite results for compounds
possessing 4-nitro and 4-trifluoromethyl groups. Indeed, compound KS-292 has an IC50
value of 1.23 µM, a bit lower than the reference compound, while compound KS-322
has an IC50 value of 5.11 µM, two fold higher than that the homologue KS-242.
The acetylation of the hydroxyethyl group was investigated for the compound with
a 4-nitro group on the third aromatic ring (compound KS-194). This compound has
an IC50 value of 1.32 µM, slightly lower than the reference compound KS-176.
The increase of inhibitory activity was obtained with the replacement of the hy-
droxyethyl group by a benzoyl group. The two compounds with this substitution on
the first aromatic ring, KS-174 and KS-184, contain a 4-nitro and a methyl group
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Figure 4.19: 3D plot of the SlogP, PM3 HOMO and VSA descriptors of the substituted
first aromatic ring. The red points are associated to substituted aromatic
rings present in compounds without inhibitory activity against BCRP, if the
substituent on the third aromatic ring is a 4-nitro group. The green points are
related to substituted aromatic rings of active BCRP inhibitors, if the third
aromatic ring has a 4-nitro group, and correspond to the compounds: (A)
KS-174, (B) KS-385, (C) KS-292, (D), KS-267, (E) KS-176, (F) KS-251, (G)
KS-194.
respectively on the third aromatic ring. The IC50 value for compound KS-174 is equal
to 1.63 µM, slightly lower than the reference compound KS-176, while the IC50 value
for compound KS-184 is equal to 0.56 µM, about 8-folds lower than the corresponding
compound with the hydroxyethyl group at the same position (KS-190, IC50 = 4.59
µM).
The absence of substituents on the first aromatic ring leads almost always to not ac-
tive compounds or to compounds with very low inhibitory activity. The exceptions are
the compound KS-166, with two methoxy groups on the third aromatic ring compound
KS-173, with an acetamide at position 4 of the third aromatic ring. The IC50-values
of these compounds against BCRP are 1.76 µM and to 2.09 µM, respectively.
Further compounds with a 4-nitro group on the third aromatic ring and bromine,
sulfonamide, dimethylamino and amide groups on the first aromatic ring were syn-
thesized by Dr. Steggemann. For these compounds no inhibitory activity against
BCRP was found. The structure-activity relashionship of the first aromatic ring can
be explained by the 3D plot of SlogP, PM3 HOMO and VSA descriptors (figure 4.19).
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These three molecular descriptors are not correlated with each other.
The most active compounds have groups, on the first aromatic ring, characterized
by high values of SlogP. The increase of the lipophilicity must be also accompanied
by an increase of the van der Waals surface area. As illustrated in figure 4.19, these
compounds must also have values of PM3 HOMO (a descriptor high correlated with
σ-Hammett) for the first aromatic ring between values of -9 eV and -10 eV. The two
compounds (KS-383 and KS-374) out of this range are not active against BCRP. It
can be concluded that for obtaining compounds with high inhibitory activity against
BCRP, the first aromatic ring must be substituted by a lipophilic group with high van
der Waals surface area. This conclusion is valid for compounds with 4-nitro substituent
on the third aromatic group and can be extended also to compounds possessing other
substituents on this position as trifluoromethyl and chloro.
As already mentioned, other compounds with the third aromatic ring substituted
by a 3,4-dimethoxy group or by acetamide are an exception to this trend. A possible
explanation of the exceptional activity of these compounds can be found observing
the van der Waals surface (VSA) of the third aromatic ring for compounds with no
substitution or with only a methyl group on the first aromatic ring. Compounds with
IC50 values higher than 10 µM or no activity against BCRP have low values of van
der Waals surface areas of between 126.79 (the aniline of compound KS-172) and
142.19 (the trifluoromethyl benzene of compound KS-358). The van der Waal surface
area value of the third aromatic ring of compound KS-173 is equal to 167.09. This
compound is a BCRP inhibitor with an IC50 value of 2.09 µM. The value of van der
Waals surface area for compound KS-166 is equal to 171.26 and its IC50 value is equal to
1.76 µM. The importance of the surface area of the third aromatic ring for compounds
without substituents on the first aromatic ring can be explained by the increase of
the importance of the interaction in which the third aromatic ring is involved after
disappearance of the interaction of the substituent on the first aromatic ring with the
binding site. Indeed, it was already demonstrated, that a bulky substituent on the
third aromatic ring contributes to an increase in the inhibitory activity against BCRP
for this class of inhibitors.
Regarding the inhibitory activity against P-gp, the absence of substituents on the
first aromatic ring leads to compound KS-166, with an IC50 value equal to 3.98 µM.
The introduction of an hydroxy or methoxy substituent on the first aromatic ring does
not really change the inhibitory activity against P-gp with respect to the compounds
without substituents at the same position. Indeed, the IC50 value of compound KS-266,
with a methoxy group on the first aromatic ring and the IC50 of compound KS-265,
with hydroxy group at the same position are respectively equal to 4.09 µM and 4.47
µM, respectively.
A severe reduction of the inhibitory activity against P-gp was measured for com-
86
4.2 Determination of the activity of a new class of BCRP-inhibitors.
pound KS-277, with a methyl group on the first aromatic ring. This compound has
an IC50 value of 13.5 µM. The presence of a chlorine group at the same position (com-
pound KS-272) leads to a loss of activity. For compounds with a nitro group or with
a trifluoromethyl group on the third aromatic ring, the only active compounds are
those with a hydroxy group on the first aromatic ring. These compounds possess low
inhibitory activity against P-gp, with IC50 values of 27.5 µM and 14.0 µM for com-
pounds KS-251 and KS-342 respectively. The presence of a benzoyl group on the first
aromatic ring leads to compounds with moderate inhibitory activity against P-gp: In-
deed, the IC50 values of compounds KS-174 and KS-184 are respectively equal to 5.18
and 6.07 µM, respectively. This result was expected, according to what was already
observed by Chiba et. al. [153].
Table 4.6: Activity of compounds with variations on the first aromatic ring. Activities
were measured using Hoechst 33342 assay and MCF-7 MX cells for BCRP
(reference substance WK-X-24: IC50 = 0.90 ± 0.07 µM) and calcein AM
assay and A2780 Adr cells for P-gp (reference substance WK-X-24: IC50 =
0.41± 0.08 µM). n.a. = no activity for concentration up to 10 µM.
Formula Compound
IC50 BCRP µM ±
SD
IC50 P-gp µM ±
SD
N
H
NH
O
OH
NO2
O
KS-176 1.58 ± 0.36 n.a.
N
H
NH
O
O
NO2
O
O
KS-194 1.32 ± 0.28 n.a.
N
H
NH
O
OCH3
NO2
O
KS-292 1.23 ± 0.40 n.a.
N
H
NH
O
OCH3
CF3
O
KS-322 5.11 ± 0.87 n.a.
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Formula Compounds
IC50 BCRP µM ±
SD
IC50 P-gp µM ±
SD
N
H
NH
O
CH3
NO2
O
KS-385 0.94 ± 0.33 n.a.
N
H
NH
O
OCH3
NO2
O
KS-267 3.56 ± 0.84 n.a.
N
H
NH
O
OCH3
Cl
O
KS-268 n.a. n.a.
N
H
NH
O
OCH3
OCH3
O
OCH3
KS-266 3.34 ± 0.25 4.09 ± 0.50
N
H
NH
O
OH
NO2
O
KS-251 1.76 ± 0.18 27.5 ± 1.9
N
H
NH
O
OH
Cl
O
KS-252 2.91 ± 0.88 n.a.
N
H
NH
O
OH
OCH3
O
OCH3
KS-265 1.16 ± 0.21 4.47 ± 1.00
N
H
NH
O
OH
CF3
O
KS-342 1.80 ± 0.43 14.0 ± 3.5
88
4.2 Determination of the activity of a new class of BCRP-inhibitors.
Formula Compounds
IC50 BCRP µM ±
SD
IC50 P-gp µM ±
SD
N
H
NH
O
O
Cl
KS-231 n.a. n.a.
N
H
NH
O
O
KS-228 n.a. n.a.
N
H
NH
O
O
OCH3
OCH3
KS-277 22.8 ± 2.8 13.5 ± 2.6
N
H
NH
O
Cl
OCH3
O
OCH3
KS-272 8.29 ± 3.10 n.a.
N
H
NH
O
Cl
CF3
O
KS-375 n.a. n.a.
N
H
NH
O
Br
NO2
O
KS-382 n.a. n.a.
N
H
NH
O
NO2
O NH2
O
KS-381 n.a. n.a.
N
H
NH
O
SO2NH2
NO2
O
KS-383 n.a. n.a.
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Formula Compounds
IC50 BCRP µM ±
SD
IC50 P-gp µM ±
SD
N
H
NH
O
N(CH3)2
NO2
O
KS-374 n.a. n.a.
N
H
NH
O
NO2
O
KS-168 13.4 ± 4.2 n.a.
N
H
NH
O
CF3
O
KS-358 n.a. n.a.
N
H
NH
O
OCH3
O
OCH3
KS-166 1.76 ± 0.64 3.98 ± 0.84
N
H
NH
O
O
NH2
KS-172 23.3 ± 8.9 n.a.
N
H
NH
O
O
NH
O
KS-173 2.09 ± 0.20 n.a.
N
H
NH
O
O
NO2
O
KS-174 1.63 ± 0.33 5.18 ± 0.28
N
H
NH
O
O
O
KS-184 0.56 ± 0.24 6.07 ± 1.48
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4.2.9 Variations of the linker position
None the compounds with meta or para substitutions on the second ring show any
activity against BCRP in the Hoechst 33342 assay, as shown in table 4.7. Therefore,
the relative position of the two amide groups seems to be crucial. Only the ortho-
substituted compounds can establish a hydrogen bond between the NH and the C=O
of the amide groups on the second ring. As already presumed analyzing the activity
of compounds with modifications in the first linker, this interaction may be important
for the active conformation of this class of compounds.
Table 4.7: Activity of compounds with variations of the linker position. Activities
were measured using Hoechst 33342 assay and MCF-7 MX cells for BCRP
(reference substance WK-X-24: IC50 = 0.90 ± 0.07 µM) and calcein AM
assay and A2780 Adr cells for P-gp (reference substance WK-X-24: IC50 =
0.41± 0.08 µM). n.a. = no activity for concentration up to 10 µM.
Formula Compound
IC50 BCRP µM ±
SD
IC50 P-gp µM ±
SD
N
H
NH
O
OH
NO2
O
KS-176 1.58 ± 0.36 n.a.
N
H
OHO
HN O
NO2
KS-279 n.a. n.a.
N
H
OHO
HN O
CF3
KS-280 n.a. n.a.
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Formula Compounds
IC50 BCRP µM ±
SD
IC50 P-gp µM ±
SD
N
H
O
NH
NH
O
O2N
OH
KS-090 n.a. n.a.
N
H
O
NH
NH
O KS-129 n.a. n.a.
N
H
O
NH
NH
O
O2N
KS-108 n.a. n.a.
N
H
O
NH
NH
O KS-109 n.a. n.a.
N
H
OHO
HN
O
O2N
KS-091 n.a. n.a.
4.2.10 Compounds containing a tetrahydroisoquinoline moiety
The compounds reported in table 4.8 contain a tetrahydroisoquinoline group in their
structure. The first compound reported in this table is compound WK-X-24 (XR9577)
that was used as reference compound in this work. As reported in the table below, the
substitution of the amide in the second linker with an urea group leads to compounds
with a high inhibitory potency against BCRP, as compound KS-105 (IC50 = 0.35
µM). The substitution of the nitro group with a methyl group leads to a decreasing
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BCRP inhibitory activity by about 3-folds (compound KS-216). A further decreasing
of the inhibitory activity is caused by substitution of the third aromatic ring with a
naphthalene (compound KS-220, IC50 = 5.17 µM). This result suggests that a slightly
hydrophobic and strong electron acceptor group as the nitro group increases the activ-
ity, as already observed for compounds without the tetrahydroisoquinoline group. The
introduction of two methoxy groups at position 4 and 5 of the tetrahydroisoquinoline
group leads to a decrease of the BCRP inhibitory activity by about 9-folds with respect
to its homologue compound KS-216 (compound KS-226, IC50 = 9.30 µM). This result
is in accordance with the Free-Wilson analysis proposed by Pick et. al. [148]. The sub-
stitution of the amide group in the first linker with an urea group (KS-136) increases
the IC50 to a value of 10.35 µM, that is about 30 folds higher. Also the inhibitory
activity of six compounds with a tetrahydroisoquinoline group but without the third
aromatic ring was tested. Between them, the only two compounds that resulted to
be BCRP inhibitors are the compounds KS-221 and KS-122. As shown on table 4.8,
the first one (IC50 = 3.47 µM) has as first linker an urea group, two methoxyl groups
on the tetrahydroisoquinoline rest and a bromine at para position on the aromatic
ring. Normally, the presence of methoxyl groups on the tetrahydroisoquinoline group
decreases the inhibitory activity of compounds against BCRP, therefore the bromine
group could be responsible of the inhibitory activity of this compound. Unfortunately,
no compounds with similar structure but without the bromine group were synthesized
to confirm this hypothesis. The other active BCRP inhibitor, KS-122, has a moderate
inhibitory activity against BCRP, with an IC50 value of 6.70 µM. Its structure has
an amide group as first linker and the terminal phenyl group is substituted at para
position with a cyano group. The analogue compound KS-210, with a methyl group
in place of the cyano group has no effects against BCRP at concentrations up to 10
µM. Four compounds with the tetrahydroisoquinoline group in their structure have
an ortho substitution on the second aromatic ring. Only one of them (KS-075, IC50
= 4.68 µM) is able to inhibit BCRP. This compound differs from the other three by
the presence of two methoxyl groups on the tetrahydroisoquinoline rest and by the
presence of an urea as first linker.
Regarding the inhibitory activity of these compounds against P-gp, the comparison
between the results of the calcein-AM assay of compounds KS-105 and KS-216 with
the results of compounds WK-X-36 and WK-X-29 [154] showed that the introduction
of an urea as second linker decreases the inhibitory activity against P-gp. A slight
improvement of the inhibitory activity against P-gp is obtained by the introduction
of two methoxy groups on the tetrahydroisoquinoline group. The introduction of a
second urea group as first linker leads to loss of inhibitory activity against P-gp (KS-
136). Between compounds without the third aromatic group, only the compounds
KS-221 and KS-122 showed to be able to inhibit P-gp, with IC50 values of 3.47 and
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6.70 µM, respectively. The compounds KS-075 and KS-098, with the two linkers on
meta position, are weak inhibitors of P-gp, with IC50 values of 21.75 and 20.50 µM,
respectively. The analogue compound KS-101 does not inhibit P-gp. It is interesting
that the presence of the urea group on the first or on the second linker does not
significantly change the inhibitory activity against P-gp. Finally, the compound KS-
132, with two amides as linkers, has an IC50 value of 4.87 µM only about 3-folds higher
than of its ortho analogue WK-X-36 (IC50 = 1.45 µM) [154].
Table 4.8: Activity of compounds presenting a tetrahedronsoquinoline group. Activ-
ities were measured using Hoechst 33342 assay and MCF-7 MX cells for
BCRP and calcein AM assay and A2780 Adr cells for P-gp. n.a. = no
activity for concentration up to 10 µM.
Formula Compound
IC50 BCRP µM ±
SD
IC50 P-gp µM ±
SD
N
H
NH
N
O
NO
WK-X-24 0.901 ± 0.066 0.415 ± 0.080
N
H
NH
NHO
NO
NO2
KS-105 0.35 ± 0.05 2.55 ± 0.71
N
H
NH
NHO
NO
KS-216 1.10 ± 0.09 3.49 ± 0.36
N
H
NH
NHO
NO
KS-220 5.17 ± 1.33 3.68 ± 0.36
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Formula Compounds
IC50 BCRP µM ±
SD
IC50 P-gp µM ±
SD
N
H
NH
NHO
NO
OCH3
OCH3
KS-226 9.30 ± 1.84 2.01 ± 0.40
NH
NH
NHO
H
NO
N
NO2
KS-136 10.4 ± 4.44 n.a.
N
H
HN
NO
Br
OCH3
OCH3
KS-221 3.47 ± 0.76 6.17 ± 0.84
N
H
NO
HN
KS-224 n.a. 9.12 ± 3.85
N
H
HN
NO
N
KS-117 n.a. n.a.
N
H
HN
NO
H3CO
OCH3
KS-115 n.a. n.a.
N
H
NO
NC
KS-122 6.70 ± 1.82 17.6 ± 1.5
N
H
NO KS-210 n.a. 10.6 ± 5.7
N
H
HN
NO
OCH3
OCH3
NH
O
NO2
KS-075 4.68 ± 1.55 21.8 ± 2.7
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Formula Compounds
IC50 BCRP µM ±
SD
IC50 P-gp µM ±
SD
N
H
O
NH
NH
O
N
KS-101 n.a. n.a.
N
H
O
NH
NH
O
O2N
N
KS-098 n.a. 20.5 ± 5.4
N
H
NO
HN O
NO2
KS-132 n.a. 4.87 ± 0.58
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4.2.11 The effect of selected compounds on the cytotoxicity of
mitoxantrone, SN-38 and Hoechst 33342
In order to investigate the influence of this new class of BCRP inhibitors on the anti-
proliferative effect of cytotoxic drugs in presence or absence of BCRP, the cytotoxicity
of SN-38 and Hoechst 33342 was tested in MDCK BCRP cells. The results of these
tests further confirm the validity of the activity data collected with the Hoechst 33342
assay. In the experiments presented in this section, different BCRP inhibitors were
added at concentrations of 5 and 10 µM to MDCK BCRP cells that were stuck on
the bottom of a Greiner 96-well plate. As control, a PBS buffer solution administered
to MDCK BCRP cells and to MDCK cells was used. The cytotoxic agent was then
added at different concentrations.
The choice of using MDCK and the MDCK BCRP cells lines instead of the MCF-
7 and MCF-7 MX cells lines was taken considering the low quality of the curves
obtained using these second cells lines. In figure 4.20 is shown the effect gives by
increasing concentrations of the inhibitor KS-407 on the dose-response curves of the
cytotoxic compound SN-38. The curves on the left side of the figure (4.20a) are
obtained using MCF-7 and MCF-7 MX cell lines, while the curves on the right side
(4.20b) are obtained using MDCK and MDCK BCRP cell lines. The MTT assay in
which MCF-7 and MCF-7 MX cell lines were used, showed a lower span between the
curve corresponding to the resistance cells and that corresponding to the parenteral
cell lines (pEC50 of 7.19 and 6.55, respectively) in respect with the MTT assay using
MDCK and MDCK BCRP cell lines (pEC50 of 6.87 and 5.93, respectively).
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Figure 4.20: The shifts of the dose-response curves caused by increasing inhibitor concen-
trations using the compound KS-407 as inhibitor in (a) MCF-7 and MCF-
7 MX cells or (b) MDCK and MDCK BCRP cells. Resistant cells (empty
square), resistant cells + 5 µM inhibitor (black square), resistant cells + 10
µM inhibitor (empty triangle), parental cells (red down triangle).
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Furthermore, the goodness of fit is higher for the curves obtained using MDCK
and MDCK BCRP cell lines in respect with the curves obtained using MCF-7 and
MCF7-MX cell lines.
In order to exclude possible artefacts, the cytotoxic effects of selected compounds
at concentrations of 5 and 10 µM on the MDCK BCRP cells also were analyzed. The
results reported in figure 4.21 showed that at the studied concentrations, no cytotoxic
effects in MDCK BCRP cells were observed.
In the light of the above observations and considerations, it was decided to use the
MDCK and MDCK BCRP cell lines for the next assays.
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Figure 4.21: Cytotoxic effects of compounds (a) KS-407, (b) KS-251, (c) KS-166, and (d)
KS-174 in MDCK BCRP cells at concentrations of 5 and 10 µM.
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The importance of the ortho connection on the second aromatic ring
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Figure 4.22: The shift of the dose-response curve of Hoechst 33342 caused by increasing
inhibitor concentrations in MCDK cells. The shifts of the dose-response curves
due (a) to compound KS-279 and (b) to compound KS-091. MDCK BCRP
cells (empty square), MDCK BCRP cells + 5 µM inhibitor (black square),
MDCK BCRP cells + 10 µM inhibitor (empty triangle), parental MDCK
cells (red down triangle).
The results of the Hoechst 33342 assay showed that only compounds with the two
linkers in ortho position on the second aromatic ring are able to effectively inhibit
BCRP. This observation was confirmed by the MTT assay. As seen in figure 4.22,
compound KS-279, that contains the two linkers in meta position and compound KS-
091, that has the two linkers in para position are both not able to resistance towards
Hoechst 33342 of MDCK BCRP cells.
Substitutions on the first aromatic ring
Figure 4.23 shows the effect on the dose-response curves of Hoechst 33342 caused by
selected BCRP inhibitors with modifications on the first aromatic ring. The results
of the MTT assays confirm that the hydroxyethyl group on the first aromatic ring
is not essential for the activity and can be replaced by other groups. In particular,
the substitutions of the hydroxyethyl group by benzoyl (compound KS-174), propyl
(compound KS-385), hydroxyl (compound KS-251) and methoxy ethyl group (com-
pound KS-292) lead to compounds that are able to completely reverse the resistance
of MDCK BCRP cells against Hoechst 33342.
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Figure 4.23: The shifts of the dose-response curves of Hoechst 33342 caused by increasing
inhibitor concentrations in MCDK cells. The used inhibitors are (a) KS-174,
(b) KS-385, (c) KS-251 and (d) KS-292. MDCK BCRP cells (empty square),
MDCK BCRP cells + 5 µM inhibitor (black square), MDCK BCRP cells +
10 µM inhibitor (empty triangle), parental MDCK cells (red down triangle)
The influence on the activity of methoxy groups on the third aromatic ring on
the activity of compounds without substituents on the first aromatic ring
The results of the Hoechst 33342 assay showed important differences of activity
between compounds without any substituent on the first aromatic ring and with dif-
ferent substituents on the third aromatic ring. Mostly compounds do not showed any
inhibitory activity or only low inhibitory activity against BCRP, with the exceptions of
compounds KS-166 (IC50 = 1.16 µM) and KS-173 (IC50 = 2.09 µM). In order to con-
firm the results obtained with Hoechst 33342 assay, the MTT assay was also performed
using low active compound KS-168 (IC50 = 13.4 µM) and the most active compound
without substituents on the first aromatic ring, KS-166. The aim of this test was to
determine if the large difference in activity between these two compounds, differing
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Figure 4.24: The shift of the dose-response curve of Hoechst 33342 caused by increasing
inhibitor concentrations in MCDK cells.(a) The shift of the dose-response
curve caused by compound KS-168. (b) The shift of the dose-response curve
caused by compound KS-166. MDCK BCRP cells (empty square), MDCK
BCRP cells + 5 µM inhibitor (black square), MDCK BCRP cells + 10 µM
inhibitor (empty triangle), parental MDCK cells (red down triangle
by only one chemical group (3,4-dimethoxy on the third aromatic ring in compound
KS-166 instead of 4-nitro in compound KS-168), is also seen with this assay. In fig-
ure 4.24, the shift of the dose-response curve of Hoechst 33342 caused by compound
KS-168 is reported on the left, and the shift of the dose-response curve of Hoechst
33342 caused by compound KS-166 is reported on the right. It is possible to see that
the shift of the dose-response curve caused by compound KS-168 is only partial and
also for an inhibitor concentration equal to 10 µM the resistance of the MDCK BCRP
cells against Hoechst 33342 is not completely reversed. In contrast, the presence of
compound KS-166 at concentration equal to 10 µM is able to completely reverse the
BCRP mediated resistance against Hoechst 33342, as shown in figure 4.24b. In con-
clusion, the results of the MTT assays for compounds without substituents on the first
aromatic ring confirmed the data obtained from the Hoechst 33342 assay.
The influence of the substituents on the third aromatic ring
The results of the Hoechst 33342 assay for compounds with modifications on the
third aromatic ring have shown that the introduction of an isopropoxy group at po-
sition para of the ring (compound KS-407) increases the inhibitory activity of the
molecule with respect to the reference compound KS-176. In order to confirm the
result of the Hoechst 33342 assay, the MTT assay was performed for two different
cytotoxic compounds, namely Hoechst 33342 and SN-38. The results, illustrated in
figure 4.25, show that compound KS-407 is able to reverse the resistance of MDCK
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Figure 4.25: The shift of the dose-response curve of cytotoxic agents caused by increasing
inhibitor concentration in MCDK cells.(a) The shift of the dose-response curve
of Hoechst 33342 caused by compound KS-407. (b) The shift of the dose-
response curve of SN-38 caused by compound KS-407. MDCK BCRP cells
(empty square), MDCK BCRP cells + 5 µM inhibitor (black square), MDCK
BCRP cells + 10 µM inhibitor (empty triangle), parental MDCK cells (red
down triangle
BCRP cells against both cytotoxic compounds. This result confirms the data obtained
from the Hoechst 33342 assay and allows to consider compound KS-407 as a potent
BCRP inhibitor.
102
4.2 Determination of the activity of a new class of BCRP-inhibitors.
4.2.12 Determination of the cytotoxicity of selected BCRP
inhibitors
In order to measure the toxicity of the studied anthranile amide derivates, MTT vi-
ability assays with selected compounds were performed. In order to determinate the
toxicity in the same organisms that were also used for the determination of the BCRP
inhibitory activity, the MCF-7 and the resistant MCF-7 MX cell lines were chosen for
the assays.
Cells were seeded in sterile 96-well plates with density of 10,000 cells per well. After 6
h incubation, the studied compounds were added at 4 different concentrations ranging
between 1 and 31,6 µM. After 72 h incubation, the MTT solution, prepared following
the standard procedure, was added to each vial. Finally, the suspension was removed
from each vial and the cells were lysed using DMSO. The absorbance of each vial was
measured using a BMG POLARstar microplate reader. Two vials were added with
DMSO and other two vials were added only with PBS. The means of the absorbance
values of those samples were used as positive and negative references and results were
expressed as mean ± SD of 3 independent experiments.
Toxicity of selected compounds with modifications on the third aromatic ring
The cytotoxicity of seven selected compounds with modifications on the third aromatic
ring was measured. The results are illustrated in figure 4.26. The results of the
cytotoxicity assays show that generally the parenteral cell line MCF-7 is more resistant
against the cytotoxic effect of the studied compounds in respect to the MCF-7 MX
cell line.
The results of these experiments show that compound KS-176 does not show cyto-
toxicity in parenteral MCF-7 cells at concentration lower than 10 µM, while its cytotox-
icity in MCF-7 MX cells at concentration up to 10 µM. At a compound concentration
equal to 31.6 µM, the decrease of the viability in both cell lines was significant. The
decrease of the viability for compound KS-176 was also observed in other compounds.
A possible explanation can be offered by the low solubility of these compounds in PBS:
They could give precipitates, at concentrations up to 10 µM, with consequent reduc-
tion of the compound concentration in the solution. Similar results were observed also
for compound KS-150, that differs from compound KS-176 only in the position of the
nitro group on the third aromatic ring (at position meta instead of para in respect to
the second linker). The same trend was also observed for compound KS-144.
Compounds containing halogens on the aromatic ring, like KS-169 (4-chlorine) and
KS-242 (4-trifluoromethyl) are not cytotoxic for the parenteral cell line MCF-7 but
show already at low concentrations high cytotoxicity in the MCF-7 MX cell line. On
the other hand, compounds KS-407 and KS-157 do not show relevant cytotoxicity in
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Figure 4.26: Cytotoxicity of compounds with substitutions on the third aromatic ring.
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both cells lines also at concentrations up to 10 µM. The low value of IC50 of compound
KS-407 and its low cytotoxicity make this compound a good candidate for further
pharmacological studies.
Toxicity of selected compounds with modifications on the second aromatic ring
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Figure 4.27: Cytotoxicity of compounds with substitutions on the second aromatic ring.
The data for the cytotoxicity of compounds with modifications on the second aro-
matic ring reported in figure 4.27 show that these compounds are cytotoxic for both
MCF-7 and MCF-7 MX cell lines. In particular, also the viability of the MCF-7 cell
line is reduced by increasing concentrations of the three investigated compounds. Re-
garding the resistant cell line MCF-7 MX, at all used compound concentrations, the
cell viability was compromised, remaining at values of about 50 % with respect to
the control. Considering the low inhibitory activity of these compounds combined
with their high cytotoxicity, it can be concluded that these compounds are not good
candidates for further investigations.
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Toxicity of selected compounds with modifications on the first aromatic ring
Six compounds with modifications of the substituent group at para position on the
first aromatic ring were selected to investigate their cytotoxicity. The result of the
cytotoxicity assay of compound KS-176 is also reported in the figure 4.28 for com-
parison. It can be seen that the methylation of the hydroxyethyl group leads to an
increase of the cytotoxicity of compound KS-292 for the MCF-7 MX cell line, while
this compound is not cytotoxic for the MCF-7 cell line, also at high concentrations.
The introduction of a methoxy group directly connected with the aromatic ring (com-
pound KS-267) leads to high cytotoxicity for the MCF-7 MX cell line and a moderate
cytotoxicity for the parental MCF-7 cell line. The presence of a hydroxy group directly
connected with the ring, as in compound KS-251, leads to complete absence of cyto-
toxicity for the MCF-7 cell line and to reduction of the cell viability in MCF-7 MX
cells only at high concentrations. The absence of substituents on the first aromatic
ring (compound KS-166) leads to appearance of cytotoxic effects in MCF-7 cells only
at concentrations higher than 10 µM, while the cell viability of the MCF-7 MX cell
line is compromised already at low compound concentrations. An analogues effect was
observed for compound KS-385, possessing a propyl group on the ring at position 4.
Finally, compound KS-174, with a benzoyl group at para position on the ring, is not
cytotoxic for the MCF-7 cell line at all the studied concentrations and shows only low
cytotoxicity for the MCF-7 MX cell line at a concentration of 31.6 µM.
106
4.2 Determination of the activity of a new class of BCRP-inhibitors.
1 3.2 10 31.6
0
50
100
150 MCF-7
MCF-7 MX
conc. of compound (µM)
vi
ab
ilit
y 
ce
lls
 (%
)
(a) KS-176
1 3.2 10 31.6
0
50
100
150 MCF-7
MCF-7 MX
conc. of compound (µM)
vi
ab
ilit
y 
ce
lls
 (%
)
(b) KS-292
1 3.2 10 31.6
0
50
100
150 MCF-7
MCF-7 MX
conc. of compound (µM)
vi
ab
ilit
y 
ce
lls
 (%
)
(c) KS-267
1 3.2 10 31.6
0
50
100
150 MCF-7
MCF-7 MX
conc. of compound (µM)
vi
ab
ilit
y 
ce
lls
 (%
)
(d) KS-251
1 3.2 10 31.6
0
50
100
150 MCF-7
MCF-7 MX
conc. of compound (µM)
vi
ab
ilit
y 
ce
lls
 (%
)
(e) KS-166
1 3.2 10 31.6
0
50
100
150 MCF-7
MCF-7 MX
conc. of compound (µM)
vi
ab
ilit
y 
ce
lls
 (%
)
(f) KS-385
1 3.2 10 31.6
0
50
100
150 MCF-7
MCF-7 MX
conc. of compound (µM)
vi
ab
ilit
y 
ce
lls
 (%
)
(g) KS-174
Figure 4.28: Cytotoxicity of compounds with substitutions on the first aromatic ring.
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Toxicity of compounds presenting an hydroxyl group at position 4 on the first
aromatic ring
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Figure 4.29: Cytotoxicity of compounds with 4-hydroxy group on the first aromatic ring
and 4-nitro (KS-251) or 3,4-dimethoxy (KS-265) on the third aromatic ring.
The results from the Hoechst 33342 assay showed that compounds with an hydroxy
group at para position on the first aromatic ring are potent BCRP inhibitors with
similar IC50 values. Regarding the cytotoxicity of these compounds, the results of
the MTT assays showed that they have only low cytotoxicity in the MCF-7 cell line
at high concentrations (higher than 10 µM). In MCF-7 MX cells, the cytotoxicity is
relevant, for compound KS-251 at concentrations higher than 3 µM. Compound KS-
256, with two methoxy groups at position 3 and 4 of the third aromatic ring, reduces
considerably the viability of the MCF-7 MX cells considerably only at concentrations
of 10 µM and higher. This last observation confirms that the presence of two methoxy
groups on the third aromatic ring generally reduces the cytotoxicity of the compounds,
as already observed for compound KS-157.
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5 Development of binary QSAR
models for classification of BCRP
inhibitors.
5.1 Aim of this work
The results of the Hoechst 33342 assay showed that a wide number of the tested
compounds are weak inhibitors of BCRP or do not have any inhibitory activity at this
transporter.
The presence of numerous inactive compounds in a dataset is a problem for two
principal reasons: the first reason is that we are interested to obtain active inhibitors
(if possible, highly active) for the studied protein target and the presence of many
inactive compounds is an indication that drastic modification of the molecular scaffold
is required or that some basic feature of the molecular structure must be modified. The
second reason is that for these compounds is not possible to determine IC50 values,
with the result that we lose information for the building of standard linear QSAR
models.
In order to understand the reasons of such consistent presence of inactive compounds
and to orient the synthesis of new BCRP inhibitors to active compounds, three machine
learning algorithms were used to classify the training dataset constituted by the newly
synthesized tariquidar analogues.
The three chosen methods are the Self-Organizing Maps (SOM), an Artificial Neu-
ral Network that uses unsupervised learning, the Support Vector Machine (SVM), a
supervised learning algorithm, and the k-Nearest Neighbor (k-NN) algorithm, a lazy-
learning algorithm.
The parameters of each used machine learning algorithm were optimized to increase
its predictivity. Finally, an external dataset of compounds with a different scaffold
was used as test set to estimate the predictivity of the best models.
The results show that the generated models could be used as filter for designing new
compounds with increased chances to be active BCRP inhibitors.
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5.2 Preparation of the molecular structures and
descriptor calculation
5.2.1 Description of the used training dataset
The compounds used for the training dataset were synthesized by Dr. Kerstin Stegge-
man, a former PhD student of our research group in order to obtain a new class of
selective BCRP-inhibitors [155].
The compounds included in the dataset are chemically derived from tariquidar and
are structurally highly similar. In the dataset are included also structures containing
the tetrahydroisoquinoline rest as present structure of tariquidar as well as compounds
without this chemical group. All compounds of this dataset have been tested in the
Hoechst 33342 assay, to evaluate their inhibitory activity against BCRP, and in the
calcein AM assay to evaluate the P-gp inhibitory activity.
In conclusion, 99 compounds were tested and classified. The dataset was divided
into two subgroups: 59 compounds with IC50 values for BCRP equal or lower than
10 µM were classified as BCRP inhibitors (class-code equal to 1). The remaining 40
compounds with an IC50 value higher than 10 µM were classified as non-inhibitors
(class-code equal to 0). The compounds used for classification and their class-codes
are reported in table 5.1.
5.2.2 Structure optimization
All the compounds mentioned in this work were drawn using the software MOE [97].
The molecular structures were optimized before calculating molecular descriptors, in
order to find the optimal conformation and to calculate the partial charges of the
atoms. The optimization consists of three different steps: the calculation of force field
partial charges, the conformational search and the recalculation of partial charges using
a quantum mechanic method.
In the first step the partial charges were calculated using the force field MMFF94x
[156]. Afterwards, a stochastic conformational search was performed using a root mean
square (RMS) gradient equal to 0.005 A˚ and an iteration limit of 10000.
Due to high flexibility of the molecular structures and the calculations performed
in vacuo, the conformation associated to the lowest potential energy was frequently
an unnaturally bent structure. The problem was solved taking the conformation with
lowest globularity instead of the conformation with lowest potential energy.
Finally, the charges of the chosen conformation were than recalculated using the
PM3 quantum mechanic method included in MOPAC and the structure minimized to
the local minimum energy.
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Table 5.1: The compounds used in the Dataset and their activity class.
Compound Class
WK-X-24 1
KS-072 1
KS-075 1
KS-094 1
KS-105 1
KS-122 1
KS-226 1
KS-136 1
KS-144 1
KS-150 1
KS-157 1
KS-159 1
KS-162 1
KS-166 1
KS-169 1
KS-174 1
KS-176 1
KS-184 1
KS-186 1
KS-187 1
KS-190 1
KS-191 1
KS-194 1
KS-196 1
KS-206 1
KS-216 1
KS-220 1
KS-221 1
KS-238 1
KS-242 1
KS-246 1
KS-249 1
KS-251 1
KS-252 1
Compound Class
KS-255 1
KS-257 1
KS-265 1
KS-266 1
KS-267 1
KS-272 1
KS-274 1
KS-282 1
KS-292 1
KS-294 1
KS-304 1
KS-305 1
KS-308 1
KS-311 1
KS-322 1
KS-342 1
KS-364 1
KS-366 1
KS-367 1
KS-371 1
KS-385 1
KS-399 1
KS-401 1
KS-173 1
KS-407 1
KS-090 0
KS-091 0
KS-092 0
KS-098 0
KS-101 0
KS-108 0
KS-109 0
KS-115 0
KS-117 0
Compound Class
KS-129 0
KS-132 0
KS-168 0
KS-170 0
KS-172 0
KS-181 0
KS-199 0
KS-210 0
KS-224 0
KS-228 0
KS-231 0
KS-237 0
KS-268 0
KS-277 0
KS-279 0
KS-280 0
KS-290 0
KS-293 0
KS-328 0
KS-348 0
KS-351 0
KS-357 0
KS-358 0
KS-360 0
KS-374 0
KS-375 0
KS-381 0
KS-382 0
KS-383 0
KS-405 0
KS-406 0
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(a) Structure with lower globularity (b) Structure with lower energy
Figure 5.1: Comparison of two different conformation of compound KS-181. The first con-
formation shows the lowest globularity (glob = 0.16) and a potential energy
value equal to 92.68 kcal/mol. The second structure has the lowest potential
energy (87.48 kcal/mol) but an high globularity value (0.36).
5.2.3 Calculation of molecular descriptors
The molecular descriptors used in this work can be divided into zero-dimensional
descriptors (0D), one-dimensional descriptors (1D), two-dimensional descriptors (2D),
and three-dimensional descriptors.
0D descriptors are simply derived from the chemical formulas of compounds. 1D
descriptors report the count of functional groups and substructures in the molecule.
2D descriptors are calculated using information deriving from the connectivity and
distance matrix of structures. For calculation of these last descriptors no informa-
tion about the molecular conformation are needed. Finally, 3D descriptors use atoms
coordinates to be calculated.
The same class of descriptors, e.g. ATS descriptors, can be 2D or 3D descriptors
according to the used kind of distance (topological or geometrical respectively). The
calculation of molecular descriptors was performed using the software MOE [97] and
the on-line version of the software DRAGON. For each molecule, 2164 descriptors
were calculated and divided into 13 classes. Those 13 classes were used separately or
in different combinations e.g. 2D and 3D RDF descriptors together or 0D, 1D, 2D,
and 3D descriptors. Descriptors with only zero values were removed. The kind of
descriptors used, the dimensionality and the number of descriptors calculated for each
class are summarized in table 5.2.
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Table 5.2: Classes and number of molecular descriptors calculated
Classes Dimensionality Number of descriptors calculated
0D, 1D and 2D MOE descriptors 0D, 1D, 2D 174
3D MOE descriptors 3D 124
Inductive descriptors MOE 3D 50
2D RDF descriptors 2D 75
3D RDF descriptors 3D 150
2D RECON descriptors 2D 143
3D RECON descriptors 3D 143
TAE RECON descriptors 3D 257
3dMORSE descriptors 3D 160
gATS descriptors 3D 260
tATS descriptors 2D 135
WHIM descriptors 3D 99
GETAWAY descriptors 3D 197
Total number 2164
5.3 Use of SOMs to discriminate between
BCRP-inhibitors and non-inhibitors
5.3.1 Identification of the optimal parameters of the SOM
In order to increase the predictivity of the model based on SOMs, the parameters of the
map were changed to find the best setting. The optimized parameters are the number
of iterations, the topology of the SOM and the dimension of the SOM. The number of
iterations refers to the number of times that the complete dataset is presented to the
SOM. The number of iterations must be enough to guarantee reaching of convergence.
The optimal number of iterations was found using the largest descriptor set of this
study (the combination of 2D, 3D and TAE RECON descriptors, in total 543 descrip-
tors) in a 9 x 9 SOM. The results show that after 4000 iterations the mean distance
between input vectors and the corresponding winning neuron appears to be constant
(fig. 5.2).
Regarding the topology of SOMs, the major problem is to ensure that all neurons
of the SOM have the same number of first-, second- and third- neighbors. This is not
possible using a classical topology, as the rectangular and hexagonal topologies. Neu-
rons at the edges of a rectangular or hexagonal SOM have incomplete neighborhood.
This problem was solved using toroidal topologies.
The optimal dimension of the SOM was determined using a grid approach, for each
used set of descriptors. Several SOMs were generated with increasing dimensions from
5 x 5 to 9 x 9 neurons. The dimension limit of 9 x 9 neurons is due to the number of
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Figure 5.2: Example of training progress for a 9 x 9 SOM using 2D, 3D and TAE RECON
descriptors.
molecules in the dataset that must be higher than the number of neurons of the SOM.
The predictivity was evaluated for each generated SOM and the results are reported
successively in this thesis.
5.3.2 Analysis of results
The package ’kohonen’ implemented in R (version 2.15.0) [157] is used in this work to
calculate self-organizing maps. Several models were generated using different sets of
descriptors. For each set, molecular descriptors with variance equal to 0 were removed.
Before training of the SOM, each column of the input matrix was normalized, sub-
tracting the mean of all values in the column and dividing by the standard deviation.
Normalization of features is necessary in this work because the ranges of the used
descriptors are widely different.
In order to obtain better prediction of the less represented class (weak active in-
hibitors), a down-sampling of the dataset was performed. In machine learning algo-
rithms unbalanced datasets can cause problems when predicting the smaller class. An
approach to solve this problem consists in taking, for training of the SOM, only as
many elements from the larger class as elements in the smaller class, obtaining in this
way a down-sampled dataset where the amount of elements of the two classes is 1:1.
The elements taken from the larger class to obtain the down-sampled database were
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randomly selected. For each training cycle, different elements were randomly selected
for the down-sampled database. This down-sampled training set was used to build the
SOM model. The SOM was trained using a learning rate decreasing linearly from 0.05
to 0.01. The initial weights were randomly generated.
The predictivity of the trained SOM was finally evaluated using the leave-one-out
(LOO) cross validation (CV). The down-sampling, and the calculation of the SOM
model were performed 100 times giving each time small difference in the accuracy
values, due to different elements in the down-sampled dataset and to different initial
weights of SOMs neurons. The predictivity of the best models was finally tested using
an external dataset (test set). The overall process is shown in figure 5.3.
The accuracy of the prediction is expressed using the parameter ”accuracy value”,
”true positive rate” (TP rate) and ”true negative rate” (TN rate). These parameters
were already explained in section 2.3.
Figure 5.3: Framework for the generation of SOM models.
0D, 1D, 2D and 3D MOE descriptors
In his 2012 publication [158], Kohonen suggests to use self-organizing maps with a
number of neurons between about 25 and 2000. Additionally, he assets that it is not
possible to know the exact dimension of the SOM array beforehand, but it has to be
determined trying several sizes and evaluating the errors. The number of neurons in
the SOM is also determined by the possible number of clusters in the dataset. Small
SOMs are enough to map datasets with few clusters, whereas datasets with more than
two clusters or with interesting fine structures need a higher resolution.
The 0D, 1D, 2D and 3D descriptors calculated with MOE were used to generate
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Figure 5.4: The Box plots report the accuracies calculated for different SOM dimensions
using combinations of 2D and 3D MOE descriptors.
SOMs of the training dataset. As shown in figure 5.4, the accuracy for SOMs generated
using 0D, 1D and 2D descriptors decreases with the size of the array. Indeed, the
highest value of accuracy was obtained using SOM dimensions of 5x5 and 6x6 neurons
(with accuracies equal to 0.73 and 0.72 respectively). The accuracy of SOMs generated
using 3D descriptors remains almost constant with the increase of the size. The best
accuracy value obtained using this set of descriptors is comparable with the best
accuracy obtained with the non-3D descriptors and is associated with a SOM size
of 8x8 neurons (accuracy equal to 0.73).
The use of both descriptors sets results in SOMs with accuracy decreasing with the
size of the array, as already observed for SOMs calculated using non-3D descriptors.
This similar trend might be due to the higher amount of non-3D descriptors with
respect to the 3D (174 descriptors against 124 descriptors respectively). The best
accuracy obtained using both the descriptors set together is equal to 0.71 for a SOM
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with size 5x5. This value is lower than the best values obtained using the separate
datasets. This result suggests that a descriptors selection could play a role in increasing
of accuracy.
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(b) 2D MOE and inductive de-
scriptors.
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Figure 5.5: Accuracies calculated for different SOM dimensions using combinations of in-
ductive, 2D and 3D MOE descriptors.
The use of inductive descriptors leads to accuracy values strongly dependent on the
size of the array. The best accuracy is obtained with an array size of 5x5 neurons
(accuracy equal to 0.74). The combination of 0D, 1D, 2D and inductive descriptors
leads also decreasing accuracy with the size of SOM. The best model obtained with
this set of descriptors has also an accuracy of 0.74 for an array size of 5x5 neurons.
The use of 3D and inductive descriptors together for the calculation of the SOM leads
to models with accuracy values independent of the size of the array. The accuracy for
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these models is between 0.71 and 0.69. The best model (accuracy equal to 0.71) is
obtained using an array size of 6x6 neurons. The model obtained by the combination
of 0D, 1D, 2D, 3D and inductive descriptors is also independent of the size of the array
and has the same trend as already observed for models generated using only 0D, 1D,
2D and 3D descriptors. This result suggests that the chemical information provided
by the inductive descriptors is probably hidden by the other descriptors.
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Figure 5.6: Accuracies calculated for different SOM dimensions using combinations of 2D
and 3D RDF descriptors.
The accuracy of SOM models calculated using 2D RDF descriptors decreases with
the size of the array. The highest accuracy is obtained by a SOM with a size of 5x5
neurons and it is equal to 0.76. The use of 3D RDF descriptors for SOMs calculation
gives higher values of accuracy and they do not depend to the size of the array. The
best model obtained using 3D RDF descriptors has an accuracy value equal to 0.79,
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associated to a SOM with an array of 9x9 neurons. The use of 2D and 3D RDF
descriptors together leads to models with accuracy that is not dependent on the array
size but with lower accuracy with respect to models generated using only 3D RDF
descriptors. This result could be explained considering the higher amount of 3D RDF
descriptors (150 descriptors) respect to 2D RDF descriptors (only 75 descriptors).
RECON descriptors
Generally, the use of RECON descriptors for calculation of SOMs leads to predictive
models with low or no dependency on the size of the array. The model generated
using 2D RECON descriptors showed the best accuracy values with respect to models
generated using 3D RECON and TAE RECON descriptors. The accuracy of SOM
models calculated using 2D RECON descriptors moderately increases with the size of
the array from 0.72 for a 5x5 neurons SOM to a value of 0.76 for an 8x8 neuron SOM.
The largest SOM generated using this set of descriptors (9x9 neurons) has a similar
accuracy, equal to 0.75. The SOM models generated using 3D RECON descriptors, in
contrast to what observed in the previous descriptor sets, has an accuracy lower than
models calculated using 2D RECON descriptors. Indeed, all the models calculated
using 3D RECON descriptors have an accuracy lower than 0.70, without dependency
on the size of the array. The combination of 2D and 3D RECON descriptors leads
to models with an accuracy slightly under what obtained using only 2D RECON
descriptors. The worsening of the accuracy value could be due to the presence of
descriptors uncorrelated with the biological activity of compounds, as already observed
for other descriptors sets. The SOM models calculated using TAE RECON descriptors
show low predictivity, with accuracy value of about 0.60 and no dependency on the
size of the array. The use of TAE descriptors in combination with the other RECON
descriptors also leads to models with lower predictivity with respect to the models
calculated only with 2D and 3D RECON descriptors.
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Figure 5.7: Accuracies calculated for different SOM dimensions using combinations of 2D,
3D and TAE RECON descriptors.
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ATS descriptors
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(b) Geometrical ATS descrip-
tors
Figure 5.8: Accuracies calculated for different SOM dimensions using combinations of topo-
logical and geometrical ATS descriptors.
The SOMs generated using ATS descriptors have high accuracy values. The use of
topological ATS descriptors leads to models with accuracy between 0.74 (5x5 neurons)
and 0.71 (7x7 neurons). The accuracies observed for those models are not correlated
with the size of the array. The models generated using geometrical ATS descriptors
have values of accuracy higher than the models generated with topological ATS de-
scriptors. The better quality of these models can be explained by the nature of the
geometrical ATS descriptors: These descriptors consider the three-dimensional struc-
ture of the compounds and not only the connection matrix, as for the topological ATS
descriptors. The best accuracy obtained for SOMs calculated with geometrical ATS
descriptors is associated with an array size of 5x5 neurons and is equal to 0.79.
Dragon descriptors
The accuracies of SOMs generated using dragon descriptors are generally low. The
models generated using 3d-MORSE and GETAWAY descriptors are not able to dis-
criminate between BRCP inhibitors and non-inhibitors, with accuracy values lower
than 0.70. Only the models based on WHIM descriptors have fair values of accuracy,
increasing with the size of the array. The best value of accuracy obtained by a SOM
calculated with the WHIM descriptors is equal to 0.73, and it is associated to an array
of 9x9 neurons.
123
5 Development of binary QSAR models for classification of BCRP inhibitors.
l
l
l
l
l
l
SOM dimension
A
cc
ur
ac
y
5x5 6x6 7x7 8x8 9x9
0.
45
0.
55
0.
65
0.
75
(a) 3d-MORSE descriptors
l
l
SOM dimension
A
cc
ur
ac
y
5x5 6x6 7x7 8x8 9x9
0.
50
0.
55
0.
60
0.
65
0.
70
0.
75
0.
80
(b) GETAWAY descriptors
l
l
l
ll
l
SOM dimension
A
cc
ur
ac
y
5x5 6x6 7x7 8x8 9x9
0.
60
0.
65
0.
70
0.
75
0.
80
(c) WHIM descriptors
Figure 5.9: Accuracies calculated for different SOM dimensions using dragon descriptors.
Discussion of results
The results summarized in fig 5.10 shown that the best values of accuracy are obtained
using RDF and geometrical ATS descriptors. In particular (table 5.3), the accuracy
of the models generated using 3D RDF descriptors in a 5x5 neurons SOM is equal to
0.79, with a true positive precision equal to 0.91 and a true negative precision equal
to 0.68. The accuracy of the model generated using gATS descriptors is comparable
to the accuracy obtained by the model calculated using 3D RDF descriptors. Also in
this case the accuracy is equal to 0.79, but the precisions of true positive and true
negative are 0.90 and 0.67, respectively.
Several chemical-physical descriptors for the compounds in the database were also
analyzed, in order to observe possible differences in the distribution of these descriptors
between active and weakly active compounds. The best statistically relevant separa-
tion is based on descriptors codifying the volume of the molecules and the molecular
surface. In particular, the difference of the mean values of van der Waals surface area
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Figure 5.10: Accuracy values of the best models for each descriptor set.
between high and low active BCRP inhibitors is well rendered (Figure 5.11a). The
Welch Two Sample t-test was used to evaluate the statistical significance. The result of
the t-test showed a p value <0.005 and t = 3.685, confirming that the two population
of values are statistically separated.
The van der Waals surface area values were also correlated with the first component
of 3D RDF and gATS descriptors (Figure 5.11c). As expected, the values are highly
correlated: the correlation between the first component of the 3D RDF descriptors
and VSA has r2 equal to 0.97 and the correlation between the first component of the
gATS descriptors and VSA has an r2 value equal to 0.98.
In order to investigate the role of logP on the activity of this class of compounds,
the mean values of logP for the two populations were compared (Figure 5.11b). The
result of the Welch Two sample t-test showed that the two mean values are not sig-
nificantly different (p value = 0.13, t = 1.52). In conclusion, the capacity of this class
of compounds to inhibit BCRP depends on the surface area of the molecule but not
on the lipophilicity. A higher value of surface area gives higher probability that the
compound is a BCRP-inhibitor.
In Fig. 5.13 is shown the distribution of active and weakly active BCRP inhibitors in
the SOM. Red areas are neurons associated with weakly active BCRP-inhibitors, while
beige areas are neurons associated with active BCRP inhibitors. For both SOMs, gen-
erated using 3D RDF and gATS descriptors, it is possible to distinguish well-separated
clusters of neurons associated with active and weakly active inhibitors. The separation
of the two clusters is already recognizable observing the principal component analysis
of the 3D RDF and gATS descriptors. As illustrated in figure 5.13a, it is possible to
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Table 5.3: Summary of BCRP classification powers by SOM approach.
Descriptors set Size Accuracy TP rate TN rate
3D-RDF 5x5 0.79 0.91 0.68
gATS 5x5 0.79 0.90 0.67
2D-3D-RDF 5x5 0.77 0.89 0.66
2D-RECON 8x8 0.76 0.87 0.65
2D-RDF 5x5 0.76 0.87 0.64
2D-IND-MOE 5x5 0.74 0.85 0.63
2D-3D-RECON 7x7 0.74 0.84 0.63
tATS 5x5 0.74 0.84 0.63
IND-MOE 5x5 0.74 0.84 0.63
2D-MOE 5x5 0.73 0.85 0.62
3D-MOE 8x8 0.73 0.83 0.63
2D-3D-IND-MOE 5x5 0.73 0.83 0.63
WHIM 9x9 0.73 0.82 0.63
2D-3D-MOE 5x5 0.72 0.82 0.62
2D-3D-TAE-RECON 8x8 0.72 0.81 0.62
3D-IND-MOE 6x6 0.71 0.81 0.61
GETAWAY 9x9 0.68 0.76 0.60
3D-RECON 8x8 0.68 0.76 0.60
3d-MORSE 5x5 0.61 0.67 0.56
TAE-RECON 6x6 0.61 0.67 0.55
distinguish the separation of the two clusters in the principal component analysis of
3D RDF descriptors. The first two components explain 64.4% of the variance. Figure
5.13c shows the 3D plot of the first 3 principal components of the 3D RDF descriptors:
in this figure the separation of the two clusters is more evident. In this last case, the
first three components explain 72.1% of the variance.
Similar results are obtained with the principal component analysis of the gATS
descriptors (Figure 5.13b and 5.13d). Also using these descriptors the separation of
the clusters in the 2D and 3D plot is clear. In this case, the first two components
explain 65,6% of the variance and the first three components 74,5% of the variance.
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Figure 5.11: (a) Differences between inhibitors (class 1) and weak inhibitors (class 0) based
on the van der Waals surface area (VSA), and (b) the logP. (c) Correlation
between the 1st principal component of the 3D-RDF descriptors and the van
der Waals surface area.
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Figure 5.12: SOMs generated using the two best descriptors sets. The color of each neuron
indicates the rate of association of the neuron to active (value = 1) or inactive
(value = 0) compounds.
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Figure 5.13: (a) Plot of the two principal components of the 3D RDF descriptors and
(b) topological ATS descriptors. (c) 3D plot representing the three principal
components of the 3D RDF descriptors and (d) topological ATS descriptors.
The blue points and spheres are associated to active BCRP inhibitors, while
red points and spheres are associated to weakly active BCRP inhibitors.
Use of an external testset
The predictivity of the developed SOM was tested using an external testset. The ex-
ternal dataset consists of 16 compounds synthesized and tested by Dr. Lars Mo¨llmann
[159]. 9 compounds have IC50 values lower than 10 µM and were classified as BCRP-
inhibitors (class 1), while 7 compounds have IC50 values higher than 10 µM or show
no activity against BCRP. These compounds were classified as non-inhibitors (class
0). The three-dimensional alignment of the active compound LM-221 with the BCRP-
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inhibitor KS-176 (figure 5.14) shows that three of the four aromatic rings of compound
LM-221 can be superposed with the three aromatic rings of compound KS-176. The
result of the three-dimensional alignment suggests that the two classes of compounds
share similar pharmacophore patterns and consequentially also a similar interaction
with the protein binding site. If we assume that compounds of two different chemical
classes, bind to the protein in the same binding site should have similar chemical fea-
tures to be active, than we can also expect that they occupy similar positions in the
chemical space and, consequentially, the same region of the SOM.
Figure 5.14: Superposition of KS-176 and LM-221.
In order to use the LM dataset as an external test set, the KS dataset and the LM
dataset were joined together. The combined descriptor matrix obtained by joining the
two separate descriptor matrices was normalized using the software R. The normalized
matrix was split again into training set and test set (the KS compounds are used as
training set and the LM compounds as test set). The normalized descriptor values
were used for training of the SOM and the test compounds were successively projected
on the SOM model. The accuracy of the prediction was calculated according to the
amount of correct predictions for the two classes.
The SOM model generated using 3D RDF descriptors is able to predict the activity of
the test set with an accuracy of 0.88. All the active compounds were correctly predicted
and 5 of 7 inactive compounds were also correctly predicted. The two false positive
compounds are LM-234 and LM-233. Both compounds have a chemical structure very
similar to the active compounds. LM-234 is an analog of compounds LM-235 but it
has a thiourea as linker instead of the urea of compound LM-235. The other false
positive compound, LM-233 is similar to compound LM-221, but its structure has a
cyclohexane instead of a phenyl ring. The active compounds of the test set are grouped
in a cluster localized in the region of the SOM corresponding to active compounds. The
correct predicted inactive compounds are localized in regions of the SOM associated
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with inactive compounds.
Table 5.4: Activity of compounds used as test set. The structures and activity of
these substances were extracted from the PhD thesis of Lars Mollmann
[159]. Activities were measured using Hoechst 33342-assay in MCF-7 MX
cells for BCRP (reference substance WK-X-24: pIC50 = 6.047± 0.032).
Structures Compounds
pIC50 BCRP µM
± SD Class
N
N
HN
N
H
O
LM-221 (1) 5.816 ± 0.032 1
N
N
HN
N
H
OO
O
LM-222 (2) 5.527 ± 0.067 1
N
N
HN
N
H
O
NO2
LM-223 (3) 6.204 ± 0.048 1
N
N
HN
N
H
O
NH2
LM-229 (4) 5.163 ± 0.101 1
N
N
N
H
NHO
O
O
LM-224 (5) 5.790 ± 0.056 1
N
N
HN
N
H
OO
O
LM-228 (6) 5.432 ± 0.058 1
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Structures Compounds
pIC50 BCRP µM
± SD Class
N
N
HN
N
H
O
O
LM-236 (7) 5.989 ± 0.055 1
N
N
HN
N
H
HN O
LM-235 (8) 5.923 ± 0.022 1
N
N
HN
OO
O
LM-209 (9) 5.801 ± 0.020 1
N
N
HN
NH2
OO
O
LM-75 (10) 4.387 ± 0.116 0
N
N
NH
LM-219 (11) n.a. 0
N
N
NH
HN
O
LM-220 (12) n.a. 0
N
N
NH
HN
O
Cl
LM-225 (13) n.a. 0
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Structures Compounds
pIC50 BCRP µM
± SD Class
N
N
NH
HN
OO
O
LM-226 (14) 4.522 ± 0.029 0
N
N
HN
N
H
HN S
LM-234 (15) n.a. 0
N
N
HN
N
H
O
LM-233 (16) n.a. 0
The SOM model generated using gATS descriptors is able to correctly predict the
activity of the test set with an accuracy value equal to 0.81. This model, as well as
the model generated using 3D RDF descriptors, is able to correctly classify all the
active compounds of the dataset. The active compounds are all localized in a cluster
corresponding to the area of the SOM associated with active compounds. Three of
the seven inactive compounds are not correctly predicted. Two of them, LM-234
and LM-233 were not correctly predicted also by the model generated using 3D RDF
descriptors. The third un-correct predicted compound, LM-220 is localized on an
ambiguously classified neuron.
In conclusion, self-organizing maps are able to discriminate between inhibitors and
non-inhibitors in the KS-dataset. The trained SOM generated using 3D RDF and
gATS descriptors can be used to predict the BCRP-inhibitory activity of other com-
pounds not structurally directly correlated to KS compounds.
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Figure 5.15: Use of externe dataset for validation. The numbers in these two illustrations
are referred to the compounds in table 5.4.
5.4 Use of SVM to discriminate between
BCRP-inhibitors and non-inhibitors
5.4.1 Generation of the models
In order to distinguish the BCRP-inhibitors and non-inhibitors in the KS dataset, the
SVM algorithm was also applied, analogously to the SOM algorithm. The SVM models
were built using the same descriptor sets previously used for the SOM models. For each
SVM model based on the RBF kernel, it is necessary to find the optimal combination
of the two parameters C and γ. In order to define the optimal combination of these
two parameters, a grid search was performed. Several SVM models were generated,
using several combinations of C and γ for values of C between 2−1 and 212 and for
values of γ between 2−12 and 1. The quality of each model was evaluated by 10-fold
cross-validation. For each descriptor set, the combination of C and γ that generates
the model with the lowest 10-fold cross-validated error was chosen to generate the final
SVM model.
The workflow used to generate and evaluate the SVM models is similar to that
used to generate the SOM models. First, all the descriptors with variance equal to 0
were deleted from the descriptor matrix. Then the descriptor values were normalized.
Similarly to SOM models, also in SVM a down-sampling step was performed, due to
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the different amount of compounds in the two classes. The SVM models were generated
using the package e1071 [160] implemented in R. The downsampling and the model
generation were performed 1000 times and the average of the accuracy is reported.
Small differences of accuracy for each single cycle are due to the different elements
randomly selected in the downsampling. For each descriptor set, the best model was
evaluated not only with cross-validation, but also using an external testset, as for the
SOM models. Also in this case the external testset is the LM dataset.
5.4.2 Evaluation of the results
Table 5.5: Summary of BCRP classification powers by SVM approach.
Descriptors set C γ Accuracy TP rate TN rate
3D-RDF 16 2−12 0.75 0.89 0.62
gATS 2 2−10 0.77 0.93 0.60
2D-3D-RDF 2 2−7 0.77 0.90 0.64
2D-RECON 4 2−12 0.67 0.95 0.38
2D-RDF 1 2−5 0.76 0.91 0.60
2D-IND-MOE 0.5 2−9 0.70 0.90 0.50
2D-3D-RECON 64 2−11 0.74 0.82 0.66
tATS 32 2−12 0.75 0.91 0.59
IND-MOE 2 2−8 0.75 0.90 0.60
2D-MOE 16 2−12 0.72 0.90 0.55
3D-MOE 16 2−12 0.71 0.88 0.54
2D-3D-IND-MOE 1 2−10 0.71 0.91 0.50
WHIM 1 2−9 0.70 0.93 0.48
2D-3D-MOE 8 2−11 0.71 0.85 0.58
2D-3D-TAE-RECON 4 2−11 0.72 0.90 0.55
3D-IND-MOE 8 2−11 0.73 0.89 0.56
GETAWAY 16 2−8 0.64 0.74 0.53
3D-RECON 32 2−12 0.70 0.85 0.55
3d-MORSE 16 2−11 0.70 0.80 0.60
TAE-RECON 8 2−12 0.70 0.90 0.50
For each descriptor set, the accuracy values and the percentage of true predicted
compounds for each class are reported in table 5.5. The best accuracy values were
obtained using 2D and 3D RDF descriptors (and their combination), gATS, tATS and
inductive descriptors. The accuracy values of the SVM models are generally lower than
the accuracy values of the corresponding SOM models. The SVM model generated
using 3D RDF descriptors leads to an accuracy equal to 0.75, lower than the accuracy
found for the SOM model with the same descriptors set (the accuracy is equal to 0.79
for the SOM model). The SVM model generated using gATS descriptors has also a
lower value of accuracy (0.77) with respect to that obtained by the SOM model (0.79).
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However, in this case, the difference between the two accuracy values is rather low. The
use of tATS descriptors (0.75), inductive descriptors (0.75) and the combination of 2D
and 3D RDF descriptors (0.71) leads to SVM models with accuracy values comparable
to the corresponding SOM models (0.74, 0.74, and 0.72, respectively). The difference
between the accuracy of the SVM model obtained using 2D RECON descriptors and
the accuracy of the SOM model obtained using the same descriptor set is considerable:
their values are equals to 0.67 for the SVM model and 0.76 for the SOM model. The
loss of predictivity of the SVM model is principally due to its very low predictivity for
the non-inhibitors compounds, compared to the SOM model.
The low predictivity for the non-inhibitors is observed for almost all the SVM mod-
els (but also for SOMs models), although the downsampling step before building of
the models. The low predictivity of inactive compounds can be explained by the use
of a too low threshold (equal to 10 µM) that discriminate between active and inactive
compounds. As a result of this, the inactive compounds share a large part of their
chemical space with the active compounds. On the other hand many active compounds
occupy a region of the chemical space where almost no inactive compounds are local-
ized. It is also possible to observe the unbalanced intersection of the two clusters in
the 2D and 3D representation of the chemical space for 3D RDF and gATS descriptors
(Figures 5.13a, 5.13b, 5.13c, and 5.13d). For this particular case of unbalanced clus-
ters intersection, the down-sampling is not enough to generate models with a balanced
prediction for active and inactive compounds.
5.4.3 Use of an external testset
The predictivity of the generated SVM model was investigated using an external test-
set. Analogously to the SOM models, the LM dataset was used as test set to test the
predictivity of the generated models. The SVM models used to predict the activity
of the LM dataset were chosen according to the accuracy values associated with the
models. The best two SVM models were generated using a combination of 2D and 3D
RDF descriptors and gATS descriptors.
In contrast to what was observed for the SOM models, SVM models are not able to
effectivelly discriminate between active and inactive compounds of the LM dataset. All
the active compounds of the test set were correctly predicted, but only 2 compounds
(LM-219 and LM-225) belonging to the inactive compounds are correctly predicted.
The predictivity of the SVM model generated using gATS descriptors is slightly better
than the model generated using 2D and 3D RDF descriptors. This model is able to
correctly predict all the active compounds of the test set but only 3 of the inactive
compounds (LM-219, LM-220, LM-225).
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5.5 Use of k-NN to discriminate between
BCRP-inhibitors and non-inhibitors
5.5.1 Generation of the models
The k-NN is the fastest and simplest classification algorithm used in this work [161].
The only parameter that needs to be optimized is the k value. It indicates the number
of neighbors around an element, for which its class has to be determined. The best
value of k was systematically searched generating several models using values between
1 and 9. Only odd values of k were used, in order to avoid cases of draws (where the
number of neighbors of the two classes are the equal: in this case, it is not possible to
determinate the class of the query element). The best value of k for each descriptor set
is reported in table 5.6. The workflow used to generate and evaluate the k-NN models
is analogous to that used to generate the SOM and the SVM models. The descriptors
with variance equal to 0 were deleted from the descriptor matrix. Then, the matrix
values were normalized. The following step is the downsampling of the elements in
the majority class (active substances). The downsampling and the generation of the
model were performed 1000 times and the average of the accuracy were reported. The
best models were used to predict the activity of an external dataset.
5.5.2 Evaluation of the results
The best k-NN models were obtained, as already observed for SOM and SVM, using
RDF and ATS descriptors. In particular, the use of 3D RDF descriptors, the combi-
nation of 2D and 3D RDF descriptors and gATS descriptors leads to the best models.
The accuracy value of the k-NN model generated using 3D RDF descriptors and of
the model obtained using 2D and 3D RDF descriptors together are 0.74 and 0.75,
respectively. Although the second model has the best accuracy, its capacity to predict
inactive compounds is lower than in the model based on only 3D RDF descriptors.
The model built using gATS descriptors has an accuracy equal to 0.73. This result
confirms that the gATS descriptors, as well as RDF are a good choice for building ma-
chine learning models useful to discriminate between active and inactive compounds
of a dataset.
5.5.3 Use of an external testset
The best k-NN models were used to predict the activity of the LM test set. The three
best model based on the k-NN algorithm are obtained using 3D RDF descriptors,
2D and 3D RDF descriptors together and gATS descriptors, the same descriptor sets
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Table 5.6: Summary of BCRP classification powers by kNN approach.
Descriptors set k Accuracy TP rate TN rate
3D-RDF 7 0.74 0.85 0.63
gATS 5 0.73 0.87 0.58
2D-3D-RDF 5 0.75 0.92 0.58
2D-RECON 3 0.70 0.85 0.54
2D-RDF 5 0.71 0.88 0.53
2D-IND-MOE 3 0.69 0.91 0.46
2D-3D-RECON 3 0.63 0.74 0.52
tATS 7 0.67 0.87 0.47
IND-MOE 3 0.66 0.82 0.50
2D-MOE 3 0.63 0.79 0.47
3D-MOE 7 0.62 0.80 0.44
2D-3D-IND-MOE 3 0.63 0.77 0.49
WHIM 3 0.66 0.84 0.47
2D-3D-MOE 3 0.63 0.72 0.54
2D-3D-TAE-RECON 7 0.59 0.85 0.33
3D-IND-MOE 3 0.62 0.80 0.45
GETAWAY 7 0.55 0.74 0.36
3D-RECON 5 0.67 0.85 0.49
3d-MORSE 5 0.55 0.65 0.46
TAE-RECON 5 0.58 0.86 0.31
as in case of SOM and SVM models. The results show that, analogously to the
SOM algorithm, the k-NN based models are mostly able to predict the activity of
the compounds in the external testset. In particular, the model generated using 3D
RDF descriptors and the model generated using gATS descriptors are both able to
correctly predict the active compounds of the LM testset. The inactive compounds
are only partially correctly predicted: The compounds LM-226, LM-234 and LM-
233 are wrongly predicted as active compounds. The k-NN model generated using
a combination of 2D and 3D RDF descriptors showed better results with respect to
the other two models: The active compounds of the LM dataset were all correctly
predicted, while only two compounds (LM-234 and LM-233) of the inactive class were
wrongly predicted. These compounds are also predicted as active compounds by the
SOM and SVM algorithms.
5.6 Comparison of the results
The comparison of the results obtained with the three machine learning algorithms
shows that all three algorithms are able to discriminate between inhibitors and non-
inhibitors of BRCP in a dataset of structurally highly similar compounds. The results
show that the most predictive classification algorithms between the three tested in this
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Figure 5.16: Summary of results.
work are the SOM and SVM algorithms. The best results obtained with these three
algorithms were given using RDF descriptors (3D or the combination of 2D and 3D
descriptors) and gATS descriptors. As shown in figure 5.16, the use of RDF descriptors
and gATS descriptors leads to high values of accuracy for the training set, as well as
comparable values of accuracy between the SOM and SVM classification algorithms,
while the k-NN classification algorithm is slightly worse than the other two. This
results suggest that the used descriptor sets are able to separate the two classes of the
dataset almost independently to the used algorithm.
The use of an external testset shows that the most predictive models generated using
the KS dataset are able to correctly classify also other BCRP-inhibitor candidates,
with less structural similarity. The best results are obtained using the SOM algorithm
and the k-NN algorithm, while the SVM algorithm gives the worst results in terms of
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Table 5.7: Summary of the predictions of the test set.
3D RDF 2D and 3D RDF gATS
Method TP TN FP FN TP TN FP FN TP TN FP FN
SOM 9 5 2 0 9 4 3 0 9 4 3 0
SVM 9 3 4 0 9 2 5 0 9 3 4 0
k-NN 9 4 3 0 9 5 2 0 9 4 3 0
predictivity. As reported in table 5.7, the correct number of predictions is higher for
SOM and k-NN, independent of the used descriptor sets. The absolutely best values
are obtained using the SOM algorithm and 3D RDF descriptors or the k-NN algorithm
with the combination of 2D and 3D RDF descriptors. As shown in table 5.8, all the
used training set and algorithm are able to correctly recognize the BCRP-inhibitors
of the test set. Between the non-inhibitors, only two compounds are never correctly
predicted: LM-234 and LM-233. This limit of the prediction capacity could due to the
extremely high structurally correlation between these two compounds and the majority
of the active compounds of the test set.
Table 5.8: Prediction of the class of the substances in the test set. A value of ”1”
indicates active compounds (BCRP inhibitors) while ”0” indicates inactive
compounds.
3D RDF 2D and 3D RDF gATS
Compound Class SOM SVM k-NN SOM SVM k-NN SOM SVM k-NN
LM-221 1 1 1 1 1 1 1 1 1 1
LM-222 1 1 1 1 1 1 1 1 1 1
LM-223 1 1 1 1 1 1 1 1 1 1
LM-229 1 1 1 1 1 1 1 1 1 1
LM-224 1 1 1 1 1 1 1 1 1 1
LM-228 1 1 1 1 1 1 1 1 1 1
LM-236 1 1 1 1 1 1 1 1 1 1
LM-235 1 1 1 1 1 1 1 1 1 1
LM-209 1 1 1 1 1 1 1 1 1 1
LM-75 0 0 1 0 0 1 0 0 1 0
LM-219 0 0 0 0 0 0 0 0 0 0
LM-220 0 0 0 0 0 1 0 1 0 0
LM-225 0 0 0 0 0 0 0 0 0 0
LM-226 0 0 1 1 0 1 0 0 1 1
LM-234 0 1 1 1 1 1 1 1 1 1
LM-233 0 1 1 1 1 1 1 1 1 1
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In conclusion, it is possible to discriminate between inhibitors and non-inhibitors in
a dataset of BCRP-inhibitors, also if the compounds are structurally highly similar,
as in the case of the KS dataset. In this case, the best results are obtained using the
SOM algorithm with the RDF and gATS descriptors calculated for the compounds
in the dataset. The generated models could be used to predict the binary activity of
other classes of substances.
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6 Structure-activity relationships of
quinazolines derivates as inhibitors
of BCRP.
6.1 Structural and activity data
The 36 quinazolines included in this work were synthesized by Dr. Kapil Juvale and
were taken from his PhD Thesis [162]. The activity data were also measured by Kapil
Juvale using the Hoechst 33342 assay at a final concentration of 1 µM in MDCK BCRP
cells. In figure 6.1 the general structure of the quinazolines included in this work is
reported and in table 6.1 the activities (pIC50) of the compounds are reported.
N
N
HN
R2
R1
6
7
5
8
4
1
3
2
Figure 6.1: The general structure of the quinazolines used in this work. The aniline sub-
structure is highlighted in green.
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Table 6.1: The compounds included in the analysis..
Compound pIC50 R
1 Positions 6 and 7 R2
KJ-98 5.59 H H Phenyl
KJ-99 5.43 2-Br H Phenyl
KJ-100 6.24 3-Br H Phenyl
KJ-101 5.17 4-Br H Phenyl
KJ-102 5.72 3-Cl H Phenyl
KJ-103 5.78 3-Cl,4-F H Phenyl
KJ-104 5.65 2-OCH3 H Phenyl
KJ-105 5.88 3-OCH3 H Phenyl
KJ-106 5.72 4-OCH3 H Phenyl
KJ-109 6.90 3-NO2 H Phenyl
KJ-110 6.01 4-NO2 H Phenyl
KJ-112 6.85 3-CN H Phenyl
KJ-113 6.60 3-CF3 H Phenyl
KJ-114 5.82 4-CF3 H Phenyl
KJ-115 6.83 3-OH H Phenyl
KJ-116 5.70 H H 3,4-Dimethoxyphenyl
KJ-117 6.54 3-Br H 3,4-Dimethoxyphenyl
KJ-118 6.38 3,4-OCH3 H 3,4-Dimethoxyphenyl
KJ-119 6.20 2-NO2 H 3,4-Dimethoxyphenyl
KJ-120 7.13 3-NO2 H 3,4-Dimethoxyphenyl
KJ-121 6.53 4-NO2 H 3,4-Dimethoxyphenyl
KJ-122 6.53 3-CF3 H 3,4-Dimethoxyphenyl
KJ-123 6.72 3-CN H 3,4-Dimethoxyphenyl
KJ-124 6.60 2-OH H 3,4-Dimethoxyphenyl
KJ-125 6.87 3-OH H 3,4-Dimethoxyphenyl
KJ-126 6.33 4-OH H 3,4-Dimethoxyphenyl
KJ-127 5.98 3-Br H H
KJ-128 5.93 3-CN H H
KJ-129 5.96 3-NO2 H H
KJ-131 5.32 3,4-OCH3 H H
KJ-132 5.76 3-Br 6,7-Dimethoxy H
KJ-133 5.64 3-CF3 6,7-Dimethoxy H
KJ-134 5.98 3-CN 6,7-Dimethoxy H
KJ-135 5.42 2-NO2 6,7-Dimethoxy H
KJ-136 6.09 3-NO2 6,7-Dimethoxy H
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Compound pIC50 R
1 Positions 6 and 7 R2
KJ-137 5.54 4-NO2 6,7-Dimethoxy H
6.2 Free-Wilson analysis
The Free-Wilson analysis directly correlates structural features of the molecules with
the activity of the compounds [163]. In this work, the Free-Wilson analysis was used to
characterize and quantify the contribution of different substituents in the structure of
quinazolines to the BCRP inhibitory activity. Furthermore, the Free-Wilson analysis
can be used to verify the quality of the biological data and find possible errors in the
biological data.
The first Free-Willson analysis was obtained using all the compounds of table 6.1.
The used matrix is shown in table 6.2. The principal substitutions of these compounds
involve the anilin substructure (R1). This aromatic ring is substituted at position 2,
3, and 4 by several groups. Altogether, 17 features of the matrix used for the Free-
Wilson analysis describe the variations at position R1. The R2 position, in the reference
compound KJ-98 is occupied by a phenyl group. This group is either replaced by an
hydrogen (code name: R2 (H)) or by a 3,4-dimethoxyphenyl group (code name: R2
(3,4-OCH3-Ph). For six compounds included in the analysis, the positions 6 and 7 are
also substituted by two methoxy groups.
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Table 6.2: The Free-Wilson matrix. Compound KJ-98 is used as reference compound.
Compound R1 R2
2-Br 2-OCH3 2-NO2 2-OH 3-Br 3-OCH3 3-NO2 3-OH 4-Br 4-OCH3 4-NO2 4-OH 3-Cl 4-F 3-CN 3-CF3 4-CF3 H 3,4-OCH3-Ph 6,7-OCH3
KJ-98
KJ-99 1
KJ-100 1
KJ-101 1
KJ-102 1
KJ-103 1 1
KJ-104 1
KJ-105 1
KJ-106 1
KJ-109 1
KJ-110 1
KJ-112 1
KJ-113 1
KJ-114 1
KJ-115 1
KJ-116 1
KJ-117 1 1
KJ-118 1 1 1
KJ-119 1 1
KJ-120 1 1
KJ-121 1 1
KJ-122 1 1
KJ-123 1 1
KJ-124 1 1
KJ-125 1 1
KJ-126 1 1
KJ-127 1 1
KJ-128 1 1
KJ-129 1 1
KJ-131 1 1 1
KJ-132 1 1 1
KJ-133 1 1 1
KJ-134 1 1 1
KJ-135 1 1 1
KJ-136 1 1 1
KJ-137 1 1 1
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Table 6.3: Result of the Free-Wilson analysis. In the table the used features, the
coefficients ± SD and the p values are reported.
Features Coefficients ± SD p values
Intercept 5.5480 ± 0.0995 < 0.001
2-Br -0.1220 ± 0.1802 0.5088
2-OCH3 0.1008 ± 0.1802 0.5843
2-NO2 0.5403 ± 0.1537 < 0.001
2-OH 0.8923 ± 0.1863 < 0.001
3-Br 0.9038 ± 0.1299 < 0.001
3-OCH3 0.3674 ± 0.1324 0.014
3-NO2 1.2931 ± 0.1299 < 0.001
3-OH 1.2218 ± 0.1448 < 0.001
4-Br -0.3825 ± 0.1801 0.051
4-OCH3 0.2014 ± 0.1324 0.1491
4-NO2 0.6656 ± 0.1342 < 0.001
4-OH 0.6223 ± 0.1863 0.004
3-Cl 0.1721 ± 0.1802 0.3547
4-F 0.0600 ± 0.2124 0.7814
3-CN 1.1431 ± 0.1299 < 0.001
3-CF3 0.8943 ± 0.1342 < 0.001
4-CF3 0.2720 ± 0.1802 0.1518
R2 (H) -0.7277 ± 0.0994 < 0.001
R2 (3,4-OCH3-Ph) 0.1597 ± 0.0728 0.0445
6,7-OCH3 0.0114 ± 0.1054 0.9157
The QSAR model obtained by this first analysis has an r2 value of 0.964 (s = 0.150, F
= 19.79 for n = 36). The coefficients reported in table 6.3 highlight the negative effect
of the substitution with bromine at position 2 and 4 of the aniline. The substitution
of the phenyl group at position R2 with an hydrogen decreases the inhibitory activity
of these compounds: this effect is also described by a negative coefficient in the Free-
Wilson analysis. The low coefficient associated with the substitutions at positions 6
and 7 evidences that the substitution with methoxy groups at these positions does not
influence the activity of these compounds.
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Table 6.4: The Free-Wilson matrix for 19 compounds. Compound KJ-98 is used as reference compound.
Compound 2-Br 2-OCH3 2-NO2 2-OH 3-Br 3-OCH3 3-NO2 3-OH 4-Br 4-OCH3 4-NO2 4-OH 3,4-OCH3-Ph
KJ-98
KJ-99 1
KJ-100 1
KJ-101 1
KJ-104 1
KJ-105 1
KJ-106 1
KJ-109 1
KJ-110 1
KJ-115 1
KJ-116 1
KJ-117 1 1
KJ-118 1 1 1
KJ-119 1 1
KJ-120 1 1
KJ-121 1 1
KJ-124 1 1
KJ-125 1 1
KJ-126 1 1
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Another Free-Wilson analysis was performed including only compounds chosen ac-
cording to the presence or absence of the chosen substituents at all three positions of
the aniline substructure. The 19 compounds with these substituents were included in
the analysis. The chosen substituents are:
• Br, NO2, OH and OCH3 at positions ortho, meta and para to the aniline (Code
names of the features: Br, OCH3, NO2, OH).
• OCH3 at positions 3 and 4 of the aromatic ring at position R2 (Code name of
the feature: 3,4-OCH3-Ph).
Table 6.5 reports the features used in the Free-Wilson analysis. Compound KJ-98,
with hydrogen atoms at all positions, is used as reference. The final model consists
of ten significant variables. The obtained QSAR model shows a very good fit (r2 =
0.988, s = 0.1177, F = 30.74 for n = 19). Furthermore, the model is able to explain the
contribution of the substituents to the activity of the compounds: as already observed
also in the first Free-Wilson model, the only two negative coefficients are associated
to the presence of bromine at position 2 and 4 of the aniline.
Table 6.5: Result of the Free-Wilson analysis. In the table the used features, the
coefficients ± SD and the p values are reported.
Features Coefficients ± SD p values
Intercept 5.513 ± 0.079 < 0.001
2-Br -0.087 ± 0.142 0.568
2-OCH3 0.136 ± 0.142 0.382
2-NO2 0.439 ± 0.148 0.032
2-OH 0.839 ± 0.148 0.002
3-Br 0.754 ± 0.114 0.001
3-OCH3 0.384 ± 0.109 0.017
3-NO2 1.378 ± 0.114 < 0.001
3-OH 1.213 ± 0.114 < 0.001
4-Br -0.347 ± 0.114 0.058
4-OCH3 0.218 ± 0.109 0.102
4-NO2 0.635 ± 0.114 0.003
4-OH 0.569 ± 0.148 0.012
3,4-OCH3-Ph 0.248 ± 0.066 0.013
This substitution decreases the BCRP-inhibitory activity of the compounds KJ-
99 and KJ-101 with respect to the reference compound. The other coefficients, all
positive, indicate that substitutions on the aniline lead to an increase of the BCRP-
inhibitory activity. The higher coefficients are associated with OH and NO2 groups, in
particular at position 3 (meta) of the aniline. These numerical values are confirmed by
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the high inhibitory activity of compounds KJ-115 (pIC50 = 6.83) and KJ-120 (pIC50
= 7.13).
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Figure 6.2: Correlation of observed versus predicted BCRP inhibition potencies using the
Free-Wilson model (n = 19).
The presence of two methoxy groups on the aromatic ring at position R2 does not
influence the activity of this class of compounds. This observation is also confirmed
by the low value of the coefficient associated with this feature (equal to 0.248). The
predicted versus observed activity values calculated by the Free-Wilson model, using
only 19 compounds are shown in figure 6.2.
6.3 Preparation of the dataset
The compounds presented in this work were built using the software MOE [97]. The
general procedure for preparation of molecular structures used in 2D-QSAR requires
the minimization of each molecule in the dataset. However, considering the low flex-
ibility and high similarity of the compounds used in this work, it was decided to
minimize only the most active compound of the dataset and to use it as template for
the superposition of the other molecules. The molecular structure of compound KJ-
120 was chosen to be minimized and then used as template. Firstly, a conformational
search was performed in order to obtain a structure as close as possible to the absolute
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energy minimum. In this first step, the charges were calculated using the MMFF94x
force field [156]. A stochastic search was performed using an iteration limit value of
1000 and RMS gradient equal to 0.005. The rejection limit was fixed at a value of
100 and the RMSD limit to a value of 0.25. Finally, the structure with lower energy
was chosen. At a later stage, new charges were assigned using the PM3 semi-empirical
method implemented in the MOPAC 6 package [164]. Finally, the other molecular
structures were superimposed on the template to obtain the final dataset.
6.4 Chemical descriptor based QSAR model
The biological activities (expressed as pIC50) of the 36 compounds included in this
analysis are uniformly distributed in a range between 5.17 and 7.13, as displaied in
table 6.1. The range of about two logarithmic units is an important prerequisite to
obtain a predictive model. The predictivity of the model was demonstrated by leave-
one-out (LOO) cross validation.
The best model developed using 2D and 3D descriptors calculated with the software
MOE uses only three descriptors: the fractional negative van der Waals surface area
(Q VSA FNEG), the critical packing parameter (vsurf CP) and the polar volume at
-1.0 (vsurf Wp3). The last two descriptors are VSURF descriptors. These descriptors
were selected from the original pool of 2D and 3D included in the software MOE
2013.08. The descriptors used in the model were selected using the genetic algorithm
based svl code ”QuaSAR-Evolution” [165]. The multiple linear regression (MLR)
analysis was performed using the software R [166], as well as the statistical analysis
of the generated QSAR model. The model generated using MLR analysis is shown
below:
pIC50 = 4.902(±0.407) + 2.148(±0.465)Q V SA FNEG
−2.178(±0.420)vsurf CP + 0.028(±0.003)vsurf Wp3
(6.1)
n = 36, r2 = 0.777, s = 0.254, F = 37.18, p < 0.00001, r2cv = 0.712
The plot of the observed versus predicted pIC50 values is reported in figure 6.3. The
relative importance of the used descriptors is equal to 0.565 for the fractional negative
van der Waals surface area, 0.633 for the critical packing parameter and 1.000 for the
polar volume at -1.0. These three descriptors are not correlated with each other.
The results shown above indicate the high quality of the model and its high predictiv-
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Figure 6.3: Correlation of observed versus predicted BCRP inhibition potencies using the
multiparametric QSAR model.
ity. The positive sign of the coefficient for the Q VSA FNEG descriptor indicates that
a increase of the molecular surface area characterized by negative charges increases the
BCRP inhibitory activity of these compounds. The critical packing parameter is the
ratio between the volumes of the hydrophobic regions and the surface of the hydrophilic
regions times the length of the hydrophobic regions [98]. This parameter is correlated
with the lipophilicity (SLogP, calculated using MOE) of the molecule. An increase of
the critical packing parameter leads to decrease of the BCRP inhibitory activity of
these compounds. The positive sign of the coefficient for the polar volume suggests
that the activity of the compounds is directly correlated with the polar area of the
molecule, as already indicated by the first parameter of the equation (Q VSA FNEG).
6.5 3D-QSAR analysis
The molecular alignment is an essential step for CoMFA and CoMSIA studies. The
minimized structure of the most active compound of this series, compound KJ-120,
which was obtained by stochastic search and consecutive geometrical optimization, was
used as a template for the molecular alignment. After the alignment of the remain-
ing compounds, the charges were recalculated using the PM3 semi-empirical method,
without a fresh optimization of the molecular geometry. The 3D-QSAR was performed
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using the software SYBYL-X 1.2 (TRIPOS) [167].
For the CoMFA calculations, the standard settings were used: The grid size was
extended 4 A˚ beyond every molecule in the three dimensions, with a spacing value of 2
A˚. The probe atom was a sp3 carbon probe with +1 charge. The steric (s), electrostatic
(e), both (b), and hydrogen bond (h+b) CoMFA fields were calculated. The PM3
charges, calculated with MOPAC, were used for the calculation of the electrostatic
fields. The steric and electrostatic cutoff values were both fixed to the standard value
of 30.0 kcal/mol.
The steric (s), electrostatic (e), hydrophobic (h), hydrogen bond donor (d), and
hydrogen bond acceptor (a) CoMSIA fields were also calculated. The grid box for
the CoMSIA calculation was generated analogously to that of the CoMFA calculation.
The probe atom with a radius of 1 A˚, hydrophobicity equal to +1, and hydrogen bond
donor-acceptor properties also equal to +1 were used.
The QSAR models for the CoMFA and CoMSIA analysis were calculated using
the Partial Least Square (PLS) method. The internal predictivity of the models was
evaluated using the Leave-One-Out (LOO) cross-validation. The quality of the non-
cross-validated model was quantified by the squared correlation coefficient (r2) and the
standard error of estimation (s).
The produced CoMFA and CoMSIA models and the statistical parameters are sum-
marized in table 6.6. The best models are reported in bold. The best values of squared
correlation coefficient and cross-validated squared correlation coefficients (q2) are ob-
tained for the CoMSIA models. In CoMSIA analysis, the electrostatic field gives the
best q2 value (equal to 0.497, nopt = 5) among the single field models. On the other
hand, the best single field model obtained by CoMFA analysis uses the hydrogen bond
field (q2 = 0.517, nopt = 3). The other fields alone are not able to generate predictive
CoMSIA models. The combined CoMSIA models with highest q2 values are a combi-
nation of hydrogen bond donor and electrostatic fields (q2 = 0.750, nopt = 6), steric,
electrostatic and hydrogen bond donor fields (q2 = 0.731, nopt = 6), and hydrogen
bond donor-acceptor, electrostatic and hydrophobic fields (q2 = 0.723, nopt = 7).
Due to the inability of the LOO-cross-validation to estimate the model capacity
to predict the activity of completely new compounds [168], further validations of the
generated models are needed. In the leave-many-out (LMO) cross-validation a number
of compounds greater than one is left out for the validation. Different authors suggest
that this cross-validation variant could give more realistic results with respect to the
leave-one-out cross-validation[168][169]. The number of groups in which the dataset
has to be divided depends on the number of compounds in the dataset. Gramatica
[168] suggests that if the number of compounds in the dataset is lower than 50, that
the number of groups must be greater than two, otherwise the predictivity of the
generated model is underestimated. In this work 10-, 5-, and 3- folds cross-validation
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Table 6.6: 3D-QSAR models using CoMFA and CoMSIA analysis and their statistical
characteristics. The best models are reported in bold.
q2 s nopt r
2 s F
CoMFA
Both 0.565 0.361 4 0.768 0.263 5.651
s 0.455 0.404 4 0.658 0.320 14.915
e 0.490 0.397 5 0.744 0.281 17.451
hb 0.517 0.374 3 0.703 0.293 25.220
s+e+hb 0.640 0.345 7 0.926 0.157 49.895
CoMSIA
a -0.023 0.528 1 0.137 0.485 5.391
d 0.129 0.487 1 0.194 0.469 8.163
d+a 0.122 0.504 3 0.405 0.415 7.264
e 0.497 0.394 5 0.733 0.287 16.437
e+a 0.691 0.320 7 0.915 0.167 43.287
e+d 0.750 0.283 6 0.912 0.167 50.362
e+h 0.480 0.408 6 0.731 0.293 13.113
e+h+a 0.719 0.305 7 0.931 0.151 54.213
e+h+d 0.703 0.313 7 0.914 0.169 42.496
e+h+d+a 0.723 0.303 7 0.940 0.141 62.509
h 0.461 0.422 7 0.728 0.300 10.699
h+a 0.596 0.366 7 0.845 0.227 21.743
h+d 0.390 0.450 7 0.751 0.287 12.082
h+d+a 0.591 0.368 7 0.841 0.229 21.149
s 0.460 0.408 5 0.628 0.339 10.133
s+a 0.513 0.376 3 0.629 0.328 18.055
s+d 0.462 0.422 7 0.726 0.301 10.575
s+e 0.512 0.388 5 0.751 0.278 18.068
s+e+a 0.685 0.323 7 0.901 0.181 36.479
s+e+d 0.731 0.293 6 0.906 0.174 46.320
s+e+h 0.476 0.403 5 0.721 0.293 15.528
s+e+h+a 0.715 0.307 7 0.928 0.154 51.741
s+e+h+a+d 0.724 0.302 7 0.936 0.145 58.768
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of the best models obtained by LOO-cross-validation was performed, in order to verify
their predictivity. In the case of the LMO-cross-validation the population of each
group is randomly selected, therefore the q2 values obtained are always different. For
this reason, each LMO-cross-validation was repeated 10 times and the means of the
obtained q2 ± SD are reported in table 6.7. The e+d model, that shows the highest
q2 value with the LOO-cross-validation (q2 = 0.750), shows a decrease of predictivity
already for the 10-folds cross-validation (q2 = 0.694). A reduction of the predictivity
is also observed for the e+h+d+a model (from q2 = 0.723 to q2 = 0.658). A slight
decrease of the q2 value is observed also for the s+e+d model.
Table 6.7: The results of the leave-many-out (LMO) cross-validation for the best 3D-
QSAR models. The average q2 and the SD are based on 10 repetitions of
the LMO protocol.
CoMSIA fields
Number of
groups
e+d s+e+d e+h+d+a
q2 ± SD q2 ± SD q2 ± SD
LOO 0.750 0.731 0.723
10 0.694 ± 0.069 0.725 ± 0.016 0.658 ± 0.121
5 0.674 ± 0.069 0.715 ± 0.053 0.645 ± 0.150
3 0.648 ± 0.087 0.624 ± 0.062 0.485 ± 0.199
A further validation method, called Y-randomization test, was applied for the best
models. It consists of randomly shuffling the activity values of the compounds and
then calculating new q2 values, obtained by LOO cross-validation [170]. The aim of
this test is to show if a correlation between the activities and the descriptors really
exists, or if the q2 values are obtained by chance. The results of this test are reported
in table 6.8. It is seen that all the best generated models have mean q2 values lower
than 0, suggesting that the predictivites obtained by LOO cross-validation are not
obtained by chance.
Table 6.8: The results of the Y-scrambling analysis. The q2 values and the SD values
are obtained from 10 repetitions of the analysis.
CoMSIA fields q2 ± SD
e+d -0.244 ± 0.133
s+e+d -0.220 ± 0.134
e+h+d+a -0.198 ± 0.163
In the light of these results the e+d and the ”s+e+d” models were chosen to explain
the activity of this class of compounds. Finally, figure 6.4 shows the correlations be-
tween observed and predicted pIC50 models for the studied compounds. The predicted
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activity values are obtained using the O`e+dO´ CoMSIA model (r2 = 0.912) and the
”s+e+d” CoMSIA model (r2 = 0.906). The plots show that for all the compounds the
predicted values are well correlated with the observed values.
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Figure 6.4: Correlation of observed versus predicted BCRP inhibition potencies using the
3D-QSAR model based on (a) the ”e+d” fields and on (b) the ”s+e+d” fields.
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The contour (STDEV*COEFF) plots of the ”e+d” CoMSIA model and of the ”s+e+d”
CoMSIA model are illustrated in figure 6.5. In particular, the figures 6.5a and 6.5b
show the contour (STDEV*COEFF) plots of the ”e+d” CoMSIA model drawn to-
gether with the most active compound of the series, compounds KJ-120 (pIC50 =
7.13) and with the low active compound KJ-131 (pIC50 = 5.32), respectively. The fig-
ures 6.5c and 6.5d show the contour (STDEV*COEFF) plots of the ”s+e+d” CoMSIA
model drawn together with the compounds KJ-120 and KJ-131, respectively. These
plots describe the contribution of the fields to the compounds activity. The green con-
tour areas mark the favorable influences of the steric field, while the yellow areas are
associated with regions where the steric field is unfavorable. It can be seen in figure
6.5c that this contour area is occupied by a phenyl rest of compound KJ-120, while
this phenyl residue is absent in the structure of compound KJ-131. An unfavorable
area for the steric field is also reported at position 4 of the aniline. This position is
not occupied by any substituent in compound KJ-120, while compound KJ-131 has a
methoxy group at the same position. Regarding the electrostatic field, blue contour
areas indicate favorable electrostatic interactions, while red contour areas unfavorable
electrostatic interactions.
The contour plot indicates that generally, the presence of polar substituents increases
the activity of the compounds if they are localized at position 4 of the aniline, while
these substituents slightly decrease the inhibitory activity if localized at position 3
of the same aromatic ring. The favorable influence of hydrogen bond donor groups
is indicated by turquoise areas and the unfavorable influence by purple areas. The
most important contribution of this field, as it is possible to observe in the contour
plot, is given by substituents at position 3 of the aniline: The presence of hydrogen-
bond donor groups at this position leads to an increase of the inhibitory activity of
the compounds. Two examples are represented by the hydroxy group of compounds
KJ-115 (pIC50 = 6.83) and KJ-125 (pIC50 = 6.87).
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(a) (b)
(c) (d)
Figure 6.5: CoMSIA contour plot (STDEV*COEFF) of the 3D-QSAR model generated
using (a) the ”e+d” fields and the most active compound KJ-120, (b) the
”e+d” fields and the low active compound KJ-131, (c) the ”s+e+d” fields
and the most active compound KJ-120, and (d) the ”s+e+d” fields and the
low active compound KJ-131. The steric bulk is favored at green (60 %) and
disfavored at yellow (10 %) regions. Polar groups are favored at blue (90 %)
and disfavored at red (15 %). H-bond donor groups are favored at turquoise
(75 %) and disfavored at purple (45 %) regions.
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7 Conclusions
The first aim of this work was the characterization of a new class of BCRP inhibitors,
structurally derived from tariquidar. Furthermore, the Hoechst 33342-assay was opti-
mized and validated and then used to determine the inhibitory activity values (IC50)
of the studied compounds. The optimization of the assay and the subsequent biolog-
ical tests were performed using MCF-7 MX cells. Considering WK-X-27 (KS-176) as
reference and starting point, several compounds with variations of the two linkers and
of the three aromatic rings were synthesized by Dr. Steggemann.
The results of the biological tests confirmed that the deletion of the tetrahydroiso-
quinoline moiety, originally included in the tariquidar structure, generally leads to loss
of inhibitory activity against P-gp, while the inhibitory activity against BCRP is not
compromised. The relative position of the two linkers in the central aromatic ring
was also found to be essential for the inhibitory activity of these compounds: Indeed,
only the ortho substituted compounds are BCRP inhibitors. The modifications of the
first linker leads to active and selective compounds only in case of KS-311 (IC50 =
0.644 µM), where the length of the linker is increased by one single carbon atom. Also
variations of the second linker generally lead to worsening of the inhibitory BCRP
activity except in case of compound KS-246, with an IC50 value of 0.52 µM.
The variations on the third aromatic ring can be explained using 2D-QSAR. The
obtained correlation shows the importance of the σ values of the substituents and their
interaction surface area for the BCRP inhibitory activity of these compounds. The
most active compound with a modification of the third aromatic ring is KS-407 (IC50
= 1.16 µM) and its activity is well predicted by the 2D-QSAR model. The substitution
of the second aromatic ring generally leads to worsening of BCRP inhibitory activity.
This effect is stronger if the substituent is at position R1 of the ring, it is weaker if the
substituent is at position R2. The inhibitory activity also decreases with increasing
van der Waals volume of the substituent. The substitution of the hydroxyethyl group
in the first aromatic ring with an hydroxy group directly connected to the ring (KS-
251) leads to a potent (IC50 BCRP = 1.76 µM) and selective (IC50 P-gp = 27.5 µM)
BCRP inhibitor, suggesting that the geometrical dimension of the pharmacophore of
this compounds class can be reduced.
Several members of this new class of BCRP inhibitors, like the potent and selective
BCRP inhibitors KS-407 and KS-251 were shown to be able to reverse the resistance
against several cytotoxic compounds like Hoechst 3342, mitoxantrone, and SN-38 in
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BCRP overexpressing cells.
Three classification algorithms, the Self-Organizing Maps (SOM), the Support Vec-
tor Machine (SVM) and the k-Nearest Neighbor (k-NN) were used to understand the
reason why several compounds do not shown any inhibitory activity against BCRP.
The best results were obtained using the 3D RDF and gATS descriptors and building
the model using the SOM algorithm. These molecular descriptors codify properties
like the molecular surface or the molecular dimension. It was also shown that the
lipophilicity does not play a major role to discriminate between active or inactive
BCRP inhibitors. Using the combination of the SOM algorithm and 3D RDF or gATS
descriptors, it is possible to discriminate between active and inactive BCRP inhibitors
with an accuracy of 0.79 using either the descriptors. The 3D RDF and gATS descrip-
tors were also successfully used in combination with the SVM and k-NN algorithms.
The SVM algorithm was able to discriminate between the two classes with an accuracy
of 0.75 for the 3D RDF descriptors and of 0.77 for the gATS descriptors. The use of
the k-NN algorithm leads to lower accuracy values: an accuracy of 0.74 was obtained
using the 3D-RDF descriptors and of 0.73 using the gATS descriptors. The trained
model was also used to predict the activity of an external test set, consisting of 16
compounds not structurally similar with the compounds included in the training set.
The results show that the classified activity data of the test set was predicted with an
accuracy of 0.88 using the SOM algorithm and 3D RDF descriptors. This result sug-
gests that this model can be used to predict classified activity values of newly designed
BCRP inhibitor candidates.
In the last project the 2D- and 3D- quantitative structure activity relationship
(QSAR) models of 36 quinazoline derivates were generated. The Free-Wilson model
highlighted the importance of hydroxy and nitro groups at position meta of the aniline
for the activity of these compounds. The chemical descriptor based QSAR model, that
was built using only three molecular descriptors has a r2 value of 0.777 and suggests
that the inhibitory activity is correlated with the distribution of the partial charges
on the molecular surface and with the lipophilicity of the molecules. Furthermore,
CoMFA and CoMSIA models were also generated. The best models are the CoMSIA
models that use the combination of electrostatic and hydrogen bond donor CoMSIA
fields (e+d model, q2 = 0.750), steric, electrostatic and hydrogen bond donor CoMSIA
fields (s+e+d model, q2 = 0.713) and electrostatic, hydrophobic, hydrogen bond donor,
and hydrogen bond acceptor CoMSIA fields (e+h+d+a model, q2 = 0.723). The gen-
erated models are stable also for 10- 5- and 3- folds cross-validation, in particular the
e+d and s+e+d models. Furthermore, the Y-randomization test demonstrated that
the obtainend q2 values of these models are not obtained by chance. In conclusion,
these 2D- and the 3D- QSAR models are highly predictive, able to explain the in-
hibitory activity of the studied compounds, and can be used for later design of new
162
BCRP inhibitors.
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